Modulation of steroid hormone uptake

ABSTRACT

The present invention discloses that cells, such as mammalian cells actively can take up steroid hormones/steroid hormone binding protein complexes via steroid hormone binding protein receptors and/or co-receptors. Furthermore, the invention relates to methods for screening for compounds, which alters uptake of such complexes, compounds identified by said methods as well as methods for treatment using said compounds and uses of said compounds for the preparation of a medicament.

BACKGROUND OF THE INVENTION

[0001] Many developmental processes in a wide variety of species are regulated by steroid hormones, all of which are synthesised from cholesterol. Being relatively small hydrophobic molecules, they are thought to be able to cross the plasma membrane by simple diffusion. Once inside the target cell, each type of steroid hormone binds tightly but reversibly to specific nuclear receptors that act as transcriptional regulators.

[0002] In the circulation steroid hormones are transported by specific plasma carrier proteins. These carriers include the sex hormone-binding globulin (SHBG), the corticoidsteroid-binding globulin (CBG) and the vitamin D-binding protein (DBP). SHBG specifically binds androgens and estrogens. Due to the high affinity between carrier and ligand and because of an excess of carrier, more than 95% of circulating steroid hormones are found in complex with their respective carriers.

[0003] According to one theory, the role of the carriers is to keep bound steroids in a biological inactive state and to regulate the plasma concentration of free hormone, which can enter the cells by passive diffusion. This concept of steroid uptake requires unspecific entry of steroid hormones into all cells of an organism in order to find their intracellular receptors. Furthermore, the amount of steroids that can be taken up depends on the systemic concentration of the free hormones and may not be increased locally in steroid responsive-tissues.

[0004] DBP is the principal carrier of vitamin D metabolites in plasma and it is estimated that only 0.003% vitamin D₃ metabolites are found in the unbound form. Epithelial cells of the renal proximal tubuli are responsible for the conversion of 25-OH vitamin D₃ to its active form. However, the amount of 25-OH vitamin D₃ that is taken up and converted by the kidney considerably exceeds the amount of precursor that can be taken up by passive diffusion only. It has been demonstrated that megalin, a member of the low density lipoprotein (LDL) receptor family is a receptor for DBP and internalises 25-OH vitamin D₃/DBP complexes into the tubular epithelium. Lack of the receptor in megalin knock-out mice results in the inability of renal epithelial cells to take up 25-OH vitamin D₃ and hence to produce the active hormone. As a consequence, receptor deficient animals exhibit vitamin D3 deficiency (Nykjaer et al, 1999).

[0005] The LDL receptor is the founding member of a family of receptors that all share the same structural motifs and furthermore include LDL receptor-related protein (LRP), megalin, the very-low-density lipoprotein (VLDL) receptor and the apolipoprotein E receptor-2 (ApoER2), LRP-1 B, MEGF-7, chicken VTG receptor, Drosophila Y1 protein, gp 330/megalin and C. elegans gp330/megalin-related protein. The modular structure of the extracellular domains of the individual receptors is very similar and has been remarkably conserved throughout evolution. Each receptor comprises a number of complement type repeat clusters, for example does the LRP receptor contain 4 such clusters. The number of complement type repeats within each cluster varies from 2 to 11. Family members have been identified in flies as well as in the nematode C. elegans. In contrast to the extracellular domains, the cytoplamic tails of the different receptors share very little sequence similarity, with the exception of a short amino-acid motif characterised by the consensus sequence Asn-Pro-Xaa-Tyr, where Xaa can be any amino acid. This motif has been shown to mediate clustering of the LDL receptor in coated pits before endocytosis.

[0006] The LDL receptor is involved in the uptake of low density lipoproteins (LDL) from the blood. After binding of LDL, LDL receptors cluster on coated pits in the plasma membrane. This step is followed by the formation and internalisation of endocytic vesicles, hydrolysis of the endocytosed lipoproteins in lysosomes and release of the lipids into the cytoplasm.

[0007] LRP is involved in the uptake of chylomicron remnants, the carriers of dietary lipids, into hepatocytes. However, LRP furthermore acts as the receptor for the abundant plasma protease inhibitor α2-macroglobulin, as well as for a number of other protease inhibitors, proteases, lipases and other functionally diverse macromolecules.

[0008] Megalin is expressed abundantly on the apical surface of the epithelial cells of proximal tubules in the kidney and the major ligands of Megalin appears to be DBP and retinol-binding protein (RBP), which is a carrier for vitamin A.

SUMMARY OF THE INVENTION

[0009] A number of steroid-responsive cells such as for example male germ cells and cells of prostate and endometrium and estrogen-dependent breast cancer cells have binding sites for various carrier proteins on their surfaces. For example SHBG binds to specific receptors in endometrium, prostate cells and breast cancer cells, and is presumably taken up by these cells via receptor mediated endocytosis (Porto et al., 1995).

[0010] Interestingly, the present invention discloses that cells, such as for example cells of epididymis and prostate actively take up steroid hormones/steroid hormone binding protein complexes, for example testosterone/SHBG complexes or complexes comprising estrogen, progesterone and/or corticoids by receptor mediated endocytosis and that the receptors involved in binding and internalising these complexes belong to the LDL receptor family. Furthermore, the present invention discloses that in some cases the presence of a co-receptor is required for the uptake of steroid hormone binding proteins into cells. These observations provide a unique possibility to specifically regulate the uptake of steroid hormones into steroid hormone responsive cells including cells that metabolise the steroid hormones.

[0011] Accordingly, it is a first aspect of the present invention to provide an in vitro method for screening for a compound which alters uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor, said method comprising

[0012] a) providing an assay for measuring binding to or uptake by the steroid hormone binding protein receptor of steroid hormones bound to or complexed with a steroid hormone binding protein,

[0013] b) adding the compound to be tested to the assay, and

[0014] c) determining the amount of steroid hormones bound to or complexed with a steroid hormone binding protein which is bound to or taken up by the steroid hormone binding protein receptor,

[0015] d) comparing the amount determined in step c) with an amount measured in the absence of the compound to be tested,

[0016] e) wherein a difference in the two amounts identifies a compound which alters the binding or uptake of steroid hormones bound to or complexed with steroid hormone binding proteins.

[0017] It is a second objective of the present invention to provide a method of screening for a compound which alters uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor, said method comprising

[0018] a) administering said compound to a mammal naturally expressing the receptor,

[0019] b) measuring expression of receptor mRNA or protein in tissues of the mammal or measuring receptor-mediated binding or transport of steroid hormones bound to or complexed with steroid hormone binding proteins or measuring uptake of steroid hormones or steroid hormone/steroid hormone binding protein complexes into cells of said mammal,

[0020] c) comparing the measurement of step b) with a measurement measured in the absence of the compound to be tested,

[0021] d) wherein a difference in the two measurements identifies a compound which alters the uptake of steroid hormones bound to or complexed with steroid hormone binding proteins.

[0022] Furthermore, it is an objective of the present invention to provide compounds identified by one of the above mentioned methods which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor.

[0023] It is a further objective of the present invention to provide a method for determining the effect of a compound on uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor, said method comprising the steps of

[0024] a) administering said compound to a mammal naturally expressing the receptor,

[0025] b) measuring expression of receptor mRNA or protein in tissues of the mammal or measuring receptor-mediated binding or transport of steroid hormones bound to or complexed with steroid hormone binding proteins or measuring uptake of steroid hormones or steroid hormone/steroid hormone binding protein complexes into cells of said mammal,

[0026] c) comparing the measurement of step b) with a measurement measured in the absence of the compound to be tested,

[0027] d) wherein the difference in the two measurements identifies the effect of said compound on the uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor.

[0028] The cells of certain tumours are dependent on steroid hormones for growth. Hence, it is desirable to inhibit uptake of steroid hormones by such cells. In particular, this is the case for cells of prostate cancer and breast cancer.

[0029] Accordingly, it is a still further objective of the present invention to provide methods of treating prostate cancer comprising administering to an individual having prostate cancer a sufficient amount of a compound which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor. It is also an objective to provide methods of treating breast cancer comprising administering to an individual having breast cancer a sufficient amount of a compound which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor.

[0030] Additionally, it is an objective of the present invention to provide a method of preventing pregnancy comprising administering to an individual in need thereof a sufficient amount of a compound which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor.

[0031] The present invention furthermore provides pharmaceutical compositions comprising a compound, which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor as well as uses of said compound for the preparation of a pharmaceutical composition for the treatment of a condition selected from the group consisting of prostate cancer and breast cancer.

[0032] Models of receptor-mediated endocytosis of steroid hormone/steroid hormone binding protein complexes according to the present invention are depicted in FIGS. 4 and 5. In the circulation, steroid hormones are transported in a complex with specific steroid hormone binding proteins (carrier) such as sex hormone-binding globulin (SHBG), corticosteroid-binding globulin (CBG), Clara cell secretory protein (CCSP), apolipoprotein D (apoD) or 24p3. Target cells take up complexed steroid hormones via endocytic receptors recognising the steroid hormone binding protein (FIG. 4). Alternatively, a steroid hormone binding protein co-receptor mediates the binding (FIG. 5). The steroid hormone/steroid hormone binding protein complexes are internalised and delivered to lysosomes. There, the steroid hormone binding protein is degraded to release the steroid hormone, which enters the cytoplasm for further metabolism. In the cytoplasm, steroid hormones may be further metabolized such as testosterone to dihydrotestosterone in principal cells of the epididymis. Alternatively, the steroid hormones interact with their nuclear hormone receptor to elicit intracellular signalling.

[0033] The uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor can be altered in a number of different ways according to the present invention. For example the uptake can be altered to decrease uptake of steroid hormones into the cells. This may be obtained for example by any of the following methods:

[0034] a) inhibiting the association between a steroid hormone and a steroid hormone binding protein and/or;

[0035] b) inhibiting the association between a steroid hormone binding protein and a steroid hormone binding protein receptor and/or;

[0036] c) inhibiting the association between a steroid hormone binding protein and a steroid hormone binding protein co-receptor and/or;

[0037] d) inhibiting the association between a steroid hormone binding protein receptor and a steroid hormone binding protein co-receptor.

FIGURES

[0038]FIG. 1. Surface-plasmon resonance analysis of binding of testosterone/SHBG complexes to purified megalin.

[0039]FIG. 2. Receptor-mediated uptake of dihydrotestosterone/SHBG complexes in BN 16 cells and keratinocytes.

[0040]FIG. 3. Histological analysis of vagina tissues from wild type and megalin knock-out mice.

[0041]FIG. 4. Model of receptor-mediated endocytosis of steroid hormone/steroid hormone binding protein (carrier) complexes.

[0042]FIG. 5. Model of uptake of steroid hormone/steroid hormone binding proteins into cells via receptor and/or co-receptor mediated endocytosis.

[0043]FIG. 6. Model of the structure of examples of steroid hormone binding protein receptors.

[0044]FIG. 7. The urogenital tract of adult wild type or megalin-deficient male mouse (megalin^(−/−)). The position of the testis is indicated by dotted line. The left testis of the receptor-deficient mice is indicated by arrow.

[0045]FIG. 8. 125I-rSHBG (400 pg) was incubated with 600 μg of membrane preparations from bovine epididymis (A) or endometrium (B) in the presence of the indicated concentrations of unlabelled rSHBG. Values are given as a percentage of 125I-rSHBG bound in the absence of competitor (100%). The data represent the means of four individual experiments (±S.E.M.). Where no error bar is shown, the values are smaller than the actual symbol.

[0046]FIG. 9. Immunohistological detection of megalin in dog and rat prostate. The arrows denote localization of the receptor on the surface of epithelial cells.

DETAILED DESCRIPTION OF THE INVENTION

[0047] Amino Acids and Nucleic Acids

[0048] Throughout the description and claims the three letter code for natural amino acids are used. Where the L or D form has not been specified it is to be understood that the amino acid in question has the natural L form, cf. Pure & Appi. Chem. Vol. (56(5) pp 595-624 (1984) or the D form, so that the peptides formed may be constituted of amino acids of L form, D form, or a sequence of mixed L forms and D forms.

[0049] Where nothing is specified it is to be understood that the C-terminal amino acid of a polypeptide of the invention exists as the free carboxylic acid, this may also be specified as “—OH”. The N-terminal amino acid of a polypeptide comprise a free amino-group, this may also be specified as “H—”.

[0050] Where nothing else is specified amino acid can be selected from any amino acid, whether naturally occurring or not, such as alfa amino acids, beta amino acids, and/or gamma amino acids. Accordingly, the group comprises but are not limited to: Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, Gly, Ser, Thr, Cys, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Aib, Nal, Sar, Orn, Lysine analogues DAP and DAPA.

[0051] The term “nucleic acid” is meant to encompass DNA and RNA as well as derivatives thereof such as peptide nucleic acids (PNA) or locked nucleic acids (LNA) throughout the description.

[0052] Steroid Hormones

[0053] The steroid hormone according to the present invention can be any steroid hormone. The term steroid hormone covers a group of small hydrophobic molecules, which are structurally derived from cholesterol. For example such a steroid hormone can be selected from the group consisting of androgens, estrogens, progestogens and corticoids.

[0054] Androgens can for example be selected from the group consisting of testosterone, dihydrotestosterone, androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) and derivatives thereof.

[0055] Estrogens can for example be selected from the group consisting of estrion, estradiol, estriol and derivatives thereof.

[0056] Progestogens can for example be selected from the group comprising progesterone, 17-hydroxy-progesterone, pregnenolone, 17-hydroxy-pregnenolone and derivatives thereof.

[0057] Corticoids can for example be selected from the group consisting of glucocorticoid, mineralcorticoid, cortisol, 11-deoxy-cortisol, corticosterone, 1-deoxy-corticosterone, 18-hydroxy-corticosterone, aldosterone and derivatives thereof.

[0058] Preferably, the steroid hormone is selected from the group consisting of androgens and estrogens. More preferably, the steroid hormone is selected from testosterone, dihydrotestosterone, estrion, estradiol and derivatives thereof.

[0059] The steroid hormone according to the present invention may be naturally occurring steroid hormones, it may be recombinantly produced steroid hormones or derivatives thereof or it may be synthetic derivatives of steroid hormones.

[0060] Steroid Hormone Binding Protein

[0061] The steroid hormone binding protein according to the present invention can be any steroid hormone binding protein.

[0062] For example the steroid hormone binding protein is selected from the group consisting of sex hormone binding globulin, corticosteroid-binding globulin, Clara cell secretory protein (CCSP), apolipoprotein D (apoD) and 24p3. Preferably, the steroid hormone binding protein is the sex hormone binding globulin. Furthermore, it is preferred that the steroid hormone binding protein according to the present invention is a human steroid hormone binding protein.

[0063] Preferred steroid hormone binding proteins according to the present invention are listed in table 1. TABLE 1 accession # Steroid hormone binding protein (human) sex hormone binding globulin cDNA: (SHBG) XM_008233 NM_001040 Gene: M31651 corticosteroid binding globulin cDNA: (CBG) XM_007483 J02943 Gene: M31662 apolipoprotein D cDNA: (apoD) XM_003067 NM_001647 24p3 cDNA: or XM_005667 lipocalin 2 NM_005564 Gene: NT_008581 Clara cell secretory protein cDNA: (CCSP) XM_006407 or Gene: Uteroglobin NT_009314

[0064] Steroid Hormone Binding Protein Receptor/Co-Receptor

[0065] The term “steroid hormone binding protein receptor” is meant to encompass any receptor, which has a steroid hormone binding protein as ligand. Preferably, the steroid hormone binding protein receptor is selected from the group consisting of receptors belonging to the low density lipoprotein (LDL) receptor gene family.

[0066] The present inventors have shown that the receptor according to the invention relates to the low density lipoprotein (LDL) receptor gene family comprising receptors selected from the group consisting of VLDL receptor, LRP-1-B, MEGF-7, ApoE receptor-2, chicken VTG receptor, Drosophila Y1 protein, LDL receptor-related protein (LRP), gp 330/megalin and C. elegans gp330/megalin-related protein. However, in respect of the present invention it has been shown that not all members of the family may be included, since for example the LDL-receptor does not exhibit sufficient steroid hormone binding protein receptor properties.

[0067] Accordingly, the steroid hormone binding protein receptor according to the present invention preferably has a binding affinity for a steroid hormone binding protein, which is at least 4 fold above the binding affinity of the LDL-receptor to said steroid hormone binding protein, such as at least 5 fold, for example at least 6 fold, such as at least 7.5 fold, for example at least 10 fold, preferably at least between 5 and 10 fold above the binding affinity of the LDL-receptor to said steroid hormone binding protein.

[0068] Preferred steroid hormone binding protein receptors according to the present invention are listed in table 2. Structural models of examples of steroid hormone binding protein receptors (LDL receptor, LRP5/6, LRP, megalin, VLDL receptor, MGEF-7, LRP1 B and ApoE receptor-2) are given in FIG. 6.

[0069] Preferably, the steroid hormone binding protein receptor is selected from the group consisting of LRP, megalin, VLDL receptor, MGEF-7, LRP1 B and ApoE receptor-2.

[0070] More preferably, the steroid hormone binding protein receptor is selected from the group consisting of ApoE receptor-2 and megalin. Yet more preferably, the steroid hormone binding protein receptor is megalin. TABLE 2 accession # receptor name(s) (human) LRP1 cDNA: LDL receptor-related protein X13916 NM_002332 alpha-2-macroglobulin receptor gene: AH003324 LRP2 cDNA: Megalin U33837 gp330/gp600 gene: NT_002176 apolipoprotein E receptor 2 cDNA: ApoE receptor 2 D50678 LRP8 gene: SEG_D86389S very low density lipoprotein cDNA: receptor D16493 VLDL receptor gene: SEG_HUMVLDLR LRP1B cDNA: NM_018557 MGEF-7 cDNA: AB011540

[0071] Furthermore, it is preferred that the steroid hormone binding protein receptor according to the present invention is a human steroid hormone binding protein receptor.

[0072] In certain cases uptake of steroid hormone binding protein into cells requires in addition to a steroid hormone binding protein receptor also a steroid hormone binding protein co-receptor. In particular, association between a steroid hormone binding protein and a steroid hormone binding protein co-receptor may be required for cellular uptake. Steroid hormone binding protein co-receptors within the scope of the present invention may for example be cubilin (see table 3).

[0073] Cubilin was first identified as a receptor for IF-B₁₂ complex in the terminal ileum (Birn et al., 1997). Cubilin directly associates with megalin (Moestrup et al., 1998), and this molecular cooperation likely provides the basis for internalization of ligands bound to cubilin. Thus, cubilin with bound ligand may undergo megalin-mediated endocytosis, unload its cargo in lysosomes, and recycle back to the plasma membrane together with megalin. For example it has been demonstrated that cubilin greatly facilitates the endocytic uptake of 25(OH)D3 DBP by sequestering the complex on the cell surface before internalization via megalin (Nykjaer et al, 2001). TABLE 3 accession # Protein name(s) (human) Cubilin cDNA: XM_011904 gene: NT_008682 (Homo sapiens chromosome 10 working draft sequence segment)

[0074] TABLE 4 RAP cDNA: Low density lipoprotein-related XM_003315 protein-associated protein 1 Gene: Alpha-2-macroglobulin receptor- AH006949 associated protein LRPAP1 Lipoprotein receptor associated protein

[0075] Cells

[0076] The cells presenting the steroid hormone binding protein receptors according to the present invention can be cells which have been grown in a tissue culture in vitro or they may be cells comprised within an individual. Said individual is preferably a mammal, more preferably a human being. Depending on the steroid hormone of the specific application of the present invention, the cells should be selected so that they preferably are responsive to said steroid hormone.

[0077] In particular, the cells may be selected from the group consisting of prostate cells, cells in epididymis, endometrial cells, ovarial cells, breast parenchymal cells, prostate carcinoma cells and breast carcinoma cells.

[0078] Any cells that have been genetically modified to express the steroid hormone binding protein receptor or co-receptor as well as the nuclear receptor may be used. Such transfected cells are preferably eukaryotic cells, more preferably mammalian cells, most preferably human cells.

[0079] Assay

[0080] The present invention does not depend on any particular type of assay for measuring binding and/or uptake into cells of steroid hormones by steroid hormone binding protein receptors. Any assay capable of measuring binding and/or uptake into cells of the steroid hormones by steroid hormone binding protein receptors can be used in conjunction with the present invention. Assays based on a specific recognition between a steroid hormone and a steroid hormone binding protein and/or a steroid hormone binding protein and a steroid hormone binding protein receptor or a steroid hormone binding protein co-receptor according to the specific application of the present invention are preferred.

[0081] For example an assay could be qualitative and/or quantitative assays involving the use of immunoreactive species, i.e. antigens, haptens and antibodies or fragments thereof.

[0082] The assay according to the present invention may in one embodiment employ standard immunohistochemical or cytochemical detection procedures, or suitable modifications thereof, for the detection of steroid hormone. Accordingly, the invention may employ any assay resulting in the recognition of steroid hormone by an immunochemical reaction with a specific so-called primary antibody capable of reacting exclusively with the steroid hormone.

[0083] The primary antibody may be labelled with an appropriate label capable of generating—directly or indirectly—a detectable signal. The label is preferably an enzyme, a radioactive isotope, a fluorescent group, a dye, a chemiluminescent molecule or a heavy metal such as gold.

[0084] In another embodiment, the invention employs the detection of the primary antibody by immunochemical reaction with specific so-called secondary antibodies capable of reacting specifically with the primary antibodies. In this case the secondary antibodies can be labelled with an appropriate label such as an enzyme, a radioactive isotope, a fluorescent group, a dye, a chemiluminescent molecule or a heavy metal such as gold.

[0085] In yet another embodiment, the present invention employs a so-called linker antibody as a means of detection of the steroid hormone. This embodiment exploits that the immunochemical reaction between the steroid hormone and the primary antibody is mediated by another immunochemical reaction involving the specific linker antibody capable of reacting simultaneously with both the primary antibody as well as another antibody to which enzymes have been attached via an immunochemical reaction, or via covalent coupling and the like.

[0086] In yet another embodiment according to the present invention, the immunochemical reaction between the steroid hormone and the primary antibody, or alternatively, between the primary antibody and the secondary antibody, is detected by means of a binding of pairs of complementary molecules other than antigens and antibodies. A complementary pair such as e.g. biotin and streptavidin is preferred. In this embodiment, one member of the complementary pair is attached to the primary or secondary antibody, and the other member of the complementary pair is contacted by any suitable label such as e.g. an enzymes, a radioactive isotope, a fluorescent group, a dye or a heavy metal such as gold.

[0087] In a preferred embodiment the assay takes advantage of the specific interaction between steroid hormones and steroid hormone binding proteins and/or the specific interaction between steroid hormone binding proteins and steroid hormone binding protein receptors or a steroid hormone binding protein co-receptors. Such an assay involves the use of one or more purified species selected from the group consisting of steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors and fragments thereof and functional homologues thereof.

[0088] In such an assay at least one of either steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors, a steroid hormone binding protein co-receptors or fragments thereof is labelled with an appropriate label capable of generating—directly or indirectly—a detectable signal. The label is preferably an enzyme, a radioactive isotope, a fluorescent group, a dye, a chemiluminescent molecule or a heavy metal such as gold. However, it is also contained within the present invention that more than one such as for example two or for example three, such as all four of steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors, a steroid hormone binding protein co-receptor or fragments thereof are labelled with a detectable label: Said detectable label may be the same for two or more species or it may be a different label for each species.

[0089] It is preferred that at least one of either steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors, a steroid hormone binding protein co-receptors or fragments thereof is immobilised on a solid support. More preferably, steroid hormone binding protein receptors or fragments thereof are immobilised. Immobilisation may be achieved by any standard method known to the person skilled in the art useful for the solid support of the specific application. The solid support can be any solid support suitable for such an assay. In some embodiments of the present invention a suitable solid support is for example a microtiter plate or a carboxymethylated dextran-gold surface.

[0090] Preferably, such an assay is a non-radioactive microtiter plate assay using purified steroid hormone binding protein receptors or fragments thereof immobilised on the plate surface.

[0091] In one preferred embodiment of the present invention the assay comprises the steps of

[0092] providing a non-radioactive microtiter plate having purified steroid hormone binding protein receptors or fragments thereof immobilised on the plate surface,

[0093] incubating the plate with the compound to be tested, and

[0094] incubating the plate with fluorescent labelled steroid binding proteins or fragments thereof and/or with fluorescent labelled steroid hormones,

[0095] determining the amount of fluorescence of the plate.

[0096] However, in another preferred embodiment the solid support is a carboxymethylated dextran-gold surface and the assay is a surface plasmon resonance analysis comprising the steps of

[0097] i) Immobilising purified steroid hormone binding protein receptor and/or fragments thereof on a carboxymethylated dextran-gold surface.

[0098] ii) Injecting the compound to be tested over the dextran-gold surface

[0099] iii) measuring the kinetics of binding in real time.

[0100] In one embodiment of the present invention the assay is a biological assay. For example such an assay comprises the steps of

[0101] a) Providing a cell which comprises a steroid hormone protein binding receptor, a steroid hormone nuclear receptor and a first nucleic acid sequence encoding a directly or indirectly detectable protein, said first nucleic acid sequence being operably linked to a second nucleic acid sequence, which can direct transcription depending on the presence of steroid hormone nuclear receptor complexed with steroid hormone.

[0102] b) Detecting said detectable protein.

[0103] c) Correlating the amount of detectable protein to the uptake of steroid hormone into said cell.

[0104] Such a cell could be any cell suitable for such an assay, for example the cell could be a cell of mammalian origin cultured in vitro or it could be a cell of mammalian origin comprised within a mammal. However, the cell could also be another cell, such as for example any other eukaryotic cell or prokaryotic cell. Examples of useful eukaryotic cells other than mammalian cells are yeast cells or an insect cells.

[0105] The steroid hormone nuclear receptor should be selected according to the individual need in a way such as it associates with the steroid hormone of the particular embodiment of the present invention.

[0106] The second nucleic acid sequence should be selected such as it can direct transcription in the cell of the particular embodiment depending on the presence of steroid hormone nuclear receptor complexed with steroid hormone. Preferably such a nucleic acid sequence comprises a minimal promoter sequence and steroid hormone nuclear receptor responsive elements. These steroid hormone nuclear receptor responsive elements should be selected according to the steroid hormone nuclear receptor of the particular embodiment.

[0107] Said detectable protein may be selected from any useful detectable protein depending on the particular assay. For example such a protein could be an enzyme or it could be a fluorescent protein. Examples of useful enzymes are luciferase or peroxidase. Examples of fluorescent proteins are green fluorescent protein (GFP), yellow fluorescent protein (YFP), blue fluorescent protein (BFP) and derivatives thereof. Preferably, the detectable protein is selected from the group consisting of luciferase and GFP.

[0108] The compound according to the present invention may be a nucleic acid sequence which potentially alters the expression of a steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor. If the compound according to the present invention is a nucleic acid sequence, which potentially is capable of decreasing the expression of a steroid hormone binding protein receptor and/or a steroid hormone binding protein co-receptor (see herein below) the assay preferably includes a cell normally expressing the steroid hormone binding protein receptor and/or the steroid hormone binding protein co-receptor.

[0109] In one embodiment such an assay comprise the following steps:

[0110] a) introducing the nucleic acid sequence into the cell expressing the steroid hormone binding protein receptor

[0111] b) detecting the presence of the steroid hormone binding protein receptor in the cell

[0112] In another embodiment the nucleic acid sequence potentially increase the expression of either steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor. In that case the assay may comprise the steps of:

[0113] a) introducing one or more nucleic acid sequences into a cell, wherein the nucleic acids encode for one or more

[0114] i) steroid hormone binding protein receptors; or

[0115] ii) steroid hormone binding protein co-receptors; or

[0116] iii) steroid hormone binding protein receptors and steroid hormone binding protein co-receptors

[0117] b) detecting the presence of steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor in said cell.

[0118] Preferably, when nucleic acid sequences according to step ii) are employed, the cell should express a steroid hormone binding protein receptor endogenously.

[0119] Nucleic acid sequences may be introduced into the cell by any standard method known to the person skilled in the art. For example transfer of a nucleic acid sequence into a cell can be accomplished by electroporation, microinjection, lipofection with for example cationic liposomes, calcium phosphate precipitation, viral transfer, retroviral transfer, adsorption or bio-ballistic transfer by for example coated gold particles. In particular, electroporation, lipofection or viral transfer are preferred methods.

[0120] Detection of the steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor in the cell can be done by a number of methods known to the person skilled in the art. For example such a method could involve immunoreactive species such as for example antibodies or fragments thereof. In particular such a method could comprise a first antibody interacting specifically with the steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor. Said first antibody could comprise a directly or indirectly detectable label or the assay could further involve a second antibody, which comprises a directly or indirectly detectable label and which reacts specifically with the first antibody. In a preferred embodiment the steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor is detected by a method which involves the use of steroid hormones and/or steroid hormone binding proteins, wherein one and/or both comprise a directly or indirectly detectable label.

[0121] The present invention also relates to methods for determining the effect of a compound on uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor following administration of said compound to a mammal naturally expressing the receptor.

[0122] Such a method involves for example measuring expression of receptor mRNA or protein in tissues of the mammal or measuring receptor-mediated binding or transport of steroid hormones bound to or complexed with steroid hormone binding proteins.

[0123] Measuring expression of protein in tissues of the mammal can be done by any of the assays as outlined herein above. In particular, the assay may involve the use of immunoreactive species or the assay may involve the use of one or more purified species selected from the group consisting of steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors, steroid hormone binding protein co-receptor and fragments thereof and functional homologues thereof.

[0124] Measuring of mRNA may be done according to any standard protocol known to the person skilled in the art. For example such an assay could be a Northern blotting assay using a nucleic acid sequence derived from the receptor of the particular embodiment as probe. The probe should be labelled with a directly or indirectly detectable label, for example a radioactive species or an enzyme. Another example of such an assay is reverse transcription polymerase chain reaction (RT-PCR). Such an RT-PCR would involve the use of specific primers chosen according to the receptor of the particular embodiment.

[0125] Determining transport of steroid hormones bound to or complexed with steroid hormone binding proteins can be done by a number of assays including the assays outlined herein above. In particular, the assay may involve the use of immunoreactive species or the assay may involve the use of one or more purified species selected from the group consisting of steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors, steroid hormone binding protein co-receptors and fragments thereof and functional homologues thereof. Furthermore, such an assay may be a biological assay as outlined herein above.

[0126] Animals Lacking Expression of a Steroid Hormone Binding Protein Receptor

[0127] In one aspect the present invention relates to animals lacking expression of one or more steroid hormone binding protein receptor(s) and/or co-receptor(s) and/or steroid hormone binding proteins and to the use of such animals for example for testing the compounds of the invention.

[0128] For example, said animals may have been genetically engineered so they lack or carry a non-functional gene for said steroid hormone binding protein receptor and/or co-receptor or for the steroid hormone binding protein itself. An example of an animal lacking a steroid hormone binding protein receptor is described in example 3.

[0129] In another example, said animals may have been genetically engineered so they lack or carry a non-functional gene for said steroid hormone binding protein receptor and/or co-receptor only in specific selected tissues, i.e. tissue specific knock out. An example of tissue specific knock out is given in example 6.

[0130] The animal may be any animal such as a mammal, however frequently it is preferred that the animal is a rodent, preferably a mouse.

[0131] In one embodiment of the present invention said animal may be used in a method for determining the effect of a compound on uptake of steroid hormones into cells via a steroid hormone binding protein receptor. In particular said animal may be used as a negative control in such a method.

[0132] For example, the method may comprise the step of administering said compound to a mammal, such as a mouse lacking expression of said steroid hormone binding protein receptor. For example, said mammal may only lack expression of said steroid hormone binding protein receptor in one or more selected tissues. The method may further comprise a step of measuring the uptake of one or more steroid hormones or one or more steroid hormone/steroid hormone binding protein complexes into cells of said animal. The method may further comprise a step of comparing said uptake with the uptake of one or more steroid hormones or one or more steroid hormone/steroid hormone binding protein complexes into cells of an animal expressing said steroid hormone binding protein receptor.

[0133] Compounds

[0134] The compounds according to the present invention, which alter the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor are preferably identified by the methods outlined herein above. The compounds could for example be polypeptides, nucleic acids or small organic molecules.

[0135] In one embodiment the compound competitively inhibits the binding or complexing of a steroid hormone to a steroid hormone binding protein. Such a compound could for example be a compound that specifically interacts with either the steroid hormone or with the steroid hormone binding protein in a way that sterically inhibits further association with either the steroid hormone or with the steroid hormone binding protein.

[0136] In another embodiment the compound competitively inhibits the binding of a steroid hormone binding protein to a steroid hormone binding protein receptor. Such a compound could for example be a compound that specifically interacts with either the steroid hormone protein or with the steroid hormone binding protein receptor in a way that sterically inhibits further association with either the steroid hormone protein or with the steroid hormone binding protein receptor.

[0137] In yet another embodiment the compound competitively inhibits the binding of a steroid hormone binding protein to a steroid hormone binding protein co-receptor.

[0138] In a still further embodiment of the present invention the compound increases the uptake of the steroid hormone.

[0139] In yet a further embodiment the compound alters dimerisation of steroid hormone binding proteins, such as it increases dimerisation of steroid hormone binding proteins.

[0140] In still another embodiment the compound has the potential to alter the expression of a steroid hormone binding protein receptor in a cell. For example, the compound may decrease the expression of a steroid hormone binding protein receptor in a cell normally expressing such a steroid hormone binding protein receptor or alternatively the compound may increase the expression of a steroid hormone binding protein receptor in a cell.

[0141] Furthermore, the compound according to the present invention may have the potential to alter the expression of a steroid hormone binding protein co-receptor in a cell. For example, the compound may decrease the expression of a steroid hormone binding protein co-receptor in a cell normally expressing such a steroid hormone binding protein receptor or alternatively the compound may increase the expression of a steroid hormone binding protein co-receptor in a cell.

[0142] The compound according to the present invention can be selected from a library of naturally occurring and synthetic compounds, which are randomly tested for alteration of the binding.

[0143] In one embodiment of the present invention, the compound is a polypeptide. For example such polypeptides could be selected from the group consisting of steroid hormone binding protein receptor domains and fragments thereof, steroid hormone binding protein co-receptor domains and fragments thereof, natural steroid hormone binding protein receptor ligands, modified steroid hormone binding proteins or fragments thereof, fragments of steroid hormone binding proteins, steroid hormone binding protein receptor antagonists, such as receptor associated protein (RAP; see table 4), and functional homologues of any of these.

[0144] In one preferred embodiment of the present invention the compound is a steroid hormone binding protein receptor domain. Preferably, said steroid hormone binding protein receptor domain is capable of binding a steroid hormone binding protein.

[0145] It has been shown that complement type repeats of LRP are capable of binding a protein designated RAP. More specifically everyone of the 8 complement type repeats of cluster 11 of LRP are able to bind RAP with the exception of repeat 8, which differs from the rest in that it lacks a negatively charged amino acid (Andersen et al., 2000, J. Biol. Chem. 275:21017-21024).

[0146] Accordingly, it is preferred that the steroid hormone binding protein receptor domain comprise at least one complement type repeat, more preferably, at least two complement type repeats. However, it is also contained within the present invention that the steroid hormone binding protein receptor domain comprise 2 complement type repeats, such as 3 complement type repeats, for example 4 complement type repeats, such as 5 complement type repeats, for example 6 complement type repeats, such as 7 complement type repeats, for example 8 complement type repeats, such as 9 complement type repeats, for example 10 complement type repeats, such as 11 complement type repeats, for example more than 11 complement type repeats. In a preferred embodiment the steroid hormone binding protein receptor domain comprises 2 complement-type repeats.

[0147] A model of the domain structure of a number of steroid hormone binding protein receptors is given in FIG. 6.

[0148] The complement type repeats preferably comprise approximately 40 amino acids, more preferably 40 amino acids, which comprise the following pattern of three disulfide bridges: CysI-CysII, Cysil-CysV and CysIV-Cys VI, wherein the roman numbers designate relative sequence position of conserved cysteine residues within the complement repeat. Furthermore, each complement type repeat preferably comprises a negatively charged amino acid residue, preferably, said negatively charged amino acid residue is placed between CysIV and CysV, more preferably it is placed in the centre position between CysIV and CysV. The negatively charged acidic amino acid residue is preferably selected from the group consisting of Asp and Glu.

[0149] In one embodiment the steroid hormone binding protein receptor domain comprises fragments of the MEGF7 polypeptide sequence (SEQ ID NO: 2). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 0.600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1576 of the MEGF7 polypeptide sequence (SEQ ID NO: 2).

[0150] In another embodiment the steroid hormone binding protein receptor domain essentially consists of or preferably consists of fragments of the MEGF7 polypeptide sequence (SEQ ID NO: 2). For example such a fragment may consist of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1576 of the MEGF7 polypeptide sequence (SEQ ID NO: 2).

[0151] In another embodiment the steroid hormone binding protein receptor domain comprise fragments of the megalin polypeptide sequence (SEQ ID NO: 3). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to. 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 2650 to 2700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2875, for example amino acid 2850 to 2900, such as amino acid 2875 to 2925, for example amino acid 2900 to 2950, such as amino acid 2925 to 2975, for example amino acid 2950 to 3000, such as amino acid 2975 to 3025, amino acid 3001 to 3050, such as amino acid 3025 to 3075, for example amino acid 3050 to 3100, such as amino acid 3075 to 3125, for example amino acid 3100 to 3150, such as amino acid 3125 to 3175, for example amino acid 3150 to 3200, such as amino acid 3175 to 3225, for example amino acid 3200 to 3250, such as amino acid 3225 to 3275, for example amino acid 3250 to 3300, such as amino acid 3275 to 3325, for example amino acid 3300 to 3350, such as amino acid 3325 to 3375, for example amino acid 3350 to 3400, such as amino acid 3375 to 3425, for example amino acid 3400 to 3450, such as amino acid 3425 to 3475, for example amino acid 3450 to 3500, such as amino acid 3475 to 3525, for example amino acid 3500 to 3550, such as amino acid 3525 to 3575, for example amino acid 3550 to 3600, such as amino acid 3575 to 3625, for example amino acid 3600 to 3650, such as amino acid 3625 to 3675, for example amino acid 3650 to 3700, such as amino acid 3675 to 3725, for example amino acid 3700 to 3750, such as amino acid 3725 to 3775, for example amino acid 3750 to 3800, such as amino acid 3775 to 3825, for example amino acid 3800 to 3850, such as amino acid 3825 to 3875, for example amino acid 3850 to 3900, such as amino acid 3875 to 3925, for example amino acid 3900 to 3950, such as amino acid 3925 to 3975, for example amino acid 3950 to 4000, such as amino acid 3975 to 4025, amino acid 4001 to 4050, such as amino acid 4025 to 4075, for example amino acid 4050 to 4100, such as amino acid 4075 to 4125, for example amino acid 4100 to 4150, such as amino acid 4125 to 4175, for example amino acid 4150 to 4200, such as amino acid 4175 to 4225, for example amino acid 4200 to 4250, such as amino acid 4225 to 4275, for example amino acid 4250 to 4300, such as amino acid 4275 to 4325, for example amino acid 4300 to 4350, such as amino acid 4325 to 4375, for example amino acid 4350 to 4400, such as amino acid 4375 to 4425, for example amino acid 4400 to 4450, such as amino acid 4425 to 4475, for example amino acid 4450 to 4500, such as amino acid 4475 to 4525, for example amino acid 4500 to 4550, such as amino acid 4525 to 4575, for example amino acid 4550 to 4600, such as amino acid 4575 to 4625, for example amino acid 4600 to 4655 of the megalin polypeptide sequence (SEQ ID NO: 3).

[0152] In another embodiment the steroid hormone binding protein receptor domain essentially consists of or preferably consists of fragments of the megalin polypeptide sequence (SEQ ID NO: 3). For example such a fragment may consist of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 2650 to 2700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2875, for example amino acid 2850 to 2900, such as amino acid 2875 to 2925, for example amino acid 2900 to 2950, such as amino acid 2925 to 2975, for example amino acid 2950 to 3000, such as amino acid 2975 to 3025, amino acid 3001 to 3050, such as amino acid 3025 to 3075, for example amino acid 3050 to 3100, such as amino acid 3075 to 3125, for example amino acid 3100 to 3150, such as amino acid 3125 to 3175, for example amino acid 3150 to 3200, such as amino acid 3175 to 3225, for example amino acid 3200 to 3250, such as amino acid 3225 to 3275, for example amino acid 3250 to 3300, such as amino acid 3275 to 3325, for example amino acid 3300 to 3350, such as amino acid 3325 to 3375, for example amino acid 3350 to 3400, such as amino acid 3375 to 3425, for example amino acid 3400 to 3450, such as amino acid 3425 to 3475, for example amino acid 3450 to 3500, such as amino acid 3475 to 3525, for example amino acid 3500 to 3550, such as amino acid 3525 to 3575, for example amino acid 3550 to 3600, such as amino acid 3575 to 3625, for example amino acid 3600 to 3650, such as amino acid 3625 to 3675, for example amino acid 3650 to 3700, such as amino acid 3675 to 3725, for example amino acid 3700 to 3750, such as amino acid 3725 to 3775, for example amino acid 3750 to 3800, such as amino acid 3775 to 3825, for example amino acid 3800 to 3850, such as amino acid 3825 to 3875, for example amino acid 3850 to 3900, such as amino acid 3875 to 3925, for example amino acid 3900 to 3950, such as amino acid 3925 to 3975, for example amino acid 3950 to 4000, such as amino acid 3975 to 4025, amino acid 4001 to 4050, such as amino acid 4025 to 4075, for example amino acid 4050 to 4100, such as amino acid 4075 to 4125, for example amino acid 4100 to 4150, such as amino acid 4125 to 4175, for example amino acid 4150 to 4200, such as amino acid 4175 to 4225, for example amino acid 4200 to 4250, such as amino acid 4225 to 4275, for example amino acid 4250 to 4300, such as amino acid 4275 to 4325, for example amino acid 4300 to 4350, such as amino acid 4325 to 4375, for example amino acid 4350 to 4400, such as amino acid 4375 to 4425, for example amino acid 4400 to 4450, such as amino acid 4425 to 4475, for example amino acid 4450 to 4500, such as amino acid 4475 to 4525, for example amino acid 4500 to 4550, such as amino acid 4525 to 4575, for example amino acid 4550 to 4600, such as amino acid 4575 to 4625, for example amino acid 4600 to 4655 of the megalin polypeptide sequence (SEQ ID NO: 3).

[0153] In another embodiment the steroid hormone binding protein receptor domain comprises fragments of the LRP1B polypeptide sequence (SEQ ID NO: 4). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 650 to 700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2875, for example amino acid 2850 to 2900, such as amino acid 2875 to 2925, for example amino acid 2900 to 2950, such as amino acid 2925 to 2975, for example amino acid 2950 to 3000, such as amino acid 2975 to 3025, amino acid 3001 to 3050, such as amino acid 3025 to 3075, for example amino acid 3050 to 3100, such as amino acid 3075 to 3125, for example amino acid 3100 to 3150, such as amino acid 3125 to 3175, for example amino acid 3150 to 3200, such as amino acid 3175 to 3225, for example amino acid 3200 to 3250, such as amino acid 3225 to 3275, for example amino acid 3250 to 3300, such as amino acid 3275 to 3325, for example amino acid 3300 to 3350, such as amino acid 3325 to 3375, for example amino acid 3350 to 3400, such as amino acid 3375 to 3425, for example amino acid 3400 to 3450, such as amino acid 3425 to 3475, for example amino acid 3450 to 3500, such as amino acid 3475 to 3525, for example amino acid 3500 to 3550, such as amino acid 3525 to 3575, for example amino acid 3550 to 3600, such as amino acid 3575 to 3625, for example amino acid 3600 to 3650, such as amino acid 3625 to 3675, for example amino acid 3650 to 3700, such as amino acid 3675 to 3725, for example amino acid 3700 to 3750, such as amino acid 3725 to 3775, for example amino acid 3750 to 3800, such as amino acid 3775 to 3825, for example amino acid 3800 to 3850, such as amino acid 3825 to 3875, for example amino acid 3850 to 3900, such as amino acid 3875 to 3925, for example amino acid 3900 to 3950, such as amino acid 3925 to 3975, for example amino acid 3950 to 4000, such as amino acid 3975 to 4025, amino acid 4001 to 4050, such as amino acid 4025 to 4075, for example amino acid 4050 to 4100, such as amino acid 4075 to 4125, for example amino acid 4100 to 4150, such as amino acid 4125 to 4175, for example amino acid 4150 to 4200, such as amino acid 4175 to 4225, for example amino acid 4200 to 4250, such as amino acid 4225 to 4275, for example amino acid 4250 to 4300, such as amino acid 4275 to 4325, for example amino acid 4300 to 4350, such as amino acid 4325 to 4375, for example amino acid 4350 to 4400, such as amino acid 4375 to 4425, for example amino acid 4400 to 4450, such as amino acid 4425 to 4475, for example amino acid 4450 to 4500, such as amino acid 4475 to 4525, for example amino acid 4500 to 4550, such as amino acid 4525 to 4575, for example amino acid 4550 to 4599 of the LRP1 B polypeptide sequence (SEQ ID NO: 4).

[0154] In another embodiment the steroid hormone binding protein receptor domain essentially consists of or preferably consists of fragments of the LRP1 B polypeptide sequence (SEQ ID NO: 4). For example such a fragment may consist of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 2650 to 2700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2875, for example amino acid 2850 to 2900, such as amino acid 2875 to 2925, for example amino acid 2900 to 2950, such as amino acid 2925 to 2975, for example amino acid 2950 to 3000, such as amino acid 2975 to 3025, amino acid 3001 to 3050, such as amino acid 3025 to 3075, for example amino acid 3050 to 3100, such as amino acid 3075 to 3125, for example amino acid 3100 to 3150, such as amino acid 3125 to 3175, for example amino acid 3150 to 3200, such as amino acid 3175 to 3225, for example amino acid 3200 to 3250, such as amino acid 3225 to 3275, for example amino acid 3250 to 3300, such as amino acid 3275 to 3325, for example amino acid 3300 to 3350, such as amino acid 3325 to 3375, for example amino acid 3350 to 3400, such as amino acid 3375 to 3425, for example amino acid 3400 to 3450, such as amino acid 3425 to 3475, for example amino acid 3450 to 3500, such as amino acid 3475 to 3525, for example amino acid 3500 to 3550, such as amino acid 3525 to 3575, for example amino acid 3550 to 3600, such as amino acid 3575 to 3625, for example amino acid 3600 to 3650, such as amino acid 3625 to 3675, for example amino acid 3650 to 3700, such as amino acid 3675 to 3725, for example amino acid 3700 to 3750, such as amino acid 3725 to 3775, for example amino acid 3750 to 3800, such as amino acid 3775 to 3825, for example amino acid 3800 to 3850, such as amino acid 3825 to 3875, for example amino acid 3850 to 3900, such as amino acid 3875 to 3925, for example amino acid 3900 to 3950, such as amino acid 3925 to 3975, for example amino acid 3950 to 4000, such as amino acid 3975 to 4025, amino acid 4001 to 4050, such as amino acid 4025 to 4075, for example amino acid 4050 to 4100, such as amino acid 4075 to 4125, for example amino acid 4100 to 4150, such as amino acid 4125 to 4175, for example amino acid 4150 to 4200, such as amino acid 4175 to 4225, for example amino acid 4200 to 4250, such as amino acid 4225 to 4275, for example amino acid 4250 to 4300, such as amino acid 4275 to 4325, for example amino acid 4300 to 4350, such as amino acid 4325 to 4375, for example amino acid 4350 to 4400, such as amino acid 4375 to 4425, for example amino acid 4400 to 4450, such as amino acid 4425 to 4475, for example amino acid 4450 to 4500, such as amino acid 4475 to 4525, for example amino acid 4500 to 4550, such as amino acid 4525 to 4575, for example amino acid 4550 to 4599 of the LRP1 B polypeptide sequence (SEQ ID NO: 4).

[0155] In one embodiment the steroid hormone binding protein receptor domain comprises fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 963 of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5).

[0156] In one embodiment the steroid hormone binding protein receptor domain essentially consists of or preferably consists of fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5). For example such a fragment may essentially consists of or preferably consists of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino-acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 963 of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5).

[0157] In another embodiment the steroid hormone binding protein receptor domain comprises fragments of the LRP polypeptide sequence (SEQ ID NO: 6). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 650 to 700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2875, for example amino acid 2850 to 2900, such as amino acid 2875 to 2925, for example amino acid 2900 to 2950, such as amino acid 2925 to 2975, for example amino acid 2950 to 3000, such as amino acid 2975 to 3025, amino acid 3001 to 3050, such as amino acid 3025 to 3075, for example amino acid 3050 to 3100, such as amino acid 3075 to 3125, for example amino acid 3100 to 3150, such as amino acid 3125 to 3175, for example amino acid 3150 to 3200, such as amino acid 3175 to 3225, for example amino acid 3200 to 3250, such as amino acid 3225 to 3275, for example amino acid 3250 to 3300, such as amino acid 3275 to 3325, for example amino acid 3300 to 3350, such as amino acid 3325 to 3375, for example amino acid 3350 to 3400, such as amino acid 3375 to 3425, for example amino acid 3400 to 3450, such as amino acid 3425 to 3475, for example amino acid 3450 to 3500, such as amino acid 3475 to 3525, for example amino acid 3500 to 3550, such as amino acid 3525 to 3575, for example amino acid 3550 to 3600, such as amino acid 3575 to 3625, for example amino acid 3600 to 3650, such as amino acid 3625 to 3675, for example amino acid 3650 to 3700, such as amino acid 3675 to 3725, for example amino acid 3700 to 3750, such as amino acid 3725 to 3775, for example amino acid 3750 to 3800, such as amino acid 3775 to 3825, for example amino acid 3800 to 3850, such as amino acid 3825 to 3875, for example amino acid 3850 to 3900, such as amino acid 3875 to 3925, for example amino acid 3900 to 3950, such as amino acid 3925 to 3975, for example amino acid 3950 to 4000, such as amino acid 3975 to 4025, amino acid 4001 to 4050, such as amino acid 4025 to 4075, for example amino acid 4050 to 4100, such as amino acid 4075 to 4125, for example amino acid 4100 to 4150, such as amino acid 4125 to 4175, for example amino acid 4150 to 4200, such as amino acid 4175 to 4225, for example amino acid 4200 to 4250, such as amino acid 4225 to 4275, for example amino acid 4250 to 4300, such as amino acid 4275 to 4325, for example amino acid 4300 to 4350, such as amino acid 4325 to 4375, for example amino acid 4350 to 4400, such as amino acid 4375 to 4425, for example amino acid 4400 to 4450, such as amino acid 4425 to 4475, for example amino acid 4450 to 4500, such as amino acid 4475 to 4525, for example amino acid 4500 to 4550, such as amino acid 4525 to 4575, for example amino acid 4550 to 4599 of the LRP polypeptide sequence (SEQ ID NO: 6).

[0158] In another embodiment the steroid hormone binding protein receptor domain essentially consists of or preferably consists of fragments of the LRP polypeptide sequence (SEQ ID NO: 6). For example such a fragment may essentially consist of or preferably consist of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 2650 to 2700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2875, for example amino acid 2850 to 2900, such as amino acid 2875 to 2925, for example amino acid 2900 to 2950, such as amino acid 2925 to 2975, for example amino acid 2950 to 3000, such as amino acid 2975 to 3025, amino acid 3001 to 3050, such as amino acid 3025 to 3075, for example amino acid 3050 to 3100, such as amino acid 3075 to 3125, for example amino acid 3100 to 3150, such as amino acid 3125 to 3175, for example amino acid 3150 to 3200, such as amino acid 3175 to 3225, for example amino acid 3200 to 3250, such as amino acid 3225 to 3275, for example amino acid 3250 to 3300, such as amino acid 3275 to 3325, for example amino acid 3300 to 3350, such as amino acid 3325 to 3375, for example amino acid 3350 to 3400, such as amino acid 3375 to 3425, for example amino acid 3400 to 3450, such as amino acid 3425 to 3475, for example amino acid 3450 to 3500, such as amino acid 3475 to 3525, for example amino acid 3500 to 3550, such as amino acid 3525 to 3575, for example amino acid 3550 to 3600, such as amino acid 3575 to 3625, for example amino acid 3600 to 3650, such as amino acid 3625 to 3675, for example amino acid 3650 to 3700, such as amino acid 3675 to 3725, for example amino acid 3700 to 3750, such as amino acid 3725 to 3775, for example amino acid 3750 to 3800, such as amino acid 3775 to 3825, for example amino acid 3800 to 3850, such as amino acid 3825 to 3875, for example amino acid 3850 to 3900, such as amino acid 3875 to 3925, for example amino acid 3900 to 3950, such as amino acid 3925 to 3975, for example amino acid 3950 to 4000, such as amino acid 3975 to 4025, amino acid 4001 to 4050, such as amino acid 4025 to 4075, for example amino acid 4050 to 4100, such as amino acid 4075 to 4125, for example amino acid 4100 to 4150, such as amino acid 4125 to 4175, for example amino acid 4150 to 4200, such as amino acid 4175 to 4225, for example amino acid 4200 to 4250, such as amino acid 4225 to 4275, for example amino acid 4250 to 4300, such as amino acid 4275 to 4325, for example amino acid 4300 to 4350, such as amino acid 4325 to 4375, for example amino acid 4350 to 4400, such as amino acid 4375 to 4425, for example amino acid 4400 to 4450, such as amino acid 4425 to 4475, for example amino acid 4450 to 4500, such as amino acid 4475 to 4525, for example amino acid 4500 to 4550, such as amino acid 4525 to 4575, for example amino acid 4550 to 4599 of the LRP polypeptide sequence (SEQ ID NO: 6).

[0159] In another embodiment the steroid hormone binding protein receptor domain comprises fragments of VLDL receptor polypeptide sequence (SEQ ID NO: 7). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 873 of the VLDL receptor polypeptide sequence (SEQ ID NO: 7).

[0160] In another embodiment the steroid hormone binding protein receptor domain essentially consists of or preferably consists of fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7). For example such a fragment may essentially consist of or preferably consist of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 873 of the VLDL receptor polypeptide sequence (SEQ ID NO: 7).

[0161] Preferably, the steroid hormone binding protein receptor domain is selected from the group consisting of fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5), fragments of the megalin polypeptide sequence (SEQ ID NO: 3) and fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7) as outlined above.

[0162] The compound according to the present invention may also be a polypeptide, wherein said polypeptide is a domain of a steroid hormone binding protein co-receptor. Preferably, such a domain is capable of associating with either a steroid hormone binding protein and/or a steroid hormone binding protein receptor. More preferably, the domain only associates with a steroid hormone binding protein or a steroid hormone binding protein receptor, but not both. Accordingly, such a polypeptide could competitively inhibit the association between a steroid hormone binding protein and a steroid hormone binding protein co-receptor or the association between a steroid hormone binding protein co-receptor and a steroid hormone binding protein receptor, which would result in decreased uptake of steroid hormone into cells.

[0163] In one embodiment the steroid hormone binding protein co-receptor domain comprises fragments of the cubilin polypeptide sequence (SEQ ID NO: 8). For example such a fragment may comprise amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350 such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid-1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 650 to 700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2887 of the cubilin polypeptide sequence (SEQ ID NO: 8).

[0164] In another embodiment the steroid hormone binding protein co-receptor domain essentially consists of or preferably consists of fragments of the cubilin polypeptide sequence (SEQ ID NO: 8). For example such a fragment may essentially consist of or preferably consist of amino acid 1 to 50, such as amino acid 25 to 75, for example amino acid 50 to 100, such as amino acid 75 to 125, for example amino acid 100 to 150, such as amino acid 125 to 175, for example amino acid 150 to 200, such as amino acid 175 to 225, for example amino acid 200 to 250, such as amino acid 225 to 275, for example amino acid 250 to 300, such as amino acid 275 to 325, for example amino acid 300 to 350, such as amino acid 325 to 375, for example amino acid 350 to 400, such as amino acid 375 to 425, for example amino acid 400 to 450, such as amino acid 425 to 475, for example amino acid 450 to 500, such as amino acid 475 to 525, for example amino acid 500 to 550, such as amino acid 525 to 575, for example amino acid 550 to 600, such as amino acid 575 to 625, for example amino acid 600 to 650, such as amino acid 625 to 675, for example amino acid 650 to 700, such as amino acid 675 to 725, for example amino acid 700 to 750, such as amino acid 725 to 775, for example amino acid 750 to 800, such as amino acid 775 to 825, for example amino acid 800 to 850, such as amino acid 825 to 875, for example amino acid 850 to 900, such as amino acid 875 to 925, for example amino acid 900 to 950, such as amino acid 925 to 975, for example amino acid 950 to 1000, such as amino acid 975 to 1025, 1000 to 1050, such as amino acid 1025 to 1075, for example amino acid 1050 to 1100, such as amino acid 1075 to 1125, for example amino acid 1100 to 1150, such as amino acid 1125 to 1175, for example amino acid 1150 to 1200, such as amino acid 1175 to 1225, for example amino acid 1200 to 1250, such as amino acid 1225 to 1275, for example amino acid 1250 to 1300, such as amino acid 1275 to 1325, for example amino acid 1300 to 1350, such as amino acid 1325 to 1375, for example amino acid 1350 to 1400, such as amino acid 1375 to 1425, for example amino acid 1400 to 1450, such as amino acid 1425 to 1475, for example amino acid 1450 to 1500, such as amino acid 1475 to 1525, for example amino acid 1500 to 1550, such as amino acid 1525 to 1575, for example amino acid 1550 to 1600, such as amino acid 1575 to 1625, for example amino acid 1600 to 1650, such as amino acid 1625 to 1675, for example amino acid 1650 to 1700, such as amino acid 1675 to 1725, for example amino acid 1700 to 1750, such as amino acid 1725 to 1775, for example amino acid 1750 to 1800, such as amino acid 1775 to 1825, for example amino acid 1800 to 1850, such as amino acid 1825 to 1875, for example amino acid 1850 to 1900, such as amino acid 1875 to 1925, for example amino acid 1900 to 1950, such as amino acid 1925 to 1975, for example amino acid 1950 to 2000, such as amino acid 1975 to 2025, amino acid 2001 to 2050, such as amino acid 2025 to 2075, for example amino acid 2050 to 2100, such as amino acid 2075 to 2125, for example amino acid 2100 to 2150, such as-amino acid 2125 to 2175, for example amino acid 2150 to 2200, such as amino acid 2175 to 2225, for example amino acid 2200 to 2250, such as amino acid 2225 to 2275, for example amino acid 2250 to 2300, such as amino acid 2275 to 2325, for example amino acid 2300 to 2350, such as amino acid 2325 to 2375, for example amino acid 2350 to 2400, such as amino acid 2375 to 2425, for example amino acid 2400 to 2450, such as amino acid 2425 to 2475, for example amino acid 2450 to 2500, such as amino acid 2475 to 2525, for example amino acid 2500 to 2550, such as amino acid 2525 to 2575, for example amino acid 2550 to 2600, such as amino acid 2575 to 2625, for example amino acid 2600 to 2650, such as amino acid 2625 to 2675, for example amino acid 2650 to 2700, such as amino acid 2675 to 2725, for example amino acid 2700 to 2750, such as amino acid 2725 to 2775, for example amino acid 2750 to 2800, such as amino acid 2775 to 2825, for example amino acid 2800 to 2850, such as amino acid 2825 to 2887 of the cubilin polypeptide sequence (SEQ ID NO: 8).

[0165] In another embodiment of the invention the polypeptide is a steroid hormone binding protein, for example SHBG.

[0166] In yet another preferred embodiment the polypeptide is a fragment of a steroid hormone binding protein. Preferably, such a fragment is capable of associating with a steroid hormone binding protein receptor or a with a steroid hormone binding protein co-receptor, more preferably, such a fragment is furthermore not capable of associating with a steroid hormone, i.e. the fragment can bind the steroid hormone binding protein receptor or the steroid hormone binding protein co-receptor and thereby inhibit binding of a steroid hormone binding protein/steroid hormone complex to said receptor/co-receptor.

[0167] In one embodiment of the present invention the steroid hormone binding protein domain is capable of associating with a steroid hormone binding protein receptor domain, preferably the steroid hormone binding protein domain is capable of associating a steroid hormone binding protein receptor domain comprising at least one complement-type repeat or even more preferably consisting of at least one complement-type repeat, such as one, for example 2, such as 3, for example 4, such as 5, for example 6, such as 7, for example 8, such as 9, for example 10, such as more than 10 complement-type repeats. The domain structure of selected examples of steroid hormone binding protein receptors is given in FIG. 6.

[0168] In one embodiment such a fragment comprise at least amino acid 47 to 167 of human SHBG (SEQ ID NO: 1), however more preferably the fragment comprise additionally 1 amino acid, such as at least 2 amino acids, for example at least 5 amino acids, such as at least 10 amino acid at the C-terminus and comprise additionally 1 amino acid, such as at least 2 amino acids, for example at least 5 amino acids, such as at least 10 amino acid at the N-terminus.

[0169] In another embodiment the fragment comprise amino acid 128-137 of human SHBG (SEQ ID NO: 1) and in yet another embodiment the fragment comprise amino acid 106 to amino acid 125 of human SHBG (SEQ ID NO: 1).

[0170] In one embodiment such a fragment consists of amino acid 47 to 167 of human SHBG (SEQ ID NO: 1), or for example the fragment consists of amino acid 128-137 of human SHBG (SEQ ID NO: 1) or the fragment consists of amino acid 106 to amino acid 125 of human SHBG (SEQ ID NO: 1).

[0171] Functional homologues of the above mentioned fragments of steroid hormone binding proteins are also within the scope of the present invention: Functional homologues are described in more detail herein below. It should be noted however, that fragments of SHBG as outlined herein above comprise the basic clusters:

[0172] Arg 47, Arg 166 and Arg 167

[0173] Lys 106, Arg 123 and Arg 125

[0174] and functional homologues preferably should be selected such as these basic clusters are maintained. Accordingly, the amino acid corresponding to: position 47 in the full length protein (SEQ ID NO: 1) is preferably selected from the group consisting of Arg and Lys, position 106 in the full length protein (SEQ ID NO: 1) is preferably selected from the group consisting of Arg and Lys, position 123 in the full length protein (SEQ ID NO: 1) is preferably selected from the group consisting of Arg and Lys, position 125 in the full length protein (SEQ ID NO: 1) is preferably selected from the group consisting of Arg and Lys, position 166 in the full length protein (SEQ ID NO: 1) is preferably selected from the group consisting of Arg and Lys, position 167 in the full length protein is preferably selected from the group consisting of Arg and Lys.

[0175] The compound according to the present invention could also be selected from the group comprising fragments of RAP that can associate with a steroid hormone binding protein receptor.

[0176] In one additional embodiment of the present invention, the compound is a nucleic acid sequence. Preferably, such a nucleic acid sequence potentially alters the expression of a steroid hormone binding protein receptor or a steroid hormone binding protein co-receptor.

[0177] In one preferred embodiment such a nucleic acid sequence comprise a DNA sequence encoding for an antisense RNA or a small interfering RNA (siRNA) of a steroid hormone binding protein receptor or the nucleic acid sequence is an antisense RNA of a steroid hormone binding protein receptor. Homologues thereof are also within the scope of the present invention. Alternatively, such a nucleic acid sequence could comprise a DNA sequence encoding for an antisense RNA of a steroid hormone binding protein co-receptor or the nucleic acid sequence is an antisense RNA of a steroid hormone binding protein co-receptor or homologues thereof.

[0178] Furthermore, the nucleic acid sequence may comprise an-antigene nucleic acid sequence, which is capable of hybridising with a gene encoding a steroid hormone binding protein receptor or a steroid hormone binding protein co-receptor and thereby inhibiting transcription of said gene. Said antigene nucleic acid sequence may be capable of hybridising to any part of said gene, for example to the promotor and/or to introns and/or to exons of sid gene. The antigene nucleic acid may be any kind of nucleic acid, for example DNA, RNA, LNA or PNA or siRNA.

[0179] In the context of the present invention the term “antisense RNA” is intended to encompass an RNA sequence transcribed from the non-coding DNA strand of a steroid hormone binding protein receptor or a steroid hormone binding protein co-receptor gene or an RNA sequence that is capable of hybridising to a steroid hormone binding protein receptor or a steroid hormone binding protein co-receptor mRNA under stringent conditions or fragments thereof.

[0180] Preferably, said antisense nucleic acid is capable of hybridising to a nucleic acid encoding a polypeptide as defined in any of SEQ ID 2, 3, 4, 5, 6, 7 or 8 or parts thereof under stringent conditions (see definition of stringent conditions herein below).

[0181] If the nucleic acid sequence is a DNA sequence encoding an antisense RNA of a steroid hormone binding protein receptor or steroid hormone binding protein co-receptor or homologues thereof, such a nucleotide sequence is preferably operably linked to nucleotide sequences that directs transcription of said DNA sequence in the cell of the particular embodiment of the invention.

[0182] In another embodiment the nucleic acid sequence comprises sequences encoding a steroid hormone binding protein receptor or steroid hormone binding protein co-receptor or homologues thereof or fragments thereof. Such a nucleic acid sequence is preferably operably linked to nucleotide sequences that directs transcription of said DNA sequence in the cell of the particular embodiment of the invention.

[0183] A variety of nucleotide sequences that directs transcription of DNA sequences are known to the person skilled in the art and such sequences should be selected according to the specific need in the individual case. For example such sequences could be promoter sequences and enhancer sequences of prokaryotic, eukaryotic or viral origin or they could be synthetic sequences.

[0184] The nucleic acid sequence may be comprised within a vector and any suitable vector known to the person skilled in the art may be employed with the present invention. A vector is cable of delivering the nucleic acid molecule into a host cell. Such a vector contains nucleic acid sequences that are not naturally found adjacent to the nucleic acid sequences of the present invention.

[0185] A vector is a replicable construct which could be any nucleic acid including DNA, RNA, LNA and PNA. Once transformed into a suitable host, the vector replicates and functions independently of the host genome, or may, in some instances, integrate into the genome itself.

[0186] Typically the vector is a viral derived vector, a retroviral derived vector, a phage, a plasmid, a cosmid, an integratable DNA fragment (i.e., integratable into the host genome by recombination), bacteria or eukaryotic cells.

[0187] Functional Homologues

[0188] Functional homologues of polypeptides according to the present invention is meant to comprise any polypeptide sequence which is capable of associating with a steroid hormone binding protein and/or steroid hormone binding protein receptor and/or steroid hormone binding protein co-receptor and thereby prevents association between the steroid hormone binding protein and/or the steroid hormone binding protein receptor or steroid hormone binding protein co-receptor.

[0189] Functional homologues according to the present invention comprise polypeptides with an amino acid sequence, which are sharing at least some homology with the predetermined polypeptide sequences as outlined herein above. For example such polypeptides are at least about 40 percent, such as at least about 50 percent homologous, for example at least about 60 percent homologous, such as at least about 70 percent homologous, for example at least about 75 percent homologous, such as at least about 80 percent homologous, for example at least about 85 percent homologous, such as at least about 90 percent homologous, for example at least 92 percent homologous, such as at least 94 percent homologous, for example at least 95 percent homologous, such as at least 96 percent homologous, for example at least 97 percent homologous, such as at least 98 percent homologous, for example at least 99 percent homologous with the predetermined polypeptide sequences as outlined herein above.

[0190] The homology between amino acid sequences may be calculated using well known algorithms such as for example any one of BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, and BLOSUM 90.

[0191] Functional homologues may comprise an amino acid sequence that comprises at least one substitution of one amino acid for any other amino acid. For example such a substitution may be a conservative amino acid substitution or it may be a non-conservative substitution.

[0192] A conservative amino acid substitution is a substitution of one amino acid within a predetermined group of amino acids for another amino acid within the same group, wherein the amino acids within predetermined groups exhibit similar or substantially similar characteristics. Within the meaning of the term “conservative amino acid substitution” as applied herein, one amino acid may be substituted for another within groups of amino acids characterised by having

[0193] i) polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gin, Ser, Thr, Tyr, and Cys,)

[0194] ii) non-polar side chains (Gly, Ala, Val, Leu, lie, Phe, Trp, Pro, and Met)

[0195] iii) aliphatic side chains (Gly, Ala Val, Leu, lie)

[0196] iv) cyclic side chains (Phe, Tyr, Trp, His, Pro)

[0197] v) aromatic side chains (Phe, Tyr, Trp)

[0198] vi) acidic side chains (Asp, Glu)

[0199] vii) basic side chains (Lys, Arg, His)

[0200] viii) amide side chains (Asn, Gln)

[0201] ix) hydroxy side chains (Ser, Thr)

[0202] x) sulphor-containing side chains (Cys, Met), and

[0203] xi) amino acids being monoamino-dicarboxylic acids or monoamino-monocarboxylic-monoamidocarboxylic acids (Asp, Glu, Asn, Gin).

[0204] Non-conservative substitutions are any other substitutions. A non-conservative substitution leading to the formation of a functional homologue would for example i) differ substantially in hydrophobicity, for example a hydrophobic residue (Val, Ile, Leu, Phe or Met) substituted for a hydrophilic residue such as Arg, Lys, Trp or Asn, or a hydrophilic residue such as Thr, Ser, His, Gln, Asn, Lys, Asp, Glu or Trp substituted for a hydrophobic residue; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

[0205] Functional homologues according to the present invention may comprise more than one such substitution, such as e.g. two amino acid substitutions, for example three or four amino acid substitutions, such as five or six amino acid substitutions, for example seven or eight amino acid substitutions, such as from 10 to 15 amino acid substitutions, for example from 15 to 25 amino acid substitution, such as from 25 to 30 amino acid substitutions, for example from 30 to 40 amino acid substitution, such as from 40 to 50 amino acid substitutions, for example from 50 to 75 amino acid substitution, such as from 75 to 100 amino acid substitutions, for example more than 100 amino acid substitutions.

[0206] The addition or deletion of an amino acid may be an addition or deletion of from 2 to 5 amino acids, such as from 5 to 10 amino acids, for example from 10 to 20 amino acids, such as from 20 to 50 amino acids. However, additions or deletions of more than 50 amino acids, such as additions from 50 to 200 amino acids, are also comprised within the present invention.

[0207] The polypeptides according to the present invention, including any variants and functional homologues thereof, may in one embodiment comprise more than 5 amino acid residues, such as more than 10 amino acid residues, for example more than 20 amino acid residues, such as more than 25 amino acid residues, for example more than 50 amino acid residues, such as more than 75 amino acid residues, for example more than 100 amino acid residues, such as more than 150 amino acid residues, for example more than 200 amino acid residues.

[0208] Additional factors may be taken into consideration when determining functional homologues according to the meaning used herein. For example functional homologues may be capable of associating with antisera which are specific for the polypeptides according to the present invention.

[0209] In a further embodiment the present invention relates to functional equivalents which comprise substituted amino acids having hydrophilic or hydropathic indices that are within +/−2.5, for example within +/−2.3, such as within +/−2.1, for example within +/−2.0, such as within +/−1.8, for example within +/−1.6, such as within +/−1.5, for example within +/−1.4, such as within +/−1.3 for example within +/−1.2, such as within +/−1.1, for example within +/−1.0, such as within +/−0.9, for example within +/−0.8, such as within +/−0.7, for example within +/−0.6, such as within +/−0.5, for example within +/−0.4, such as within +/−0.3, for example within +/−0.25, such as within +/−0.2 of the value of the amino acid it has substituted.

[0210] The importance of the hydrophilic and hydropathic amino acid indices in conferring interactive biologic function on a protein is well understood in the art (Kyte & Doolittle, 1982 and Hopp, U.S. Pat. No. 4,554,101, each incorporated herein by reference).

[0211] The amino acid hydropathic index values as used herein are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); rnethionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (4.5) (Kyte & Doolittle, 1982).

[0212] The amino acid hydrophilicity values are: arginine (+3.0); lysine (+3.0); aspartate (+3.0.+−0.1); glutamate (+3.0.+−0.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5 .+−0.1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4) (U.S. Pat. No. 4,554,101).

[0213] Substitution of amino acids can therefore in one embodiment be made based upon their hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

[0214] In addition to the polypeptide compounds described herein, sterically similar compounds may be formulated to mimic the key portions of the peptide structure and that such compounds may also be used in the same manner as the peptides of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. For example, esterification and other alkylations may be employed to modify the amino terminus of, e.g., a di-arginine peptide backbone, to mimic a tetra peptide structure. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

[0215] Peptides with N-terminal alkylations and C-terminal esterifications are also encompassed within the present invention. Functional equivalents also comprise glycosylated and covalent or aggregative conjugates, including dimers or unrelated chemical moieties. Such functional equivalents are prepared by linkage of functionalities to groups which are found in fragment including at any one or both of the N- and C-termini, by means known in the art.

[0216] Functional equivalents may thus comprise fragments conjugated to aliphatic or acyl esters or amides of the carboxyl terminus, alkylamines or residues containing carboxyl side chains, e.g., conjugates to alkylamines at aspartic acid residues; O-acyl derivatives of hydroxyl group-containing residues and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g. conjugates with Met-Leu-Phe. Derivatives of the acyl groups are selected from the group of alkyl-moieties (including C3 to C10 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known per se for use in cross-linking proteins to insoluble matrices through reactive side groups.

[0217] Homologues of nucleic acid sequences within the scope of the present invention are nucleic acid sequences, which encodes an RNA and/or a protein with similar biological function, and which is either

[0218] a) at least 50% identical, such as at least 60% identical, for example at least 70% identical, such as at least 75% identical, for example at least 80% identical, such as at least 85% identical, for example at least 90% identical, such as at least 95% identical

[0219] b) or able to hybridise to the complementary strand of said nucleic acid sequence under stringent conditions.

[0220] Stringent conditions as used herein shall denote stringency as normally applied in connection with Southern blotting and hybridisation as described e.g. by Southern E. M., 1975, J. Mol. Biol. 98:503-517. For such purposes it is routine practise to include steps of prehybridization and hybridization. Such steps are normally performed using solutions containing 6×SSPE, 5% Denhardt's, 0.5% SDS, 50% formamide, 100 μg/ml denaturated salmon testis DNA (incubation for 18 hrs at 42° C.), followed by washings with 2×SSC and 0.5% SDS (at room temperature and at 37° C.), and a washing with 0.1×SSC and 0.5% SDS (incubation at 68° C. for 30 min), as described by Sambrook et al., 1989, in “Molecular Cloning/A Laboratory Manual”, Cold Spring Harbor), which is incorporated herein by reference.

[0221] Homologous of nucleic acid sequences also encompass nucleic acid sequences which comprise additions and/or deletions. Such additions and/or deletions may be internal or at the end. Additions and/or deletions may be of 1-5 nucleotides, such as 5 to 10 nucleotide, for example 10 to 50 nucleotides, such as 50 to 100 nucleotides, for example at least 100 nucleotides.

[0222] Medical Use

[0223] A number of clinical conditions may be treated by functional inhibition or functional activation of steroid hormones. Accordingly, the compounds according to the invention that alter the uptake of steroid hormones into cells presenting a steroid hormone binding receptor may be useful in treatment of said clinical conditions.

[0224] Hence, it is an object of the present invention to provide use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment of a clinical condition associated with a steroid hormone.

[0225] The clinical conditions associated with a steroid hormone may for example be a condition characterised by dependency on one or more steroid hormones or by insufficiency of one or more steroid hormones.

[0226] Hence, in one embodiment of the present invention the clinical condition may be characterised by the undesirable presence and/or growth of cells dependent on one or more steroid hormones. For example, the cells of certain tumours are dependent on steroid hormones for growth.

[0227] The clinical condition may for example be selected from the group consisting of prostate cancer and breast cancer. In the prior art several strategies have been used to functional inhibit steroid hormone function in prostate or breast cancer. An overview of the various mechanisms of antagonists in steroid dependent tumour therapy is given in FIG. 10.

[0228] The compounds according to the present invention useful in tumour therapy are in particular inhibitors of steroid hormone uptake into cells. Because said inhibitors primarily inhibit active receptor mediated or receptor/co-receptor mediated uptake of steroid hormones into cells, they will in general not inhibit diffusion of steroid hormones into cells. Accordingly, primarily tissues depending on large amounts of steroid hormones through uptake via receptors will be affected by the treatment.

[0229] Compounds useful for treatment of breast cancer in particular include compounds that inhibit or reduce cellular uptake of estrogens, such as estradiols, for example 17β-estradiol.

[0230] Compounds useful for treatment of prostate cancer in particular include compounds that inhibit or reduce cellular uptake of androgens, such as testosterone. In one embodiment said compounds are capable of inhibiting uptake of androgens, by inhibiting uptake of steroid hormone/steroid hormone binding protein complexes by megalin and/or the ApoER2.

[0231] Cells of the prostate of several mammalian species expresses steroid hormone binding protein receptors. For example epithelial cells of dog and rat prostate expresses megalin (see example 5 and FIG. 9). Accordingly, it is preferred that compounds for treatment of prostate cancer inhibit or reduce cellular uptake of androgens, such as testosterone complexed to an androgen binding protein such as SHBG by the megalin receptor.

[0232] The compounds according to the present invention that may be used to treat prostate cancer or breast cancer, may be used alone or in combination with one or more other therapies against cancer. Such therapies include but are not limited to surgery, chemotherapy, radiotherapy, gene therapy, therapy with cytokines and immunotherapy.

[0233] In one preferred embodiment the compounds of the invention may be administered either simultaneously or sequentially in any order in combination with one or more other steroid hormone antagonist. Said antagonist may for example be any of the antagonist mentioned in FIG. 10. For breast cancer therapy, the antagonist may for example be selected from the group consisting of LHRH, aromatase inhibitors, estrogen receptor antagonists and α-estrogens. For prostate cancer therapy, the antagonist may for example be selected from the group consisting of LHRH, androgen receptor antagonists and α-androgens.

[0234] Contraception

[0235] In one aspect the present invention relates to contraceptive compositions comprising one or more compounds according to the invention. The present invention also relates to methods of preventing pregnancy comprising administering a sufficient amount of a compound, which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor. Furthermore the invention provides use of such a compound for the preparation of a composition that may be useful to prevent pregnancy.

[0236] In the male genital tract, SHBG is produced by Sertoli cells in the testis and secreted into the lumen of the seminiferous tubules [Feldman et al, 1981, French et al., 1973]. There it binds testosterone, present in large amounts in the testicular fluids. Via the efferent ducts, SHBG is transported to the epididymis and internalised by principal cells lining the epididymal duct [Feldman et al., 1981, Gerard et al., 1988]. Because the principal cells in the epididymis are responsible for the conversion of testosterone into 5α-dihydrotestosterone (DHT) that is required for sperm maturation, endocytic uptake of SHBG may be a route to deliver testosterone to these cells. Binding studies indicate that the receptor binds SHBG with a Kd of 50 nM when assayed in membrane suspensions, and a Kd of 0.5 μM in solubilized membranes [Fraira et al., 1991].

[0237] Steroid hormone binding protein receptors are expressed in the epididymis, for example megalin and ApoER2 are expressed in the epididymis.

[0238] Hence, sperm maturation in the epididymis may be dependent on uptake of testosterone into the principal cells. It is therefore an object of the present invention to provide a contraceptive composition, comprising a compound capable of altering the uptake of a steroid hormone into cells of the epididymis. More preferably, said compound is capable of inhibiting or reducing the uptake of an androgen into cells of the epididymis, even more preferably, said compound is capable of inhibiting or reducing the uptake of testosterone into the principal cells of the epidymis.

[0239] Such contraceptive compositions are in particular useful for male contraception.

[0240] Furthermore, the present invention provides methods of preventing pregnancy comprising administering a sufficient amount of a compound capable of altering the uptake of a steroid hormone into cells of the epididymis. More preferably, said compound is capable of inhibiting or reducing the uptake of an androgen into cells of the epididymis, even more preferably, said compound is capable of inhibiting or reducing the uptake of testosterone into the principal cells of the epidymis.

[0241] Pharmaceutical Compositions

[0242] The individual to receive treatment is any animal, however, preferably the individual is a human being.

[0243] In the embodiments of the present invention providing methods of preventing pregnancy, the individual is preferably a male individual.

[0244] The main routes of drug delivery according to the present invention are intravenous, oral, and topical, as will be described below. Other drug-administration methods, such as subcutaneous injection, which are effective to deliver the drug to a target site or to introduce the drug into the bloodstream, are also contemplated.

[0245] The mucosal membrane to which the pharmaceutical preparation of the invention is administered may be any mucosal membrane of the mammal to which the biologically active substance is to be given, e.g. in the nose, vagina, eye, mouth, genital tract, lungs, gastrointestinal tract, or rectum.

[0246] Compounds of the invention may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. The compounds may also be administered by inhalation, that is by intranasal and oral inhalation administration.

[0247] The compounds according to the invention may be administered with at least one other compound. The compounds may be administered simultaneously, either as separate formulations or combined in a unit dosage form, or administered sequentially.

[0248] The dosage requirements will vary with the particular drug composition employed, the route of administration and the particular individual being treated. Ideally, an individual to be treated by the present method will receive a pharmaceutically effective amount of the compound in the maximum tolerated dose; generally no higher than that required before drug resistance develops.

[0249] For all methods of use disclosed herein for the compounds, the daily oral dosage regimen will preferably be from about 0.01 to about 80 mg/kg of total body weight. The daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognised by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

[0250] The term “unit dosage form” as used herein refers to physically discrete units suitable as unitary dosages for human and animal individuals, each unit containing a predetermined quantity of a compound, alone or in combination with other agents, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier, or vehicle. The specifications for the unit dosage forms of the present invention depend on the particular compound or compounds employed and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host. The dose administered should be an “effective amount” or an amount necessary to achieve an “effective level” in the individual patient.

[0251] Since the “effective level” is used as the preferred endpoint for dosing, the actual dose and schedule can vary, depending on interindividual differences in pharmacokinetics, drug distribution, and metabolism. The “effective level” can be defined, for example, as the blood or tissue level desired in the individual that corresponds to a concentration of one or more compounds according to the invention.

[0252] Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pa. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

[0253] Pharmaceutical acceptable salts of the compounds according to the present invention should also be considered to fall within the scope of the present invention. Pharmaceutically acceptable salts are prepared in a standard manner. If the parent compound is a base it is treated with an excess of an organic or inorganic acid in a suitable solvent. If the parent compound is an acid, it is treated with an inorganic or organic base in a suitable solvent.

[0254] The compounds of the invention may be administered in the form of an alkali metal or earth alkali metal salt thereof, concurrently, simultaneously, or together with a pharmaceutically acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parenteral (including subcutaneous) route, in an effective amount.

[0255] Examples of pharmaceutically acceptable acid addition salts for use in the present inventive pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, p-toluenesulphonic acids, and arylsulphonic, for example.

[0256] Whilst it is possible for the compounds or salts of the present invention to be administered as the raw chemical, it is preferred to present them in the form of a pharmaceutical formulation. Accordingly, the present invention further provides a pharmaceutical formulation, for medicinal application, which comprises a compound of the present invention or a pharmaceutically acceptable salt thereof, as herein defined, and a pharmaceutically acceptable carrier therefor.

[0257] The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms may comprise the compounds of the invention or its pharmaceutically acceptable salt or a crystal form thereof as the active component. The pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilisers, lubricants, suspending agents, binders, preservatives, wetting agents, tablet disintegrating agents, or an encapsulating material.

[0258] Preferably, the composition will be about 0.5% to 75% by weight of a compound or compounds of the invention, with the remainder consisting of suitable pharmaceutical excipients. For oral administration, such excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like.

[0259] In powders, the carrier is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably containing from one to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral administration.

[0260] Drops according to the present invention may comprise sterile or non-sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100° C. for half an hour. Alternatively, the solution may be sterilised by filtration and transferred to the container aseptically. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

[0261] Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.

[0262] Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, toothpaste, gel dentrifrice, chewing gum, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.

[0263] The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

[0264] Oils useful in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

[0265] Suitable soaps for use in parenteral formulations include fatty alkali metal, ammbnium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides; (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-.beta.-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.

[0266] The parenteral formulations typically will contain from about 0.5 to about 25% by weight of the active ingredient in solution. Preservatives and buffers may be used. In order to minimise or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

[0267] The compounds of the invention can also be delivered topically. Regions for topical administration include the skin surface and also mucous membrane tissues of the vagina, rectum, nose, mouth, and throat. Compositions for topical administration via the skin and mucous membranes should not give rise to signs of irritation, such as swelling or redness.

[0268] The topical composition may include a pharmaceutically acceptable carrier adapted for topical administration. Thus, the composition may take the form of a suspension, solution, ointment, lotion, sexual lubricant, cream, foam, aerosol, spray, suppository, implant, inhalant, tablet, capsule, dry powder, syrup, balm or lozenge, for example. Methods for preparing such compositions are well known in the pharmaceutical industry.

[0269] The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.

[0270] Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturiser such as glycerol or an oil such as castor oil or arachis oil.

[0271] The pharmaceutical active compound described herein can be administered transdermally. Transdermal administration typically involves the delivery of a pharmaceutical agent for percutaneous passage of the drug into the systemic circulation of the patient. The skin sites include anatomic regions for transdermally administering the drug and include the forearm, abdomen, chest, back, buttock, mastoidal area, and the like.

[0272] Transdermal delivery is accomplished by exposing a source of the active compound to a patient's skin for an extended period of time. Transdermal patches have the added advantage of providing controlled delivery of a pharmaceutical agent-chemical modifier complex to the body. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery: Fundamentals and Applications, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery of Drugs, Vols. 1-3, Kydonieus and Bemer (eds.), CRC Press, (1987). Such dosage forms can be made by dissolving, dispersing, or otherwise incorporating the pharmaceutical active compound in a proper medium, such as an elastomeric matrix material. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.

[0273] The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

[0274] The active compound may be formulated into a suppository comprising, for example, about 0.5% to about 50% of a compound of the invention, disposed in a polyethylene glycol (PEG) carrier (e.g., PEG 1000 [96%] and PEG 4000 [4%].

[0275] The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0276] When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.

[0277] Pharmaceutical compositions usually comprise a carrier. Illustrative solid carrier include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions, and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyviriylpyrrolidine, low melting waxes and ion exchange resins.

[0278] Illustrative liquid carriers include syrup, peanut oil, olive oil, water, etc. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carders are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurised compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilised by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form.

[0279] The carrier or excipient may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate along or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like. When formulated for oral administration, 0.01% Tween 80 in PHOSAL PG-50 (phospholipid concentrate with 1,2-propylene glycol, A. Nattermann & Cie. GmbH) has been recognised as providing an acceptable oral formulation for other compounds, and may be adapted to formulations for various compounds of this invention.

EXAMPLES Example 1

[0280] Surface-plasmon resonance analysis of binding of testosterone/SHBG complexes to purified megalin.

[0281] Purified native megalin (51.4 fmol/mm²) and reduced megalin (43.8 fmol/mm²) were immobilised on sensor chips, and the on and off rates for binding of 1 μM testosterone/SHBG complexes were recorded. The results are shown in FIG. 1. Nonspecific response from a blank chip exposed to a similar flow with the ligand have been subtracted. As shown, the testosterone/SHBG complex bound in a reversible manner to native megalin. The calculated affinity is approximately 140 nM. By comparison, no detectable binding was observed to the reduced and denatured receptor. In conclusion, complexes between testosterone and SHBG can bind megalin with high affinity.

Example 2

[0282] Receptor-mediated uptake of dihydrotestosterone/SHBG complexes into BN 16 cells and keratinocytes.

[0283] Brown Norway yolk sac carcinoma cells (BN16 cells) expressing megalin and primary cultures of human keratinocytes devoid of megalin were incubated with complexes of [³H]-dihydrotestosterone (DHT) and sex hormone binding globulin (SHBG). After 1 hr of incubation at 37° C., the cells were washed and the amount of cell-associated [³H]-DHT determined. As shown in FIG. 2A only the megalin expressing BN16 cells efficiently take up the steroid, whereas keratinocytes hardly take up any steroid.

[0284] BN16 cells were incubated with complexes of [³H]-DHT and SHBG. In addition, the medium included gluthathion S-transferase (GST), a fusion protein of GST and the receptor-associated protein (GST-RAP) or chloroquine, an inhibitor of endocytosis. After 4 hours incubation at 37° C., the cells were washed and the amount of cell-associated [³H]-DHT determined. In the presence of GST, which does not interfere with receptor-mediated endocytosis, significant amounts of [³H]-DHT (300×10³ cpm) were detected in BN16 cells, indicating cellular uptake. In contrast, a 75% reduction in [³H]-DHT uptake (70×10³ cpm) was observed in the presence of the megalin inhibitor RAP. Similar effects were observed in the presence of chloroquine. In conclusion, these findings indicate megalin-mediated uptake of DHT/SHBG complexes into cells.

Example 3

[0285] Histological analysis of wild type and megalin-deficient mouse.

[0286] Vagina tissues were dissected from adult wild type (+/+) and megalin-deficient female mice (−/−) and prepared for routine paraffin embedding and sectioning. The tissue sections were stained with hematoxilin and eosin and are shown in FIG. 3. The wild type vagina illustrates normally developed stroma and hypertrophied epithelium. Note the estrogen-induced cornification of the epithelial surface that occurs during sexual maturation. In contrast, vagina tissue from receptor-deficient mice is characterized by a hypoplastic epithelium and lack of cornification. Instead, an additional layer of mucoid cells is detectable on the luminal surface of the epithelial cells. These alteration are consistent with a lack of estrogen-induced actions during puberty. In conclusion, the findings in the megalin knockout mice suggest a status of estrogen-insensitivity due to a lack of megalin-mediated uptake of estrogens.

[0287] The urogenital tract was dissected from adult wild type or megalin-deficient male mice (megalin^(−/−)). The urogenital tracts are depicted in FIG. 7. The left testis of the receptor-deficient mice does not descent into the scrotum but remains in the abdominal cavity (unilateral cryptorchidism). Due to its exposure to a higher temperature in the body cavity, the non-descendent testis (arrow) regresses (as seen by its smaller size). Identical defects can be observed in rats treated with the nuclear androgen receptor antagonist flutamide (Zakaria et al., 2000). This finding suggests that megalin is responsible for uptake of androgens into the developing urogenital system and that absence of the receptor results in the lack of androgen signaling.

Example 4

[0288] Competition of SHBG for Membrane-Binding

[0289] To test whether recombinant SHBG (rSHBG) interacts with SHBG receptors and in particular whether rSHBG can act as an inhibitor of SHBG binding to an SHBG receptor, the binding of rSHBG to bovine epididymis and endometrium membranes permeabilized in digitonin was assayed. Binding was performed in the presence of testosterone, to achieve steroid hormone-steroid hormone binding protein complex formation.

[0290] Briefly, purified recombinant SHBG was labelled with ¹²⁵I using the Iodo-Gen™ method [specific radioactivity (13-15)×10³ c.p.m./ng]. 400 pg of ¹²⁵I—SHBG was mixed with 600 μg of purified membranes (either bovine epididymis or bovine endometrium membranes permeabilized in digitonin) in a total volume of 200 μl of reaction buffer [10 mM Hepes, pH 7.4, 2 mM CaCl₂, 1 mM MgCl₂, 1% (w/v) BSA, 1 lM ZnCl₂, 11M testosterone and 301 g/ml digitonin]. In addition, the reaction mixture included the concentrations of unlabelled SHBG indicated in FIG. 8. The reaction mixture was incubated at 4° C. for 18 h and then precipitated on Millipore filters (GVWP 2932A) using a vacuum suction device. The filters were washed extensively with reaction buffer and the amount of bound radioactivity was determined.

[0291] As seen in FIG. 8, saturable binding of ¹²⁵I-labelled rSHBG to both membrane preparations was observed. Values are given as a percentage of ²⁵¹I-rSHBG bound in the absence of competitor (100%). The data represent the means of four individual experiments (±S.E.M.). Where no error bar is shown, the values are smaller than the actual symbol. The affinity of binding to the permeabilized epididymis membranes was in perfect agreement with published data for the native protein (Kd 0.5 μM).

Example 5

[0292] Detection of Megalin in Prostate

[0293] Normal prostate tissue was dissected from dog and from rat males. The tissues were prepared for routine paraffin embedding and sectioning. The tissue sections were stained with goat anti-megalin antibodies followed by peroxidase-conjugated antigoat IgG. Bound IgG was visualized with diaminobenzidine.

[0294]FIG. 9 depicts the immunohistological detection of megalin in dog and rat prostate. The arrows denote localization of the receptor on the surface of epithelial cells. Expression of the receptor in these cell type suggests that it may be involved in benign hyperplasia and malignant prostate cancer. In particular, expression of megalin in dog prostate is interesting, because this dog model develops prostate hyperplasia and prostate cancer.

Example 6

[0295] Tissue Specific Knock-Out of Megalin

[0296] Below is given an example of a model for testing the role of a steroid hormone binding protein receptor/co-receptor in a specific tissue. The model may be employed with any steroid hormone binding protein receptor/co-receptor, however the example describes tissue specific knock-out of megalin.

[0297] In order to further substantiate the role of megalin in steroid hormone metabolism, mice lacking the receptor in specific steroid-responsive tissues (e.g., uterus, epididymus, prostate, breast) using conditional or tissue-specific gene targeting is generated. Lack of the receptor in such tissues should result in a phenotype identical to one seen in mice with genetic or pharmacological defects of androgen or estrogen receptors.

[0298] To produce mice with a megalin gene defect in steroid-responsive tissues, a mouse line is generated carrying a megalin gene tagged with two adjacent recombination sites (IoxP sites). This mouse line (megalin^(flox/flox)) is crossed with mice carrying a Cre-recombinase transgene under breast-, prostate- or epididymus-specific promoter elements (Cre⁺) to produce mice doubly transgenic for megalin^(flox/flox) and Cre⁺(megalin^(flox/flox)/Cre⁺). Cre recombinase is a bacterial enzyme that recombines two adjacent IoxP sites to delete the intermittent sequence elements. Thus, tissue specific expression of Cre recombinase in breast, epididymis or prostate of megalin^(flox/flox)/Cre⁺ mice results in organ-specific deletion of the receptor gene.

REFERENCES

[0299] Birn, H. Verroust, P. J., Nexo, E., Hager, H., Jacobsen, C., Christensen, E. I. & Moestrup, S. K. (1997) J. Biol. Chem. 272, 26497-26504.

[0300] Feldman, M., Lea, 0. A., Petrusz, P., Tres, L. L., Kierszenbaum, A. L. and French, F. S. (1981) Androgen-binding protein. Purfication from rat epididymis, characterization, and immunocytochemical localization. J. Biol. Chem. 256, 5170-5175.

[0301] Frairia, R., Fortunati, N., Berta, L., Fazzari, A., Fissore, F. and Gaidano, G. (1991) Sex steroid binding protein (SBP) receptors in estrogen sensitive tissues. J. Steroid Biochem. Mol. Biol. 40, 805-812

[0302] French, F. S. and Ritzen, E. M. (1973) A high-affinity androgen-binding protein (ABP) in rat testis: evidence for secretion into efferent duct fluid and absorption by epididymis. Endocrinology 93, 88-95.

[0303] Gerard, A., Khanfri, J., Gueant, J. L., Fremont, S., Nicolas, J. P., Grignon, G. and Gerard, H. (1988) Electron microscope radioautographic evidence of in vivo androgen-binding protein internalization in the rat epididymis principal cells. Endocrinology 122, 1297-1307.

[0304] Moestrup, S. K., Kozyraki, R., Kristiansen, M., Kaysen, J. H., Rasmussen, H. H., Brault, D., Pontillon, F., Goda, F. O., Christensen, E. I., Hammond, T. G., et al. (1998) J. Biol. Chem. 273, 5235-5242.

[0305] Anders Nykjaer* †, John C. Fyfe ‡, Renata Kozyraki*, Jo{umlaut over ()} rg-Robert Leheste §, Christian Jacobsen*, Morten S. Nielsen*, Pierre J. Verroust ¶, Maria Aminoff_Albert de la Chapelle**, Søoren K. Moestrup*, Rahul Ray ††, Jørgen Gliemann*, Thomas E. Willnow §, and Erik I. Christensen ‡‡, 2001, Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D3; PNAS, vol. 98, no.24, p. 13895-13900

[0306] Zakaria et al., Comparative studies of fertility and histological development of contralateral scrotal testes in two rat models of unilateral cryptorchidism. (2000) Pediatr. Surg. Int. 16: 498-501.

1 8 1 402 PRT Homo sapiens 1 Met Glu Ser Arg Gly Pro Leu Ala Thr Ser Arg Leu Leu Leu Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Arg His Thr Arg Gln Gly Trp Ala Leu Arg Pro 20 25 30 Val Leu Pro Thr Gln Ser Ala His Asp Pro Pro Ala Val His Leu Ser 35 40 45 Asn Gly Pro Gly Gln Glu Pro Ile Ala Val Met Thr Phe Asp Leu Thr 50 55 60 Lys Ile Thr Lys Thr Ser Ser Ser Phe Glu Val Arg Thr Trp Asp Pro 65 70 75 80 Glu Gly Val Ile Phe Tyr Gly Asp Thr Asn Pro Lys Asp Asp Trp Phe 85 90 95 Met Leu Gly Leu Arg Asp Gly Arg Pro Glu Ile Gln Leu His Asn His 100 105 110 Trp Ala Gln Leu Thr Val Gly Ala Gly Pro Arg Leu Asp Asp Gly Arg 115 120 125 Trp His Gln Val Glu Val Lys Met Glu Gly Asp Ser Val Leu Leu Glu 130 135 140 Val Asp Gly Glu Glu Val Leu Arg Leu Arg Gln Val Ser Gly Pro Leu 145 150 155 160 Thr Ser Lys Arg His Pro Ile Met Arg Ile Ala Leu Gly Gly Leu Leu 165 170 175 Phe Pro Ala Ser Asn Leu Arg Leu Pro Leu Val Pro Ala Leu Asp Gly 180 185 190 Cys Leu Arg Arg Asp Ser Trp Leu Asp Lys Gln Ala Glu Ile Ser Ala 195 200 205 Ser Ala Pro Thr Ser Leu Arg Ser Cys Asp Val Glu Ser Asn Pro Gly 210 215 220 Ile Phe Leu Pro Pro Gly Thr Gln Ala Glu Phe Asn Leu Arg Asp Ile 225 230 235 240 Pro Gln Pro His Ala Glu Pro Trp Ala Phe Ser Leu Asp Leu Gly Leu 245 250 255 Lys Gln Ala Ala Gly Ser Gly His Leu Leu Ala Leu Gly Thr Pro Glu 260 265 270 Asn Pro Ser Trp Leu Ser Leu His Leu Gln Asp Gln Lys Val Val Leu 275 280 285 Ser Ser Gly Ser Gly Pro Gly Leu Asp Leu Pro Leu Val Leu Gly Leu 290 295 300 Pro Leu Gln Leu Lys Leu Ser Met Ser Arg Val Val Leu Ser Gln Gly 305 310 315 320 Ser Lys Met Lys Ala Leu Ala Leu Pro Pro Leu Gly Leu Ala Pro Leu 325 330 335 Leu Asn Leu Trp Ala Lys Pro Gln Gly Arg Leu Phe Leu Gly Ala Leu 340 345 350 Pro Gly Glu Asp Ser Ser Thr Ser Phe Cys Leu Asn Gly Leu Trp Ala 355 360 365 Gln Gly Gln Arg Leu Asp Val Asp Gln Ala Leu Asn Arg Ser His Glu 370 375 380 Ile Trp Thr His Ser Cys Pro Gln Ser Pro Gly Asn Gly Thr Asp Ala 385 390 395 400 Ser His 2 1576 PRT Homo sapiens 2 Leu Cys Asn Gly Val Asn Asp Cys Gly Asp Asn Ser Asp Glu Ser Pro 1 5 10 15 Gln Gln Asn Cys Arg Pro Arg Thr Gly Glu Glu Asn Cys Asn Val Asn 20 25 30 Asn Gly Gly Cys Ala Gln Lys Cys Gln Met Val Arg Gly Ala Val Gln 35 40 45 Cys Thr Cys His Thr Gly Tyr Arg Leu Thr Glu Asp Gly His Thr Cys 50 55 60 Gln Asp Val Asn Glu Cys Ala Glu Glu Gly Tyr Cys Ser Gln Gly Cys 65 70 75 80 Thr Asn Ser Glu Gly Ala Phe Gln Cys Trp Cys Glu Thr Gly Tyr Glu 85 90 95 Leu Arg Pro Asp Arg Arg Ser Cys Lys Ala Leu Gly Pro Glu Pro Val 100 105 110 Leu Leu Phe Ala Asn Arg Ile Asp Ile Arg Gln Val Leu Pro His Arg 115 120 125 Ser Glu Tyr Thr Leu Leu Leu Asn Asn Leu Glu Asn Ala Ile Ala Leu 130 135 140 Asp Phe His His Arg Arg Glu Leu Val Phe Trp Ser Asp Val Thr Leu 145 150 155 160 Asp Arg Ile Leu Arg Ala Asn Leu Asn Gly Ser Asn Val Glu Glu Val 165 170 175 Val Ser Thr Gly Leu Glu Ser Pro Gly Gly Leu Ala Val Asp Trp Val 180 185 190 His Asp Lys Leu Tyr Trp Thr Asp Ser Gly Thr Ser Arg Ile Glu Val 195 200 205 Ala Asn Leu Asp Gly Ala His Arg Lys Val Leu Leu Trp Gln Asn Leu 210 215 220 Glu Lys Pro Arg Ala Ile Ala Leu His Pro Met Glu Gly Thr Ile Tyr 225 230 235 240 Trp Thr Asp Trp Gly Asn Thr Pro Arg Ile Glu Ala Ser Ser Met Asp 245 250 255 Gly Ser Gly Arg Arg Ile Ile Ala Asp Thr His Leu Phe Trp Pro Asn 260 265 270 Gly Leu Thr Ile Asp Tyr Ala Gly Arg Arg Met Tyr Trp Val Asp Ala 275 280 285 Lys His His Val Ile Glu Arg Ala Asn Leu Asp Gly Ser His Arg Lys 290 295 300 Ala Val Ile Ser Gln Gly Leu Pro His Pro Phe Ala Ile Thr Val Phe 305 310 315 320 Glu Asp Ser Leu Tyr Trp Thr Asp Trp His Thr Lys Ser Ile Asn Ser 325 330 335 Ala Asn Lys Phe Thr Gly Lys Asn Gln Glu Ile Ile Arg Asn Lys Leu 340 345 350 His Phe Pro Met Asp Ile His Thr Leu His Pro Gln Arg Gln Pro Ala 355 360 365 Gly Lys Asn Arg Cys Gly Asp Asn Asn Gly Gly Cys Thr His Leu Cys 370 375 380 Leu Pro Ser Gly Gln Asn Tyr Thr Cys Ala Cys Pro Thr Gly Phe Arg 385 390 395 400 Lys Ile Ser Ser His Ala Cys Ala Gln Ser Leu Asp Lys Phe Leu Leu 405 410 415 Phe Ala Arg Arg Met Asp Ile Arg Arg Ile Ser Phe Asp Thr Glu Asp 420 425 430 Leu Ser Asp Asp Val Ile Pro Leu Ala Asp Val Arg Ser Ala Val Ala 435 440 445 Leu Asp Trp Asp Ser Arg Asp Asp His Val Tyr Trp Thr Asp Val Ser 450 455 460 Thr Asp Thr Ile Ser Arg Ala Lys Trp Asp Gly Thr Gly Gln Glu Val 465 470 475 480 Val Val Asp Thr Ser Leu Glu Ser Pro Ala Gly Leu Ala Ile Asp Trp 485 490 495 Val Thr Asn Lys Leu Tyr Trp Thr Asp Ala Gly Thr Asp Arg Ile Glu 500 505 510 Val Ala Asn Thr Asp Gly Ser Met Arg Thr Val Leu Ile Trp Glu Asn 515 520 525 Leu Asp Arg Pro Arg Asp Ile Val Val Glu Pro Met Gly Gly Tyr Met 530 535 540 Tyr Trp Thr Asp Trp Gly Ala Ser Pro Lys Ile Glu Arg Ala Gly Met 545 550 555 560 Asp Ala Ser Gly Arg Gln Val Ile Ile Ser Ser Asn Leu Thr Trp Pro 565 570 575 Asn Gly Leu Ala Ile Asp Tyr Gly Ser Gln Arg Leu Tyr Trp Ala Asp 580 585 590 Ala Gly Met Lys Thr Ile Glu Phe Ala Gly Leu Asp Gly Ser Lys Arg 595 600 605 Lys Val Leu Ile Gly Ser Gln Leu Pro His Pro Phe Gly Leu Thr Leu 610 615 620 Tyr Gly Glu Arg Ile Tyr Trp Thr Asp Trp Gln Thr Lys Ser Ile Gln 625 630 635 640 Ser Ala Asp Arg Leu Thr Gly Leu Asp Arg Glu Thr Leu Gln Glu Asn 645 650 655 Leu Glu Asn Leu Met Asp Ile His Val Phe His Arg Arg Arg Pro Pro 660 665 670 Val Ser Thr Pro Cys Ala Met Glu Asn Gly Gly Cys Ser His Leu Cys 675 680 685 Leu Arg Ser Pro Asn Pro Ser Gly Phe Ser Cys Thr Cys Pro Thr Gly 690 695 700 Ile Asn Leu Leu Ser Asp Gly Lys Thr Cys Ser Pro Gly Met Asn Ser 705 710 715 720 Phe Leu Ile Phe Ala Arg Arg Ile Asp Ile Arg Met Val Ser Leu Asp 725 730 735 Ile Pro Tyr Phe Ala Asp Val Val Val Pro Ile Asn Ile Thr Met Lys 740 745 750 Asn Thr Ile Ala Val Gly Val Asp Pro Gln Glu Gly Lys Val Tyr Trp 755 760 765 Ser Asp Ser Thr Leu His Arg Ile Ser Arg Ala Asn Leu Asp Gly Ser 770 775 780 Gln His Glu Asp Ile Ile Thr Thr Gly Leu Gln Thr Thr Asp Gly Leu 785 790 795 800 Ala Val Asp Ala Ile Gly Arg Lys Val Tyr Trp Thr Asp Thr Gly Thr 805 810 815 Asn Arg Ile Glu Val Gly Asn Leu Asp Gly Ser Met Arg Lys Val Leu 820 825 830 Val Trp Gln Asn Leu Asp Ser Pro Arg Ala Ile Val Leu Tyr His Glu 835 840 845 Met Gly Phe Met Tyr Trp Thr Asp Trp Gly Glu Asn Ala Lys Leu Glu 850 855 860 Arg Ser Gly Met Asp Gly Ser Asp Arg Ala Val Leu Ile Asn Asn Asn 865 870 875 880 Leu Gly Trp Pro Asn Gly Leu Thr Val Asp Lys Ala Ser Ser Gln Leu 885 890 895 Leu Trp Ala Asp Ala His Thr Glu Arg Ile Glu Ala Ala Asp Leu Asn 900 905 910 Gly Ala Asn Arg His Thr Leu Val Ser Pro Val Gln His Pro Tyr Gly 915 920 925 Leu Thr Leu Leu Asp Ser Tyr Ile Tyr Trp Thr Asp Trp Gln Thr Arg 930 935 940 Ser Ile His Arg Ala Asp Lys Gly Thr Gly Ser Asn Val Ile Leu Val 945 950 955 960 Arg Ser Asn Leu Pro Gly Leu Met Asp Met Gln Ala Val Asp Arg Ala 965 970 975 Gln Pro Leu Gly Phe Asn Lys Cys Gly Ser Arg Asn Gly Gly Cys Ser 980 985 990 His Leu Cys Leu Pro Arg Pro Ser Gly Phe Ser Cys Ala Cys Pro Thr 995 1000 1005 Gly Ile Gln Leu Lys Gly Asp Gly Lys Thr Cys Asp Pro Ser Pro 1010 1015 1020 Glu Thr Tyr Leu Leu Phe Ser Ser Arg Gly Ser Ile Arg Arg Ile 1025 1030 1035 Ser Leu Asp Thr Ser Asp His Thr Asp Val His Val Pro Val Pro 1040 1045 1050 Glu Leu Asn Asn Val Ile Ser Leu Asp Tyr Asp Ser Val Asp Gly 1055 1060 1065 Lys Val Tyr Tyr Thr Asp Val Phe Leu Asp Val Ile Arg Arg Ala 1070 1075 1080 Asp Leu Asn Gly Ser Asn Met Glu Thr Val Ile Gly Arg Gly Leu 1085 1090 1095 Lys Thr Thr Asp Gly Leu Ala Val Asp Trp Val Ala Arg Asn Leu 1100 1105 1110 Tyr Trp Thr Asp Thr Gly Arg Asn Thr Ile Glu Ala Ser Arg Leu 1115 1120 1125 Asp Gly Ser Cys Arg Lys Val Leu Ile Asn Asn Ser Leu Asp Glu 1130 1135 1140 Pro Arg Ala Ile Ala Val Phe Pro Arg Lys Gly Tyr Leu Phe Trp 1145 1150 1155 Thr Asp Trp Gly His Ile Ala Lys Ile Glu Arg Ala Asn Leu Asp 1160 1165 1170 Gly Ser Glu Arg Lys Val Leu Ile Asn Thr Asp Leu Gly Trp Pro 1175 1180 1185 Asn Gly Leu Thr Leu Asp Tyr Asp Thr Arg Arg Ile Tyr Trp Val 1190 1195 1200 Asp Ala His Leu Asp Arg Ile Glu Ser Ala Asp Leu Asn Gly Lys 1205 1210 1215 Leu Arg Gln Val Leu Val Gly His Val Ser His Pro Phe Ala Leu 1220 1225 1230 Thr Gln Gln Asp Arg Trp Ile Tyr Trp Thr Asp Trp Gln Thr Lys 1235 1240 1245 Ser Ile Gln Arg Val Asp Lys Tyr Ser Gly Arg Asn Lys Glu Thr 1250 1255 1260 Val Leu Ala Asn Val Glu Gly Leu Met Asp Ile Ile Val Val Ser 1265 1270 1275 Pro Gln Arg Gln Thr Gly Thr Asn Ala Cys Gly Val Asn Asn Gly 1280 1285 1290 Gly Cys Thr His Leu Cys Phe Ala Arg Ala Ser Asp Phe Val Cys 1295 1300 1305 Ala Cys Pro Asp Glu Pro Asp Ser Gln Pro Cys Ser Leu Val Pro 1310 1315 1320 Gly Leu Val Pro Pro Ala Pro Arg Ala Thr Gly Met Ser Glu Lys 1325 1330 1335 Ser Pro Val Leu Pro Asn Thr Pro Pro Thr Thr Leu Tyr Ser Ser 1340 1345 1350 Thr Thr Arg Thr Arg Thr Ser Leu Glu Glu Val Glu Gly Arg Cys 1355 1360 1365 Ser Glu Arg Asp Ala Arg Leu Gly Leu Cys Ala Arg Ser Asn Asp 1370 1375 1380 Ala Val Pro Ala Ala Pro Gly Glu Gly Leu His Ile Ser Tyr Ala 1385 1390 1395 Ile Gly Gly Leu Leu Ser Ile Leu Leu Ile Leu Val Val Ile Ala 1400 1405 1410 Ala Leu Met Leu Tyr Arg His Lys Lys Ser Lys Phe Thr Asp Pro 1415 1420 1425 Gly Met Gly Asn Leu Thr Tyr Ser Asn Pro Ser Tyr Arg Thr Ser 1430 1435 1440 Thr Gln Glu Val Lys Ile Glu Ala Ile Pro Lys Pro Ala Met Tyr 1445 1450 1455 Asn Gln Leu Cys Tyr Lys Lys Glu Gly Gly Pro Asp His Asn Tyr 1460 1465 1470 Thr Lys Glu Lys Ile Lys Ile Val Glu Gly Ile Cys Leu Leu Ser 1475 1480 1485 Gly Asp Asp Ala Glu Trp Asp Asp Leu Lys Gln Leu Arg Ser Ser 1490 1495 1500 Arg Gly Gly Leu Leu Arg Asp His Val Cys Met Lys Thr Asp Thr 1505 1510 1515 Val Ser Ile Gln Ala Ser Ser Gly Ser Leu Asp Asp Thr Glu Met 1520 1525 1530 Glu Gln Leu Leu Gln Glu Glu Gln Ser Glu Cys Ser Ser Val His 1535 1540 1545 Thr Ala Ala Thr Pro Glu Arg Arg Gly Ser Leu Pro Asp Thr Gly 1550 1555 1560 Trp Lys His Glu Arg Lys Leu Ser Ser Glu Ser Gln Val 1565 1570 1575 3 4655 PRT Homo sapiens 3 Met Asp Arg Gly Pro Ala Ala Val Ala Cys Thr Leu Leu Leu Ala Leu 1 5 10 15 Val Ala Cys Leu Ala Pro Ala Ser Gly Gln Glu Cys Asp Ser Ala His 20 25 30 Phe Arg Cys Gly Ser Gly His Cys Ile Pro Ala Asp Trp Arg Cys Asp 35 40 45 Gly Thr Lys Asp Cys Ser Asp Asp Ala Asp Glu Ile Gly Cys Ala Val 50 55 60 Val Thr Cys Gln Gln Gly Tyr Phe Lys Cys Gln Ser Glu Gly Gln Cys 65 70 75 80 Ile Pro Ser Ser Trp Val Cys Asp Gln Asp Gln Asp Cys Asp Asp Gly 85 90 95 Ser Asp Glu Arg Gln Asp Cys Ser Gln Ser Thr Cys Ser Ser His Gln 100 105 110 Ile Thr Cys Ser Asn Gly Gln Cys Ile Pro Ser Glu Tyr Arg Cys Asp 115 120 125 His Val Arg Asp Cys Pro Asp Gly Ala Asp Glu Asn Asp Cys Gln Tyr 130 135 140 Pro Thr Cys Glu Gln Leu Thr Cys Asp Asn Gly Ala Cys Tyr Asn Thr 145 150 155 160 Ser Gln Lys Cys Asp Trp Lys Val Asp Cys Arg Asp Ser Ser Asp Glu 165 170 175 Ile Asn Cys Thr Glu Ile Cys Leu His Asn Glu Phe Ser Cys Gly Asn 180 185 190 Gly Glu Cys Ile Pro Arg Ala Tyr Val Cys Asp His Asp Asn Asp Cys 195 200 205 Gln Asp Gly Ser Asp Glu His Ala Cys Asn Tyr Pro Thr Cys Gly Gly 210 215 220 Tyr Gln Phe Thr Cys Pro Ser Gly Arg Cys Ile Tyr Gln Asn Trp Val 225 230 235 240 Cys Asp Gly Glu Asp Asp Cys Lys Asp Asn Gly Asp Glu Asp Gly Cys 245 250 255 Glu Ser Gly Pro His Asp Val His Lys Cys Ser Pro Arg Glu Trp Ser 260 265 270 Cys Pro Glu Ser Gly Arg Cys Ile Ser Ile Tyr Lys Val Cys Asp Gly 275 280 285 Ile Leu Asp Cys Pro Gly Arg Glu Asp Glu Asn Asn Thr Ser Thr Gly 290 295 300 Lys Tyr Cys Ser Met Thr Leu Cys Ser Ala Leu Asn Cys Gln Tyr Gln 305 310 315 320 Cys His Glu Thr Pro Tyr Gly Gly Ala Cys Phe Cys Pro Pro Gly Tyr 325 330 335 Ile Ile Asn His Asn Asp Ser Arg Thr Cys Val Glu Phe Asp Asp Cys 340 345 350 Gln Ile Trp Gly Ile Cys Asp Gln Lys Cys Glu Ser Arg Pro Gly Arg 355 360 365 His Leu Cys His Cys Glu Glu Gly Tyr Ile Leu Glu Arg Gly Gln Tyr 370 375 380 Cys Lys Ala Asn Asp Ser Phe Gly Glu Ala Ser Ile Ile Phe Ser Asn 385 390 395 400 Gly Arg Asp Leu Leu Ile Gly Asp Ile His Gly Arg Ser Phe Arg Ile 405 410 415 Leu Val Glu Ser Gln Asn Arg Gly Val Ala Val Gly Val Ala Phe His 420 425 430 Tyr His Leu Gln Arg Val Phe Trp Thr Asp Thr Val Gln Asn Lys Val 435 440 445 Phe Ser Val Asp Ile Asn Gly Leu Asn Ile Gln Glu Val Leu Asn Val 450 455 460 Ser Val Glu Thr Pro Glu Asn Leu Ala Val Asp Trp Val Asn Asn Lys 465 470 475 480 Ile Tyr Leu Val Glu Thr Lys Val Asn Arg Ile Asp Met Val Asn Leu 485 490 495 Asp Gly Ser Tyr Arg Val Thr Leu Ile Thr Glu Asn Leu Gly His Pro 500 505 510 Arg Gly Ile Ala Val Asp Pro Thr Val Gly Tyr Leu Phe Phe Ser Asp 515 520 525 Trp Glu Ser Leu Ser Gly Glu Pro Lys Leu Glu Arg Ala Phe Met Asp 530 535 540 Gly Ser Asn Arg Lys Asp Leu Val Lys Thr Lys Leu Gly Trp Pro Ala 545 550 555 560 Gly Val Thr Leu Asp Met Ile Ser Lys Arg Val Tyr Trp Val Asp Ser 565 570 575 Arg Phe Asp Tyr Ile Glu Thr Val Thr Tyr Asp Gly Ile Gln Arg Lys 580 585 590 Thr Val Val His Gly Gly Ser Leu Ile Pro His Pro Phe Gly Val Ser 595 600 605 Leu Phe Glu Gly Gln Val Phe Phe Thr Asp Trp Thr Lys Met Ala Val 610 615 620 Leu Lys Ala Asn Lys Phe Thr Glu Thr Asn Pro Gln Val Tyr Tyr Gln 625 630 635 640 Ala Ser Leu Arg Pro Tyr Gly Val Thr Val Tyr His Ser Leu Arg Gln 645 650 655 Pro Tyr Ala Thr Asn Pro Cys Lys Asp Asn Asn Gly Gly Cys Glu Gln 660 665 670 Val Cys Val Leu Ser His Arg Thr Asp Asn Asp Gly Leu Gly Phe Arg 675 680 685 Cys Lys Cys Thr Phe Gly Phe Gln Leu Asp Thr Asp Glu Arg His Cys 690 695 700 Ile Ala Val Gln Asn Phe Leu Ile Phe Ser Ser Gln Val Ala Ile Arg 705 710 715 720 Gly Ile Pro Phe Thr Leu Ser Thr Gln Glu Asp Val Met Val Pro Val 725 730 735 Ser Gly Asn Pro Ser Phe Phe Val Gly Ile Asp Phe Asp Ala Gln Asp 740 745 750 Ser Thr Ile Phe Phe Ser Asp Met Ser Lys His Met Ile Phe Lys Gln 755 760 765 Lys Ile Asp Gly Thr Gly Arg Glu Ile Leu Ala Ala Asn Arg Val Glu 770 775 780 Asn Val Glu Ser Leu Ala Phe Asp Trp Ile Ser Lys Asn Leu Tyr Trp 785 790 795 800 Thr Asp Ser His Tyr Lys Ser Ile Ser Val Met Arg Leu Ala Asp Lys 805 810 815 Thr Arg Arg Thr Val Val Gln Tyr Leu Asn Asn Pro Arg Ser Val Val 820 825 830 Val His Pro Phe Ala Gly Tyr Leu Phe Phe Thr Asp Trp Phe Arg Pro 835 840 845 Ala Lys Ile Met Arg Ala Trp Ser Asp Gly Ser His Leu Leu Pro Val 850 855 860 Ile Asn Thr Thr Leu Gly Trp Pro Asn Gly Leu Ala Ile Asp Trp Ala 865 870 875 880 Ala Ser Arg Leu Tyr Trp Val Asp Ala Tyr Phe Asp Lys Ile Glu His 885 890 895 Ser Thr Phe Asp Gly Leu Asp Arg Arg Arg Leu Gly His Ile Glu Gln 900 905 910 Met Thr His Pro Phe Gly Leu Ala Ile Phe Gly Glu His Leu Phe Phe 915 920 925 Thr Asp Trp Arg Leu Gly Ala Ile Ile Arg Val Arg Lys Ala Asp Gly 930 935 940 Gly Glu Met Thr Val Ile Arg Ser Gly Ile Ala Tyr Ile Leu His Leu 945 950 955 960 Lys Ser Tyr Asp Val Asn Ile Gln Thr Gly Ser Asn Ala Cys Asn Gln 965 970 975 Pro Thr His Pro Asn Gly Asp Cys Ser His Phe Cys Phe Pro Val Pro 980 985 990 Asn Phe Gln Arg Val Cys Gly Cys Pro Tyr Gly Met Arg Leu Ala Ser 995 1000 1005 Asn His Leu Thr Cys Glu Gly Asp Pro Thr Asn Glu Pro Pro Thr 1010 1015 1020 Glu Gln Cys Gly Leu Phe Ser Phe Pro Cys Lys Asn Gly Arg Cys 1025 1030 1035 Val Pro Asn Tyr Tyr Leu Cys Asp Gly Val Asp Asp Cys His Asp 1040 1045 1050 Asn Ser Asp Glu Gln Leu Cys Gly Thr Leu Asn Asn Thr Cys Ser 1055 1060 1065 Ser Ser Ala Phe Thr Cys Gly His Gly Glu Cys Ile Pro Ala His 1070 1075 1080 Trp Arg Cys Asp Lys Arg Asn Asp Cys Val Asp Gly Ser Asp Glu 1085 1090 1095 His Asn Cys Pro Thr His Ala Pro Ala Ser Cys Leu Asp Thr Gln 1100 1105 1110 Tyr Thr Cys Asp Asn His Gln Cys Ile Ser Lys Asn Trp Val Cys 1115 1120 1125 Asp Thr Asp Asn Asp Cys Gly Asp Gly Ser Asp Glu Lys Asn Cys 1130 1135 1140 Asn Ser Thr Glu Thr Cys Gln Pro Ser Gln Phe Asn Cys Pro Asn 1145 1150 1155 His Arg Cys Ile Asp Leu Ser Phe Val Cys Asp Gly Asp Lys Asp 1160 1165 1170 Cys Val Asp Gly Ser Asp Glu Val Gly Cys Val Leu Asn Cys Thr 1175 1180 1185 Ala Ser Gln Phe Lys Cys Ala Ser Gly Asp Lys Cys Ile Gly Val 1190 1195 1200 Thr Asn Arg Cys Asp Gly Val Phe Asp Cys Ser Asp Asn Ser Asp 1205 1210 1215 Glu Ala Gly Cys Pro Thr Arg Pro Pro Gly Met Cys His Ser Asp 1220 1225 1230 Glu Phe Gln Cys Gln Glu Asp Gly Ile Cys Ile Pro Asn Phe Trp 1235 1240 1245 Glu Cys Asp Gly His Pro Asp Cys Leu Tyr Gly Ser Asp Glu His 1250 1255 1260 Asn Ala Cys Val Pro Lys Thr Cys Pro Ser Ser Tyr Phe His Cys 1265 1270 1275 Asp Asn Gly Asn Cys Ile His Arg Ala Trp Leu Cys Asp Arg Asp 1280 1285 1290 Asn Asp Cys Gly Asp Met Ser Asp Glu Lys Asp Cys Pro Thr Gln 1295 1300 1305 Pro Phe Arg Cys Pro Ser Trp Gln Trp Gln Cys Leu Gly His Asn 1310 1315 1320 Ile Cys Val Asn Leu Ser Val Val Cys Asp Gly Ile Phe Asp Cys 1325 1330 1335 Pro Asn Gly Thr Asp Glu Ser Pro Leu Cys Asn Gly Asn Ser Cys 1340 1345 1350 Ser Asp Phe Asn Gly Gly Cys Thr His Glu Cys Val Gln Glu Pro 1355 1360 1365 Phe Gly Ala Lys Cys Leu Cys Pro Leu Gly Phe Leu Leu Ala Asn 1370 1375 1380 Asp Ser Lys Thr Cys Glu Asp Ile Asp Glu Cys Asp Ile Leu Gly 1385 1390 1395 Ser Cys Ser Gln His Cys Tyr Asn Met Arg Gly Ser Phe Arg Cys 1400 1405 1410 Ser Cys Asp Thr Gly Tyr Met Leu Glu Ser Asp Gly Arg Thr Cys 1415 1420 1425 Lys Val Thr Ala Ser Glu Ser Leu Leu Leu Leu Val Ala Ser Gln 1430 1435 1440 Asn Lys Ile Ile Ala Asp Ser Val Thr Ser Gln Val His Asn Ile 1445 1450 1455 Tyr Ser Leu Val Glu Asn Gly Ser Tyr Ile Val Ala Val Asp Phe 1460 1465 1470 Asp Ser Ile Ser Gly Arg Ile Phe Trp Ser Asp Ala Thr Gln Gly 1475 1480 1485 Lys Thr Trp Ser Ala Phe Gln Asn Gly Thr Asp Arg Arg Val Val 1490 1495 1500 Phe Asp Ser Ser Ile Ile Leu Thr Glu Thr Ile Ala Ile Asp Trp 1505 1510 1515 Val Gly Arg Asn Leu Tyr Trp Thr Asp Tyr Ala Leu Glu Thr Ile 1520 1525 1530 Glu Val Ser Lys Ile Asp Gly Ser His Arg Thr Val Leu Ile Ser 1535 1540 1545 Lys Asn Leu Thr Asn Pro Arg Gly Leu Ala Leu Asp Pro Arg Met 1550 1555 1560 Asn Glu His Leu Leu Phe Trp Ser Asp Trp Gly His His Pro Arg 1565 1570 1575 Ile Glu Arg Ala Ser Met Asp Gly Ser Met Arg Thr Val Ile Val 1580 1585 1590 Gln Asp Lys Ile Phe Trp Pro Cys Gly Leu Thr Ile Asp Tyr Pro 1595 1600 1605 Asn Arg Leu Leu Tyr Phe Met Asp Ser Tyr Leu Asp Tyr Met Asp 1610 1615 1620 Phe Cys Asp Tyr Asn Gly His His Arg Arg Gln Val Ile Ala Ser 1625 1630 1635 Asp Leu Ile Ile Arg His Pro Tyr Ala Leu Thr Leu Phe Glu Asp 1640 1645 1650 Ser Val Tyr Trp Thr Asp Arg Ala Thr Arg Arg Val Met Arg Ala 1655 1660 1665 Asn Lys Trp His Gly Gly Asn Gln Ser Val Val Met Tyr Asn Ile 1670 1675 1680 Gln Trp Pro Leu Gly Ile Val Ala Val His Pro Ser Lys Gln Pro 1685 1690 1695 Asn Ser Val Asn Pro Cys Ala Phe Ser Arg Cys Ser His Leu Cys 1700 1705 1710 Leu Leu Ser Ser Gln Gly Pro His Phe Tyr Ser Cys Val Cys Pro 1715 1720 1725 Ser Gly Trp Ser Leu Ser Pro Asp Leu Leu Asn Cys Leu Arg Asp 1730 1735 1740 Asp Gln Pro Phe Leu Ile Thr Val Arg Gln His Ile Ile Phe Gly 1745 1750 1755 Ile Ser Leu Asn Pro Glu Val Lys Ser Asn Asp Ala Met Val Pro 1760 1765 1770 Ile Ala Gly Ile Gln Asn Gly Leu Asp Val Glu Phe Asp Asp Ala 1775 1780 1785 Glu Gln Tyr Ile Tyr Trp Val Glu Asn Pro Gly Glu Ile His Arg 1790 1795 1800 Val Lys Thr Asp Gly Thr Asn Arg Thr Val Phe Ala Ser Ile Ser 1805 1810 1815 Met Val Gly Pro Ser Met Asn Leu Ala Leu Asp Trp Ile Ser Arg 1820 1825 1830 Asn Leu Tyr Ser Thr Asn Pro Arg Thr Gln Ser Ile Glu Val Leu 1835 1840 1845 Thr Leu His Gly Asp Ile Arg Tyr Arg Lys Thr Leu Ile Ala Asn 1850 1855 1860 Asp Gly Thr Ala Leu Gly Val Gly Phe Pro Ile Gly Ile Thr Val 1865 1870 1875 Asp Pro Ala Arg Gly Lys Leu Tyr Trp Ser Asp Gln Gly Thr Asp 1880 1885 1890 Ser Gly Val Pro Ala Lys Ile Ala Ser Ala Asn Met Asp Gly Thr 1895 1900 1905 Ser Val Lys Thr Leu Phe Thr Gly Asn Leu Glu His Leu Glu Cys 1910 1915 1920 Val Thr Leu Asp Ile Glu Glu Gln Lys Leu Tyr Trp Ala Val Thr 1925 1930 1935 Gly Arg Gly Val Ile Glu Arg Gly Asn Val Asp Gly Thr Asp Arg 1940 1945 1950 Met Ile Leu Val His Gln Leu Ser His Pro Trp Gly Ile Ala Val 1955 1960 1965 His Asp Ser Phe Leu Tyr Tyr Thr Asp Glu Gln Tyr Glu Val Ile 1970 1975 1980 Glu Arg Val Asp Lys Ala Thr Gly Ala Asn Lys Ile Val Leu Arg 1985 1990 1995 Asp Asn Val Pro Asn Leu Arg Gly Leu Gln Val Tyr His Arg Arg 2000 2005 2010 Asn Ala Ala Glu Ser Ser Asn Gly Cys Ser Asn Asn Met Asn Ala 2015 2020 2025 Cys Gln Gln Ile Cys Leu Pro Val Pro Gly Gly Leu Phe Ser Cys 2030 2035 2040 Ala Cys Ala Thr Gly Phe Lys Leu Asn Pro Asp Asn Arg Ser Cys 2045 2050 2055 Ser Pro Tyr Asn Ser Phe Ile Val Val Ser Met Leu Ser Ala Ile 2060 2065 2070 Arg Gly Phe Ser Leu Glu Leu Ser Asp His Ser Glu Thr Met Val 2075 2080 2085 Pro Val Ala Gly Gln Gly Arg Asn Ala Leu His Val Asp Val Asp 2090 2095 2100 Val Ser Ser Gly Phe Ile Tyr Trp Cys Asp Phe Ser Ser Ser Val 2105 2110 2115 Ala Ser Asp Asn Ala Ile Arg Arg Ile Lys Pro Asp Gly Ser Ser 2120 2125 2130 Leu Met Asn Ile Val Thr His Gly Ile Gly Glu Asn Gly Val Arg 2135 2140 2145 Gly Ile Ala Val Asp Trp Val Ala Gly Asn Leu Tyr Phe Thr Asn 2150 2155 2160 Ala Phe Val Ser Glu Thr Leu Ile Glu Val Leu Arg Ile Asn Thr 2165 2170 2175 Thr Tyr Arg Arg Val Leu Leu Lys Val Thr Val Asp Met Pro Arg 2180 2185 2190 His Ile Val Val Asp Pro Lys Asn Arg Tyr Leu Phe Trp Ala Asp 2195 2200 2205 Tyr Gly Gln Arg Pro Lys Ile Glu Arg Ser Phe Leu Asp Cys Thr 2210 2215 2220 Asn Arg Thr Val Leu Val Ser Glu Gly Ile Val Thr Pro Arg Gly 2225 2230 2235 Leu Ala Val Asp Arg Ser Asp Gly Tyr Val Tyr Trp Val Asp Asp 2240 2245 2250 Ser Leu Asp Ile Ile Ala Arg Ile Arg Ile Asn Gly Glu Asn Ser 2255 2260 2265 Glu Val Ile Arg Tyr Gly Ser Arg Tyr Pro Thr Pro Tyr Gly Ile 2270 2275 2280 Thr Val Phe Glu Asn Ser Ile Ile Trp Val Asp Arg Asn Leu Lys 2285 2290 2295 Lys Ile Phe Gln Ala Ser Lys Glu Pro Glu Asn Thr Glu Pro Pro 2300 2305 2310 Thr Val Ile Arg Asp Asn Ile Asn Trp Leu Arg Asp Val Thr Ile 2315 2320 2325 Phe Asp Lys Gln Val Gln Pro Arg Ser Pro Ala Glu Val Asn Asn 2330 2335 2340 Asn Pro Cys Leu Glu Asn Asn Gly Gly Cys Ser His Leu Cys Phe 2345 2350 2355 Ala Leu Pro Gly Leu His Thr Pro Lys Cys Asp Cys Ala Phe Gly 2360 2365 2370 Thr Leu Gln Ser Asp Gly Lys Asn Cys Ala Ile Ser Thr Glu Asn 2375 2380 2385 Phe Leu Ile Phe Ala Leu Ser Asn Ser Leu Arg Ser Leu His Leu 2390 2395 2400 Asp Pro Glu Asn His Ser Pro Pro Phe Gln Thr Ile Asn Val Glu 2405 2410 2415 Arg Thr Val Met Ser Leu Asp Tyr Asp Ser Val Ser Asp Arg Ile 2420 2425 2430 Tyr Phe Thr Gln Asn Leu Ala Ser Gly Val Gly Gln Ile Ser Tyr 2435 2440 2445 Ala Thr Leu Ser Ser Gly Ile His Thr Pro Thr Val Ile Ala Ser 2450 2455 2460 Gly Ile Gly Thr Ala Asp Gly Ile Ala Phe Asp Trp Ile Thr Arg 2465 2470 2475 Arg Ile Tyr Tyr Ser Asp Tyr Leu Asn Gln Met Ile Asn Ser Met 2480 2485 2490 Ala Glu Asp Gly Ser Asn Arg Thr Val Ile Ala Arg Val Pro Lys 2495 2500 2505 Pro Arg Ala Ile Val Leu Asp Pro Cys Gln Gly Tyr Leu Tyr Trp 2510 2515 2520 Ala Asp Trp Asp Thr His Ala Lys Ile Glu Arg Ala Thr Leu Gly 2525 2530 2535 Gly Asn Phe Arg Val Pro Ile Val Asn Ser Ser Leu Val Met Pro 2540 2545 2550 Ser Gly Leu Thr Leu Asp Tyr Glu Glu Asp Leu Leu Tyr Trp Val 2555 2560 2565 Asp Ala Ser Leu Gln Arg Ile Glu Arg Ser Thr Leu Thr Gly Val 2570 2575 2580 Asp Arg Glu Val Ile Val Asn Ala Ala Val His Ala Phe Gly Leu 2585 2590 2595 Thr Leu Tyr Gly Gln Tyr Ile Tyr Trp Thr Asp Leu Tyr Thr Gln 2600 2605 2610 Arg Ile Tyr Arg Ala Asn Lys Tyr Asp Gly Ser Gly Gln Ile Ala 2615 2620 2625 Met Thr Thr Asn Leu Leu Ser Gln Pro Arg Gly Ile Asn Thr Val 2630 2635 2640 Val Lys Asn Gln Lys Gln Gln Cys Asn Asn Pro Cys Glu Gln Phe 2645 2650 2655 Asn Gly Gly Cys Ser His Ile Cys Ala Pro Gly Pro Asn Gly Ala 2660 2665 2670 Glu Cys Gln Cys Pro His Glu Gly Asn Trp Tyr Leu Ala Asn Asn 2675 2680 2685 Arg Lys His Cys Ile Val Asp Asn Gly Glu Arg Cys Gly Ala Ser 2690 2695 2700 Ser Phe Thr Cys Ser Asn Gly Arg Cys Ile Ser Glu Glu Trp Lys 2705 2710 2715 Cys Asp Asn Asp Asn Asp Cys Gly Asp Gly Ser Asp Glu Met Glu 2720 2725 2730 Ser Val Cys Ala Leu His Thr Cys Ser Pro Thr Ala Phe Thr Cys 2735 2740 2745 Ala Asn Gly Arg Cys Val Gln Tyr Ser Tyr Arg Cys Asp Tyr Tyr 2750 2755 2760 Asn Asp Cys Gly Asp Gly Ser Asp Glu Ala Gly Cys Leu Phe Arg 2765 2770 2775 Asp Cys Asn Ala Thr Thr Glu Phe Met Cys Asn Asn Arg Arg Cys 2780 2785 2790 Ile Pro Arg Glu Phe Ile Cys Asn Gly Val Asp Asn Cys His Asp 2795 2800 2805 Asn Asn Thr Ser Asp Glu Lys Asn Cys Pro Asp Arg Thr Cys Gln 2810 2815 2820 Ser Gly Tyr Thr Lys Cys His Asn Ser Asn Ile Cys Ile Pro Arg 2825 2830 2835 Val Tyr Leu Cys Asp Gly Asp Asn Asp Cys Gly Asp Asn Ser Asp 2840 2845 2850 Glu Asn Pro Thr Tyr Cys Thr Thr His Thr Cys Ser Ser Ser Glu 2855 2860 2865 Phe Gln Cys Ala Ser Gly Arg Cys Ile Pro Gln His Trp Tyr Cys 2870 2875 2880 Asp Gln Glu Thr Asp Cys Phe Asp Ala Ser Asp Glu Pro Ala Ser 2885 2890 2895 Cys Gly His Ser Glu Arg Thr Cys Leu Ala Asp Glu Phe Lys Cys 2900 2905 2910 Asp Gly Gly Arg Cys Ile Pro Ser Glu Trp Ile Cys Asp Gly Asp 2915 2920 2925 Asn Asp Cys Gly Asp Met Ser Asp Glu Asp Lys Arg His Gln Cys 2930 2935 2940 Gln Asn Gln Asn Cys Ser Asp Ser Glu Phe Leu Cys Val Asn Asp 2945 2950 2955 Arg Pro Pro Asp Arg Arg Cys Ile Pro Gln Ser Trp Val Cys Asp 2960 2965 2970 Gly Asp Val Asp Cys Thr Asp Gly Tyr Asp Glu Asn Gln Asn Cys 2975 2980 2985 Thr Arg Arg Thr Cys Ser Glu Asn Glu Phe Thr Cys Gly Tyr Gly 2990 2995 3000 Leu Cys Ile Pro Lys Ile Phe Arg Cys Asp Arg His Asn Asp Cys 3005 3010 3015 Gly Asp Tyr Ser Asp Glu Arg Gly Cys Leu Tyr Gln Thr Cys Gln 3020 3025 3030 Gln Asn Gln Phe Thr Cys Gln Asn Gly Arg Cys Ile Ser Lys Thr 3035 3040 3045 Phe Val Cys Asp Glu Asp Asn Asp Cys Gly Asp Gly Ser Asp Glu 3050 3055 3060 Leu Met His Leu Cys His Thr Pro Glu Pro Thr Cys Pro Pro His 3065 3070 3075 Glu Phe Lys Cys Asp Asn Gly Arg Cys Ile Glu Met Met Lys Leu 3080 3085 3090 Cys Asn His Leu Asp Asp Cys Leu Asp Asn Ser Asp Glu Lys Gly 3095 3100 3105 Cys Gly Ile Asn Glu Cys His Asp Pro Ser Ile Ser Gly Cys Asp 3110 3115 3120 His Asn Cys Thr Asp Thr Leu Thr Ser Phe Tyr Cys Ser Cys Arg 3125 3130 3135 Pro Gly Tyr Lys Leu Met Ser Asp Lys Arg Thr Cys Val Asp Ile 3140 3145 3150 Asp Glu Cys Thr Glu Met Pro Phe Val Cys Ser Gln Lys Cys Glu 3155 3160 3165 Asn Val Ile Gly Ser Tyr Ile Cys Lys Cys Ala Pro Gly Tyr Leu 3170 3175 3180 Arg Glu Pro Asp Gly Lys Thr Cys Arg Gln Asn Ser Asn Ile Glu 3185 3190 3195 Pro Tyr Leu Ile Phe Ser Asn Arg Tyr Tyr Leu Arg Asn Leu Thr 3200 3205 3210 Ile Asp Gly Tyr Phe Tyr Ser Leu Ile Leu Glu Gly Leu Asp Asn 3215 3220 3225 Val Val Ala Leu Asp Phe Asp Arg Val Glu Lys Arg Leu Tyr Trp 3230 3235 3240 Ile Asp Thr Gln Arg Gln Val Ile Glu Arg Met Phe Leu Asn Lys 3245 3250 3255 Thr Asn Lys Glu Thr Ile Ile Asn His Arg Leu Pro Ala Ala Glu 3260 3265 3270 Ser Leu Ala Val Asp Trp Val Ser Arg Lys Leu Tyr Trp Leu Asp 3275 3280 3285 Ala Arg Leu Asp Gly Leu Phe Val Ser Asp Leu Asn Gly Gly His 3290 3295 3300 Arg Arg Met Leu Ala Gln His Cys Val Asp Ala Asn Asn Thr Phe 3305 3310 3315 Cys Phe Asp Asn Pro Arg Gly Leu Ala Leu His Pro Gln Tyr Gly 3320 3325 3330 Tyr Leu Tyr Trp Ala Asp Trp Gly His Arg Ala Tyr Ile Gly Arg 3335 3340 3345 Val Gly Met Asp Gly Thr Asn Lys Ser Val Ile Ile Ser Thr Lys 3350 3355 3360 Leu Glu Trp Pro Asn Gly Ile Thr Ile Asp Tyr Thr Asn Asp Leu 3365 3370 3375 Leu Tyr Trp Ala Asp Ala His Leu Gly Tyr Ile Glu Tyr Ser Asp 3380 3385 3390 Leu Glu Gly His His Arg His Thr Val Tyr Asp Gly Ala Leu Pro 3395 3400 3405 His Pro Phe Ala Ile Thr Ile Phe Glu Asp Thr Ile Tyr Trp Thr 3410 3415 3420 Asp Trp Asn Thr Arg Thr Val Glu Lys Gly Asn Lys Tyr Asp Gly 3425 3430 3435 Ser Asn Arg Gln Thr Leu Val Asn Thr Thr His Arg Pro Phe Asp 3440 3445 3450 Ile His Val Tyr His Pro Tyr Arg Gln Pro Ile Val Ser Asn Pro 3455 3460 3465 Cys Gly Thr Asn Asn Gly Gly Cys Ser His Leu Cys Leu Ile Lys 3470 3475 3480 Pro Gly Gly Lys Gly Phe Thr Cys Glu Cys Pro Asp Asp Phe Arg 3485 3490 3495 Thr Leu Gln Leu Ser Gly Ser Thr Tyr Cys Met Pro Met Cys Ser 3500 3505 3510 Ser Thr Gln Phe Leu Cys Ala Asn Asn Glu Lys Cys Ile Pro Ile 3515 3520 3525 Trp Trp Lys Cys Asp Gly Gln Lys Asp Cys Ser Asp Gly Ser Asp 3530 3535 3540 Glu Leu Ala Leu Cys Pro Gln Arg Phe Cys Arg Leu Gly Gln Phe 3545 3550 3555 Gln Cys Ser Asp Gly Asn Cys Thr Ser Pro Gln Thr Leu Cys Asn 3560 3565 3570 Ala His Gln Asn Cys Pro Asp Gly Ser Asp Glu Asp Arg Leu Leu 3575 3580 3585 Cys Glu Asn His His Cys Asp Ser Asn Glu Trp Gln Cys Ala Asn 3590 3595 3600 Lys Arg Cys Ile Pro Glu Ser Trp Gln Cys Asp Thr Phe Asn Asp 3605 3610 3615 Cys Glu Asp Asn Ser Asp Glu Asp Ser Ser His Cys Ala Ser Arg 3620 3625 3630 Thr Cys Arg Pro Gly Gln Phe Arg Cys Ala Asn Gly Arg Cys Ile 3635 3640 3645 Pro Gln Ala Trp Lys Cys Asp Val Asp Asn Asp Cys Gly Asp His 3650 3655 3660 Ser Asp Glu Pro Ile Glu Glu Cys Met Ser Ser Ala His Leu Cys 3665 3670 3675 Asp Asn Phe Thr Glu Phe Ser Cys Lys Thr Asn Tyr Arg Cys Ile 3680 3685 3690 Pro Lys Trp Ala Val Cys Asn Gly Val Asp Asp Cys Arg Asp Asn 3695 3700 3705 Ser Asp Glu Gln Gly Cys Glu Glu Arg Thr Cys His Pro Val Gly 3710 3715 3720 Asp Phe Arg Cys Lys Asn His His Cys Ile Pro Leu Arg Trp Gln 3725 3730 3735 Cys Asp Gly Gln Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Asn 3740 3745 3750 Cys Ala Pro Arg Glu Cys Thr Glu Ser Glu Phe Arg Cys Val Asn 3755 3760 3765 Gln Gln Cys Ile Pro Ser Arg Trp Ile Cys Asp His Tyr Asn Asp 3770 3775 3780 Cys Gly Asp Asn Ser Asp Glu Arg Asp Cys Glu Met Arg Thr Cys 3785 3790 3795 His Pro Glu Tyr Phe Gln Cys Thr Ser Gly His Cys Val His Ser 3800 3805 3810 Glu Leu Lys Cys Asp Gly Ser Ala Asp Cys Leu Asp Ala Ser Asp 3815 3820 3825 Glu Ala Asp Cys Pro Thr Arg Phe Pro Asp Gly Ala Tyr Cys Gln 3830 3835 3840 Ala Thr Met Phe Glu Cys Lys Asn His Val Cys Ile Pro Pro Tyr 3845 3850 3855 Trp Lys Cys Asp Gly Asp Asp Asp Cys Gly Asp Gly Ser Asp Glu 3860 3865 3870 Glu Leu His Leu Cys Leu Asp Val Pro Cys Asn Ser Pro Asn Arg 3875 3880 3885 Phe Arg Cys Asp Asn Asn Arg Cys Ile Tyr Ser His Glu Val Cys 3890 3895 3900 Asn Gly Val Asp Asp Cys Gly Asp Gly Thr Asp Glu Thr Glu Glu 3905 3910 3915 His Cys Arg Lys Pro Thr Pro Lys Pro Cys Thr Glu Tyr Glu Tyr 3920 3925 3930 Lys Cys Gly Asn Gly His Cys Ile Pro His Asp Asn Val Cys Asp 3935 3940 3945 Asp Ala Asp Asp Cys Gly Asp Trp Ser Asp Glu Leu Gly Cys Asn 3950 3955 3960 Lys Gly Lys Glu Arg Thr Cys Ala Glu Asn Ile Cys Glu Gln Asn 3965 3970 3975 Cys Thr Gln Leu Asn Glu Gly Gly Phe Ile Cys Ser Cys Thr Ala 3980 3985 3990 Gly Phe Glu Thr Asn Val Phe Asp Arg Thr Ser Cys Leu Asp Ile 3995 4000 4005 Asn Glu Cys Glu Gln Phe Gly Thr Cys Pro Gln His Cys Arg Asn 4010 4015 4020 Thr Lys Gly Ser Tyr Glu Cys Val Cys Ala Asp Gly Phe Thr Ser 4025 4030 4035 Met Ser Asp Arg Pro Gly Lys Arg Cys Ala Ala Glu Gly Ser Ser 4040 4045 4050 Pro Leu Leu Leu Leu Pro Asp Asn Val Arg Ile Arg Lys Tyr Asn 4055 4060 4065 Leu Ser Ser Glu Arg Phe Ser Glu Tyr Leu Gln Asp Glu Glu Tyr 4070 4075 4080 Ile Gln Ala Val Asp Tyr Asp Trp Asp Pro Lys Asp Ile Gly Leu 4085 4090 4095 Ser Val Val Tyr Tyr Thr Val Arg Gly Glu Gly Ser Arg Phe Gly 4100 4105 4110 Ala Ile Lys Arg Ala Tyr Ile Pro Asn Phe Glu Ser Gly Arg Asn 4115 4120 4125 Asn Leu Val Gln Glu Val Asp Leu Lys Leu Lys Tyr Val Met Gln 4130 4135 4140 Pro Asp Gly Ile Ala Val Asp Trp Val Gly Arg His Ile Tyr Trp 4145 4150 4155 Ser Asp Val Lys Asn Lys Arg Ile Glu Val Ala Lys Leu Asp Gly 4160 4165 4170 Arg Tyr Arg Lys Trp Leu Ile Ser Thr Asp Leu Asp Gln Pro Ala 4175 4180 4185 Ala Ile Ala Val Asn Pro Lys Leu Gly Leu Met Phe Trp Thr Asp 4190 4195 4200 Trp Gly Lys Glu Pro Lys Ile Glu Ser Ala Trp Met Asn Gly Glu 4205 4210 4215 Asp Arg Asn Ile Leu Val Phe Glu Asp Leu Gly Trp Pro Thr Gly 4220 4225 4230 Leu Ser Ile Asp Tyr Leu Asn Asn Asp Arg Ile Tyr Trp Ser Asp 4235 4240 4245 Phe Lys Glu Asp Val Ile Glu Thr Ile Lys Tyr Asp Gly Thr Asp 4250 4255 4260 Arg Arg Val Ile Ala Lys Glu Ala Met Asn Pro Tyr Ser Leu Asp 4265 4270 4275 Ile Phe Glu Asp Gln Leu Tyr Trp Ile Ser Lys Glu Lys Gly Glu 4280 4285 4290 Val Trp Lys Gln Asn Lys Phe Gly Gln Gly Lys Lys Glu Lys Thr 4295 4300 4305 Leu Val Val Asn Pro Trp Leu Thr Gln Val Arg Ile Phe His Gln 4310 4315 4320 Leu Arg Tyr Asn Lys Ser Val Pro Asn Leu Cys Lys Gln Ile Cys 4325 4330 4335 Ser His Leu Cys Leu Leu Arg Pro Gly Gly Tyr Ser Cys Ala Cys 4340 4345 4350 Pro Gln Gly Ser Ser Phe Ile Glu Gly Ser Thr Thr Glu Cys Asp 4355 4360 4365 Ala Ala Ile Glu Leu Pro Ile Asn Leu Pro Pro Pro Cys Arg Cys 4370 4375 4380 Met His Gly Gly Asn Cys Tyr Phe Asp Glu Thr Asp Leu Pro Lys 4385 4390 4395 Cys Lys Cys Pro Ser Gly Tyr Thr Gly Lys Tyr Cys Glu Met Ala 4400 4405 4410 Phe Ser Lys Gly Ile Ser Pro Gly Thr Thr Ala Val Ala Val Leu 4415 4420 4425 Leu Thr Ile Leu Leu Ile Val Val Ile Gly Ala Leu Ala Ile Ala 4430 4435 4440 Gly Phe Phe His Tyr Arg Arg Thr Gly Ser Leu Leu Pro Ala Leu 4445 4450 4455 Pro Lys Leu Pro Ser Leu Ser Ser Leu Val Lys Pro Ser Glu Asn 4460 4465 4470 Gly Asn Gly Val Thr Phe Arg Ser Gly Ala Asp Leu Asn Met Asp 4475 4480 4485 Ile Gly Val Ser Gly Phe Gly Pro Glu Thr Ala Ile Asp Arg Ser 4490 4495 4500 Met Ala Met Ser Glu Asp Phe Val Met Glu Met Gly Lys Gln Pro 4505 4510 4515 Ile Ile Phe Glu Asn Pro Met Tyr Ser Ala Arg Asp Ser Ala Val 4520 4525 4530 Lys Val Val Gln Pro Ile Gln Val Thr Val Ser Glu Asn Val Asp 4535 4540 4545 Asn Lys Asn Tyr Gly Ser Pro Ile Asn Pro Ser Glu Ile Val Pro 4550 4555 4560 Glu Thr Asn Pro Thr Ser Pro Ala Ala Asp Gly Thr Gln Val Thr 4565 4570 4575 Lys Trp Asn Leu Phe Lys Arg Lys Ser Lys Gln Thr Thr Asn Phe 4580 4585 4590 Glu Asn Pro Ile Tyr Ala Gln Met Glu Asn Glu Gln Lys Glu Ser 4595 4600 4605 Val Ala Ala Thr Pro Pro Pro Ser Pro Ser Leu Pro Ala Lys Pro 4610 4615 4620 Lys Pro Pro Ser Arg Arg Asp Pro Thr Pro Thr Tyr Ser Ala Thr 4625 4630 4635 Glu Asp Thr Phe Lys Asp Thr Ala Asn Leu Val Lys Glu Asp Ser 4640 4645 4650 Glu Val 4655 4 4599 PRT Homo sapiens misc_feature (4343)..(4343) Xaa can be any naturally occurring amino acid 4 Met Ser Glu Phe Leu Leu Ala Leu Leu Thr Leu Ser Gly Leu Leu Pro 1 5 10 15 Ile Ala Arg Val Leu Thr Val Gly Ala Asp Arg Asp Gln Gln Leu Cys 20 25 30 Asp Pro Gly Glu Phe Leu Cys His Asp His Val Thr Cys Val Ser Gln 35 40 45 Ser Trp Leu Cys Asp Gly Asp Pro Asp Cys Pro Asp Asp Ser Asp Glu 50 55 60 Ser Leu Asp Thr Cys Pro Glu Glu Val Glu Ile Lys Cys Pro Leu Asn 65 70 75 80 His Ile Ala Cys Leu Gly Thr Asn Lys Cys Val His Leu Ser Gln Leu 85 90 95 Cys Asn Gly Val Leu Asp Cys Pro Asp Gly Tyr Asp Glu Gly Val His 100 105 110 Cys Gln Glu Leu Leu Ser Asn Cys Gln Gln Leu Asn Cys Gln Tyr Lys 115 120 125 Cys Thr Met Val Arg Asn Ser Thr Arg Cys Tyr Cys Glu Asp Gly Phe 130 135 140 Glu Ile Thr Glu Asp Gly Arg Ser Cys Lys Asp Gln Asp Glu Cys Ala 145 150 155 160 Val Tyr Gly Thr Cys Ser Gln Thr Cys Arg Asn Thr His Gly Ser Tyr 165 170 175 Thr Cys Ser Cys Val Glu Gly Tyr Leu Met Gln Pro Asp Asn Arg Ser 180 185 190 Cys Lys Ala Lys Ile Glu Pro Thr Asp Arg Pro Pro Ile Leu Leu Ile 195 200 205 Ala Asn Phe Glu Thr Ile Glu Val Phe Tyr Leu Asn Gly Ser Lys Met 210 215 220 Ala Thr Leu Ser Ser Val Asn Gly Asn Glu Ile His Thr Leu Asp Phe 225 230 235 240 Ile Tyr Asn Glu Asp Met Ile Cys Trp Ile Glu Ser Arg Glu Ser Ser 245 250 255 Asn Gln Leu Lys Cys Ile Gln Ile Thr Lys Ala Gly Gly Leu Thr Asp 260 265 270 Glu Trp Thr Ile Asn Ile Leu Gln Ser Phe His Asn Val Gln Gln Met 275 280 285 Ala Ile Asp Trp Leu Thr Arg Asn Leu Tyr Phe Val Asp His Val Gly 290 295 300 Asp Arg Ile Phe Val Cys Asn Ser Asn Gly Ser Val Cys Val Thr Leu 305 310 315 320 Ile Asp Leu Glu Leu His Asn Pro Lys Ala Ile Ala Val Asp Pro Ile 325 330 335 Ala Gly Lys Leu Phe Phe Thr Asp Tyr Gly Asn Val Ala Lys Val Glu 340 345 350 Arg Cys Asp Met Asp Gly Met Asn Arg Thr Arg Ile Ile Asp Ser Lys 355 360 365 Thr Glu Gln Pro Ala Ala Leu Ala Leu Asp Leu Val Asn Lys Leu Val 370 375 380 Tyr Trp Val Asp Leu Tyr Leu Asp Tyr Val Gly Val Val Asp Tyr Gln 385 390 395 400 Gly Lys Asn Arg His Thr Val Ile Gln Gly Arg Gln Val Arg His Leu 405 410 415 Tyr Gly Ile Thr Val Phe Glu Asp Tyr Leu Tyr Ala Thr Asn Ser Asp 420 425 430 Asn Tyr Asn Ile Val Arg Ile Asn Arg Phe Asn Gly Thr Asp Ile His 435 440 445 Ser Leu Ile Lys Ile Glu Asn Ala Trp Gly Ile Arg Ile Tyr Gln Lys 450 455 460 Arg Thr Gln Pro Thr Val Arg Ser His Ala Cys Glu Val Asp Pro Tyr 465 470 475 480 Gly Met Pro Gly Gly Cys Ser His Ile Cys Leu Leu Ser Ser Ser Tyr 485 490 495 Lys Thr Arg Thr Cys Arg Cys Arg Thr Gly Phe Asn Leu Gly Ser Asp 500 505 510 Gly Arg Ser Cys Lys Arg Pro Lys Asn Glu Leu Phe Leu Phe Tyr Gly 515 520 525 Lys Gly Arg Pro Gly Ile Val Arg Gly Met Asp Leu Asn Thr Lys Ile 530 535 540 Ala Asp Glu Tyr Met Ile Pro Ile Glu Asn Leu Val Asn Pro Arg Ala 545 550 555 560 Leu Asp Phe His Ala Glu Thr Asn Tyr Ile Tyr Phe Ala Asp Thr Thr 565 570 575 Ser Phe Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu Arg Glu Thr 580 585 590 Ile Leu Lys Asp Asp Leu Asp Asn Val Glu Gly Ile Ala Val Asp Trp 595 600 605 Ile Gly Asn Asn Leu Tyr Trp Thr Asn Asp Gly His Arg Lys Thr Ile 610 615 620 Asn Val Ala Arg Leu Glu Lys Ala Ser Gln Ser Arg Lys Thr Leu Leu 625 630 635 640 Glu Gly Glu Met Ser His Pro Arg Gly Ile Val Val Asp Pro Val Asn 645 650 655 Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Glu Ile Asp Asp Ser 660 665 670 Val Gly Arg Ile Glu Lys Ala Trp Met Asp Gly Phe Asn Arg Gln Ile 675 680 685 Phe Val Thr Ser Lys Met Leu Trp Pro Asn Gly Leu Thr Leu Asp Phe 690 695 700 His Thr Asn Thr Leu Tyr Trp Cys Asp Ala Tyr Tyr Asp His Ile Glu 705 710 715 720 Lys Val Phe Leu Asn Gly Thr His Arg Lys Ile Val Tyr Ser Gly Arg 725 730 735 Glu Leu Asn His Pro Phe Gly Leu Ser His His Gly Asn Tyr Val Phe 740 745 750 Trp Thr Asp Tyr Met Asn Gly Ser Ile Phe Gln Leu Asp Leu Ile Thr 755 760 765 Ser Glu Val Thr Leu Leu Arg His Glu Arg Pro Pro Leu Phe Gly Leu 770 775 780 Gln Ile Tyr Asp Pro Arg Lys Gln Gln Gly Asp Asn Met Cys Arg Val 785 790 795 800 Asn Asn Gly Gly Cys Ser Thr Leu Cys Leu Ala Ile Pro Gly Gly Arg 805 810 815 Val Cys Ala Cys Ala Asp Asn Gln Leu Leu Asp Glu Asn Gly Thr Thr 820 825 830 Cys Thr Phe Asn Pro Gly Glu Ala Leu Pro His Ile Cys Lys Ala Gly 835 840 845 Glu Phe Arg Cys Lys Asn Arg His Cys Ile Gln Ala Arg Trp Lys Cys 850 855 860 Asp Gly Asp Asp Asp Cys Leu Asp Gly Ser Asp Glu Asp Ser Val Asn 865 870 875 880 Cys Phe Asn His Ser Cys Pro Asp Asp Gln Phe Lys Cys Gln Asn Asn 885 890 895 Arg Cys Ile Pro Lys Arg Trp Leu Cys Asp Gly Ala Asn Asp Cys Gly 900 905 910 Ser Asn Glu Asp Glu Ser Asn Gln Thr Cys Thr Ala Arg Thr Cys Gln 915 920 925 Val Asp Gln Phe Ser Cys Gly Asn Gly Arg Cys Ile Pro Arg Ala Trp 930 935 940 Leu Cys Asp Arg Glu Asp Asp Cys Gly Asp Gln Thr Asp Glu Met Ala 945 950 955 960 Ser Cys Glu Phe Pro Thr Cys Glu Pro Leu Thr Gln Phe Val Cys Lys 965 970 975 Ser Gly Arg Cys Ile Ser Ser Lys Trp His Cys Asp Ser Asp Asp Asp 980 985 990 Cys Gly Asp Gly Ser Asp Glu Val Gly Cys Val His Ser Cys Phe Asp 995 1000 1005 Asn Gln Phe Arg Cys Ser Ser Gly Arg Cys Ile Pro Gly His Trp 1010 1015 1020 Ala Cys Asp Gly Asp Asn Asp Cys Gly Asp Phe Ser Asp Glu Ala 1025 1030 1035 Gln Ile Asn Cys Thr Lys Glu Glu Ile His Ser Pro Ala Gly Cys 1040 1045 1050 Asn Gly Asn Glu Phe Gln Cys His Pro Asp Gly Asn Cys Val Pro 1055 1060 1065 Asp Leu Trp Arg Cys Asp Gly Glu Lys Asp Cys Glu Asp Gly Ser 1070 1075 1080 Asp Glu Lys Gly Cys Asn Gly Thr Ile Arg Leu Cys Asp His Lys 1085 1090 1095 Thr Lys Phe Ser Cys Trp Ser Thr Gly Arg Cys Ile Asn Lys Ala 1100 1105 1110 Trp Val Cys Asp Gly Asp Ile Asp Cys Glu Asp Gln Ser Asp Glu 1115 1120 1125 Asp Asp Cys Asp Ser Phe Leu Cys Gly Pro Pro Lys His Pro Cys 1130 1135 1140 Ala Asn Asp Thr Ser Val Cys Leu Gln Pro Glu Lys Leu Cys Asn 1145 1150 1155 Gly Lys Lys Asp Cys Pro Asp Gly Ser Asp Glu Gly Tyr Leu Cys 1160 1165 1170 Asp Glu Cys Ser Leu Asn Asn Gly Gly Cys Ser Asn His Cys Ser 1175 1180 1185 Val Val Pro Gly Arg Gly Ile Val Cys Ser Cys Pro Glu Gly Leu 1190 1195 1200 Gln Leu Asn Lys Asp Asn Lys Thr Cys Glu Ile Val Asp Tyr Cys 1205 1210 1215 Ser Asn His Leu Lys Cys Ser Gln Val Cys Glu Gln His Lys His 1220 1225 1230 Thr Val Lys Cys Ser Cys Tyr Glu Gly Trp Lys Leu Asp Val Asp 1235 1240 1245 Gly Glu Ser Cys Thr Ser Val Asp Pro Phe Glu Ala Phe Ile Ile 1250 1255 1260 Phe Ser Ile Arg His Glu Ile Arg Arg Ile Asp Leu His Lys Arg 1265 1270 1275 Asp Tyr Ser Leu Leu Val Pro Gly Leu Arg Asn Thr Ile Ala Leu 1280 1285 1290 Asp Phe His Phe Asn Gln Ser Leu Leu Tyr Trp Thr Asp Val Val 1295 1300 1305 Glu Asp Arg Ile Tyr Arg Gly Lys Leu Ser Glu Ser Gly Gly Val 1310 1315 1320 Ser Ala Ile Glu Val Val Val Glu His Gly Leu Ala Thr Pro Glu 1325 1330 1335 Gly Leu Thr Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Ile Asp 1340 1345 1350 Ser Asn Leu Asp Gln Ile Glu Val Ala Lys Leu Asp Gly Ser Leu 1355 1360 1365 Arg Thr Thr Leu Ile Ala Gly Ala Met Glu His Pro Arg Ala Ile 1370 1375 1380 Ala Leu Asp Pro Arg Tyr Gly Ile Leu Phe Trp Thr Asp Trp Asp 1385 1390 1395 Ala Asn Phe Pro Arg Ile Glu Ser Ala Ser Met Ser Gly Ala Gly 1400 1405 1410 Arg Lys Thr Ile Tyr Lys Asp Met Lys Thr Gly Ala Trp Pro Asn 1415 1420 1425 Gly Leu Thr Val Asp His Phe Glu Lys Arg Ile Val Trp Thr Asp 1430 1435 1440 Ala Arg Ser Asp Ala Ile Tyr Ser Ala Leu Tyr Asp Gly Thr Asn 1445 1450 1455 Met Ile Glu Ile Ile Arg Gly His Glu Tyr Leu Ser His Pro Phe 1460 1465 1470 Ala Val Ser Leu Tyr Gly Ser Glu Val Tyr Trp Thr Asp Trp Arg 1475 1480 1485 Thr Asn Thr Leu Ser Lys Ala Asn Lys Trp Thr Gly Gln Asn Val 1490 1495 1500 Ser Val Ile Gln Lys Thr Ser Ala Gln Pro Phe Asp Leu Gln Ile 1505 1510 1515 Tyr His Pro Ser Arg Gln Pro Gln Ala Pro Asn Pro Cys Ala Ala 1520 1525 1530 Asn Asp Gly Lys Gly Pro Cys Ser His Met Cys Leu Ile Asn His 1535 1540 1545 Asn Arg Ser Ala Ala Cys Ala Cys Pro His Leu Met Lys Leu Ser 1550 1555 1560 Ser Asp Lys Lys Thr Cys Tyr Glu Met Lys Lys Phe Leu Leu Tyr 1565 1570 1575 Ala Arg Arg Ser Glu Ile Arg Gly Val Asp Ile Asp Asn Pro Tyr 1580 1585 1590 Phe Asn Phe Ile Thr Ala Phe Thr Val Pro Asp Ile Asp Asp Val 1595 1600 1605 Thr Val Ile Asp Phe Asp Ala Ser Glu Glu Arg Leu Tyr Trp Thr 1610 1615 1620 Asp Ile Lys Thr Gln Thr Ile Lys Arg Ala Phe Ile Asn Gly Thr 1625 1630 1635 Gly Leu Glu Thr Val Ile Ser Arg Asp Ile Gln Ser Ile Arg Gly 1640 1645 1650 Leu Ala Val Asp Trp Val Ser Arg Asn Leu Tyr Trp Ile Ser Ser 1655 1660 1665 Glu Phe Asp Glu Thr Gln Ile Asn Val Ala Arg Leu Asp Gly Ser 1670 1675 1680 Leu Lys Thr Ser Ile Ile His Gly Ile Asp Lys Pro Gln Cys Leu 1685 1690 1695 Ala Ala His Pro Val Arg Gly Lys Leu Tyr Trp Thr Asp Gly Asn 1700 1705 1710 Thr Ile Asn Met Ala Asn Met Asp Gly Ser Asn Ser Lys Ile Leu 1715 1720 1725 Phe Gln Asn Gln Lys Glu Pro Val Gly Leu Ser Ile Asp Tyr Val 1730 1735 1740 Glu Asn Lys Leu Tyr Trp Ile Ser Ser Gly Asn Gly Thr Ile Asn 1745 1750 1755 Arg Cys Asn Leu Asp Gly Gly Asn Leu Glu Val Ile Glu Ser Met 1760 1765 1770 Lys Glu Glu Leu Thr Lys Ala Thr Ala Leu Thr Ile Met Asp Lys 1775 1780 1785 Lys Leu Trp Trp Ala Asp Gln Asn Leu Ala Gln Leu Gly Thr Cys 1790 1795 1800 Ser Lys Arg Asp Gly Arg Asn Pro Thr Ile Leu Arg Asn Lys Thr 1805 1810 1815 Ser Gly Val Val His Met Lys Val Tyr Asp Lys Glu Ala Gln Gln 1820 1825 1830 Gly Ser Asn Ser Cys Gln Leu Asn Asn Gly Gly Cys Ser Gln Leu 1835 1840 1845 Cys Leu Pro Thr Ser Glu Thr Thr Arg Thr Cys Met Cys Thr Val 1850 1855 1860 Gly Tyr Tyr Leu Gln Lys Asn Arg Met Ser Cys Gln Gly Ile Glu 1865 1870 1875 Ser Phe Leu Met Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro 1880 1885 1890 Leu Glu Pro Ser Asp Lys Met Asp Ala Leu Met Pro Ile Ser Gly 1895 1900 1905 Thr Ser Phe Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr 1910 1915 1920 Ile Tyr Trp Thr Asp Met Gly Phe Asn Lys Ile Ser Arg Ala Lys 1925 1930 1935 Arg Asp Gln Thr Trp Lys Glu Asp Ile Ile Thr Asn Gly Leu Gly 1940 1945 1950 Arg Val Glu Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr 1955 1960 1965 Trp Thr Asp His Gly Phe Asn Leu Ile Glu Val Ala Arg Leu Asn 1970 1975 1980 Gly Ser Phe Arg Tyr Val Ile Ile Ser Gln Gly Leu Asp Gln Pro 1985 1990 1995 Arg Ser Ile Ala Val His Pro Glu Lys Gly Leu Leu Phe Trp Thr 2000 2005 2010 Glu Trp Gly Gln Met Pro Cys Ile Gly Lys Ala Arg Leu Asp Gly 2015 2020 2025 Ser Glu Lys Val Val Leu Val Ser Met Gly Ile Ala Trp Pro Asn 2030 2035 2040 Gly Ile Ser Ile Asp Tyr Glu Glu Asn Lys Leu Tyr Trp Cys Asp 2045 2050 2055 Ala Arg Thr Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Gly 2060 2065 2070 Asn Arg Glu Met Val Leu Ser Gly Ser Asn Val Asp Met Phe Ser 2075 2080 2085 Val Ala Val Phe Gly Ala Tyr Ile Tyr Trp Ser Asp Arg Ala His 2090 2095 2100 Ala Asn Gly Ser Val Arg Arg Gly His Lys Asn Asp Ala Thr Glu 2105 2110 2115 Thr Ile Thr Met Arg Thr Gly Leu Gly Val Asn Leu Lys Glu Val 2120 2125 2130 Lys Ile Phe Asn Arg Val Arg Glu Lys Gly Thr Asn Val Cys Ala 2135 2140 2145 Arg Asp Asn Gly Gly Cys Lys Gln Leu Cys Leu Tyr Arg Gly Asn 2150 2155 2160 Ser Arg Arg Thr Cys Ala Cys Ala His Gly Tyr Leu Ala Glu Asp 2165 2170 2175 Gly Val Thr Cys Leu Arg His Glu Gly Tyr Leu Leu Tyr Ser Gly 2180 2185 2190 Arg Thr Ile Leu Lys Ser Ile His Leu Ser Asp Glu Thr Asn Leu 2195 2200 2205 Asn Ser Pro Ile Arg Pro Tyr Glu Asn Pro Arg Tyr Phe Lys Asn 2210 2215 2220 Val Ile Ala Leu Ala Phe Asp Tyr Asn Gln Arg Arg Lys Gly Thr 2225 2230 2235 Asn Arg Ile Phe Tyr Ser Asp Ala His Phe Gly Asn Ile Gln Leu 2240 2245 2250 Ile Lys Asp Asn Trp Glu Asp Arg Gln Val Ile Val Glu Asn Val 2255 2260 2265 Gly Ser Val Glu Gly Leu Ala Tyr His Arg Ala Trp Asp Thr Leu 2270 2275 2280 Tyr Trp Thr Ser Ser Thr Thr Ser Ser Ile Thr Arg His Thr Val 2285 2290 2295 Asp Gln Thr Arg Pro Gly Ala Phe Asp Arg Glu Ala Val Ile Thr 2300 2305 2310 Met Ser Glu Asp Asp His Pro His Val Leu Ala Leu Asp Glu Cys 2315 2320 2325 Gln Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser 2330 2335 2340 Ile Met Arg Ser Thr Leu Thr Gly Lys Asn Ala Gln Val Val Val 2345 2350 2355 Ser Thr Asp Ile Leu Thr Pro Asn Gly Leu Thr Ile Asp Tyr Arg 2360 2365 2370 Ala Glu Lys Leu Tyr Phe Ser Asp Gly Ser Leu Gly Lys Ile Glu 2375 2380 2385 Arg Cys Glu Tyr Asp Gly Ser Gln Arg His Val Ile Val Lys Ser 2390 2395 2400 Gly Pro Gly Thr Phe Leu Ser Leu Ala Val Tyr Asp Asn Tyr Ile 2405 2410 2415 Phe Trp Ser Asp Trp Gly Arg Arg Ala Ile Leu Arg Ser Asn Lys 2420 2425 2430 Tyr Thr Gly Gly Asp Thr Lys Ile Leu Arg Ser Asp Ile Pro His 2435 2440 2445 Gln Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys 2450 2455 2460 Glu Leu Ser Pro Cys Ala Leu Leu Asn Gly Gly Cys His Asp Leu 2465 2470 2475 Cys Leu Leu Thr Pro Asn Gly Arg Val Asn Cys Ser Cys Arg Gly 2480 2485 2490 Asp Arg Ile Leu Leu Glu Asp Asn Arg Cys Val Thr Lys Asn Ser 2495 2500 2505 Ser Cys Asn Ala Tyr Ser Glu Phe Glu Cys Gly Asn Gly Glu Cys 2510 2515 2520 Ile Asp Tyr Gln Leu Thr Cys Asp Gly Ile Pro His Cys Lys Asp 2525 2530 2535 Lys Ser Asp Glu Lys Leu Leu Tyr Cys Glu Asn Arg Ser Cys Arg 2540 2545 2550 Arg Gly Phe Lys Pro Cys Tyr Asn Arg Arg Cys Ile Pro His Gly 2555 2560 2565 Lys Leu Cys Asp Gly Glu Asn Asp Cys Gly Asp Asn Ser Asp Glu 2570 2575 2580 Leu Asp Cys Lys Val Ser Thr Cys Ala Thr Val Glu Phe Arg Cys 2585 2590 2595 Ala Asp Gly Thr Cys Ile Pro Arg Ser Ala Arg Cys Asn Gln Asn 2600 2605 2610 Ile Asp Cys Ala Asp Ala Ser Asp Glu Lys Asn Cys Asn Asn Thr 2615 2620 2625 Asp Cys Thr His Phe Tyr Lys Leu Gly Val Lys Thr Thr Gly Phe 2630 2635 2640 Ile Arg Cys Asn Ser Thr Ser Leu Cys Val Leu Pro Thr Trp Ile 2645 2650 2655 Cys Asp Gly Ser Asn Asp Cys Gly Asp Tyr Ser Asp Glu Leu Lys 2660 2665 2670 Cys Pro Val Gln Asn Lys His Lys Cys Glu Glu Asn Tyr Phe Ser 2675 2680 2685 Cys Pro Ser Gly Arg Cys Ile Leu Asn Thr Trp Ile Cys Asp Gly 2690 2695 2700 Gln Lys Asp Cys Glu Asp Gly Arg Asp Glu Phe His Cys Asp Ser 2705 2710 2715 Ser Cys Ser Trp Asn Gln Phe Ala Cys Ser Ala Gln Lys Cys Ile 2720 2725 2730 Ser Lys His Trp Ile Cys Asp Gly Glu Asp Asp Cys Gly Asp Gly 2735 2740 2745 Leu Asp Glu Ser Asp Ser Ile Cys Gly Ala Ile Thr Cys Ala Ala 2750 2755 2760 Asp Met Phe Ser Cys Gln Gly Ser Arg Ala Cys Val Pro Arg His 2765 2770 2775 Trp Leu Cys Asp Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu 2780 2785 2790 Leu Ser Thr Ala Gly Cys Ala Pro Asn Asn Thr Cys Asp Glu Asn 2795 2800 2805 Ala Phe Met Cys His Asn Lys Val Cys Ile Pro Lys Gln Phe Val 2810 2815 2820 Cys Asp His Asp Asp Asp Cys Gly Asp Gly Ser Asp Glu Ser Pro 2825 2830 2835 Gln Cys Gly Tyr Arg Gln Cys Gly Thr Glu Glu Phe Ser Cys Ala 2840 2845 2850 Asp Gly Arg Cys Leu Leu Asn Thr Gln Trp Gln Cys Asp Gly Asp 2855 2860 2865 Phe Asp Cys Pro Asp His Ser Asp Glu Ala Pro Leu Asn Pro Lys 2870 2875 2880 Cys Lys Ser Ala Glu Gln Ser Cys Asn Ser Ser Phe Phe Met Cys 2885 2890 2895 Lys Asn Gly Arg Cys Ile Pro Ser Gly Gly Leu Cys Asp Asn Lys 2900 2905 2910 Asp Asp Cys Gly Asp Gly Ser Asp Glu Arg Asn Cys His Ile Asn 2915 2920 2925 Glu Cys Leu Ser Lys Lys Val Ser Gly Cys Ser Gln Asp Cys Gln 2930 2935 2940 Asp Leu Pro Val Ser Tyr Lys Cys Lys Cys Trp Pro Gly Phe Gln 2945 2950 2955 Leu Lys Asp Asp Gly Lys Thr Cys Val Asp Ile Asp Glu Cys Ser 2960 2965 2970 Ser Gly Phe Pro Cys Ser Gln Gln Cys Ile Asn Thr Tyr Gly Thr 2975 2980 2985 Tyr Lys Cys Leu Cys Thr Asp Gly Tyr Glu Ile Gln Pro Asp Asn 2990 2995 3000 Pro Asn Gly Cys Lys Ser Leu Ser Asp Glu Glu Pro Phe Leu Ile 3005 3010 3015 Leu Ala Asp His His Glu Ile Arg Lys Ile Ser Thr Asp Gly Ser 3020 3025 3030 Asn Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Val Ile Ala Ile 3035 3040 3045 Asp Phe Asp Tyr Arg Glu Glu Phe Ile Tyr Trp Ile Asp Ser Ser 3050 3055 3060 Arg Pro Asn Gly Ser Arg Ile Asn Arg Met Cys Leu Asn Gly Ser 3065 3070 3075 Asp Ile Lys Val Val His Asn Thr Ala Val Pro Asn Ala Leu Ala 3080 3085 3090 Val Asp Trp Ile Gly Lys Asn Leu Tyr Trp Ser Asp Thr Glu Lys 3095 3100 3105 Arg Ile Ile Glu Val Ser Lys Leu Asn Gly Leu Tyr Pro Thr Ile 3110 3115 3120 Leu Val Ser Lys Arg Leu Lys Phe Pro Arg Asp Leu Ser Leu Asp 3125 3130 3135 Pro Gln Ala Gly Tyr Leu Tyr Trp Ile Asp Cys Cys Glu Tyr Pro 3140 3145 3150 His Ile Gly Arg Val Gly Met Asp Gly Thr Asn Gln Ser Val Val 3155 3160 3165 Ile Glu Thr Lys Ile Ser Arg Pro Met Ala Leu Thr Ile Asp Tyr 3170 3175 3180 Val Asn Arg Arg Leu Tyr Trp Ala Asp Glu Asn His Ile Glu Phe 3185 3190 3195 Ser Asn Met Asp Gly Ser His Arg His Lys Val Pro Asn Gln Asp 3200 3205 3210 Ile Pro Gly Val Ile Ala Leu Thr Leu Phe Glu Asp Tyr Ile Tyr 3215 3220 3225 Trp Thr Asp Gly Lys Thr Lys Ser Leu Ser Arg Ala His Lys Thr 3230 3235 3240 Ser Gly Ala Asp Arg Leu Ser Leu Ile Tyr Ser Trp His Ala Ile 3245 3250 3255 Thr Asp Ile Gln Val Tyr His Ser Tyr Arg Gln Pro Asp Val Ser 3260 3265 3270 Lys His Leu Cys Met Ile Asn Asn Gly Gly Cys Ser His Leu Cys 3275 3280 3285 Leu Leu Ala Pro Gly Lys Thr His Thr Cys Ala Cys Pro Thr Asn 3290 3295 3300 Phe Tyr Leu Ala Ala Asp Asn Arg Thr Cys Leu Ser Asn Cys Thr 3305 3310 3315 Ala Ser Gln Phe Arg Cys Lys Thr Asp Lys Cys Ile Pro Phe Trp 3320 3325 3330 Trp Lys Cys Asp Thr Val Asp Asp Cys Gly Asp Gly Ser Asp Glu 3335 3340 3345 Pro Asp Asp Cys Pro Glu Phe Arg Cys Gln Pro Gly Arg Phe Gln 3350 3355 3360 Cys Gly Thr Gly Leu Cys Ala Leu Pro Ala Phe Ile Cys Asp Gly 3365 3370 3375 Glu Asn Asp Cys Gly Asp Asn Ser Asp Glu Leu Asn Cys Asp Thr 3380 3385 3390 His Val Cys Leu Ser Gly Gln Phe Lys Cys Thr Lys Asn Gln Lys 3395 3400 3405 Cys Ile Pro Val Asn Leu Arg Cys Asn Gly Gln Asp Asp Cys Gly 3410 3415 3420 Asp Glu Glu Asp Glu Arg Asp Cys Pro Glu Asn Ser Cys Ser Pro 3425 3430 3435 Asp Tyr Phe Gln Cys Lys Thr Thr Lys His Cys Ile Ser Lys Leu 3440 3445 3450 Trp Val Cys Asp Glu Asp Pro Asp Cys Ala Asp Ala Ser Asp Glu 3455 3460 3465 Ala Asn Cys Asp Lys Lys Thr Cys Gly Pro His Glu Phe Gln Cys 3470 3475 3480 Lys Asn Asn Asn Cys Ile Pro Asp His Trp Arg Cys Asp Ser Gln 3485 3490 3495 Asn Asp Cys Ser Asp Asn Ser Asp Glu Glu Asn Cys Lys Pro Gln 3500 3505 3510 Thr Cys Thr Leu Lys Asp Phe Leu Cys Ala Asn Gly Asp Cys Val 3515 3520 3525 Ser Ser Arg Phe Trp Cys Asp Gly Asp Phe Asp Cys Ala Asp Gly 3530 3535 3540 Ser Asp Glu Arg Asn Cys Glu Thr Ser Cys Ser Lys Asp Gln Phe 3545 3550 3555 Arg Cys Ser Asn Gly Gln Cys Ile Pro Ala Lys Trp Lys Cys Asp 3560 3565 3570 Gly His Glu Asp Cys Lys Tyr Gly Glu Asp Glu Lys Ser Cys Glu 3575 3580 3585 Pro Ala Ser Pro Thr Cys Ser Ser Arg Glu Tyr Ile Cys Ala Ser 3590 3595 3600 Asp Gly Cys Ile Ser Ala Ser Leu Lys Cys Asn Gly Glu Tyr Asp 3605 3610 3615 Cys Ala Asp Gly Ser Asp Glu Met Asp Cys Val Thr Glu Cys Lys 3620 3625 3630 Glu Asp Gln Phe Arg Cys Lys Asn Lys Ala His Cys Ile Pro Ile 3635 3640 3645 Arg Trp Leu Cys Asp Gly Ile His Asp Cys Val Asp Gly Ser Asp 3650 3655 3660 Glu Glu Asn Cys Glu Arg Gly Gly Asn Ile Cys Arg Ala Asp Glu 3665 3670 3675 Phe Leu Cys Asn Asn Ser Leu Cys Lys Leu His Phe Trp Val Cys 3680 3685 3690 Asp Gly Glu Asp Asp Cys Gly Asp Asn Ser Asp Glu Ala Pro Asp 3695 3700 3705 Met Cys Val Lys Phe Leu Cys Pro Ser Thr Arg Pro His Arg Cys 3710 3715 3720 Arg Asn Asn Arg Ile Cys Leu Gln Ser Glu Gln Met Cys Asn Gly 3725 3730 3735 Ile Asp Glu Cys Gly Asp Asn Ser Asp Glu Asp His Cys Gly Gly 3740 3745 3750 Lys Leu Thr Tyr Lys Ala Arg Pro Cys Lys Lys Asp Glu Phe Ala 3755 3760 3765 Cys Ser Asn Lys Lys Cys Ile Pro Met Asp Leu Gln Cys Asp Arg 3770 3775 3780 Leu Asp Asp Cys Gly Asp Gly Ser Asp Glu Gln Gly Cys Arg Ile 3785 3790 3795 Ala Pro Thr Glu Tyr Thr Cys Glu Asp Asn Val Asn Pro Cys Gly 3800 3805 3810 Asp Asp Ala Tyr Cys Asn Gln Ile Lys Thr Ser Val Phe Cys Arg 3815 3820 3825 Cys Lys Pro Gly Phe Gln Arg Asn Met Lys Asn Arg Gln Cys Glu 3830 3835 3840 Asp Leu Asn Glu Cys Leu Val Phe Gly Thr Cys Ser His Gln Cys 3845 3850 3855 Ile Asn Val Glu Gly Ser Tyr Lys Cys Val Cys Asp Gln Asn Phe 3860 3865 3870 Gln Glu Arg Asn Asn Thr Cys Ile Ala Glu Gly Ser Glu Asp Gln 3875 3880 3885 Val Leu Tyr Ile Ala Asn Asp Thr Asp Ile Leu Gly Phe Ile Tyr 3890 3895 3900 Pro Phe Asn Tyr Ser Gly Asp His Gln Gln Ile Ser His Ile Glu 3905 3910 3915 His Asn Ser Arg Ile Thr Gly Met Asp Val Tyr Tyr Gln Arg Asp 3920 3925 3930 Met Ile Ile Trp Ser Thr Gln Phe Asn Pro Gly Gly Ile Phe Tyr 3935 3940 3945 Lys Arg Ile His Gly Arg Glu Lys Arg Gln Ala Asn Ser Gly Leu 3950 3955 3960 Ile Cys Pro Glu Phe Lys Arg Pro Arg Asp Ile Ala Val Asp Trp 3965 3970 3975 Val Ala Gly Asn Ile Tyr Trp Thr Asp His Ser Arg Met His Trp 3980 3985 3990 Phe Ser Tyr Tyr Thr Thr His Trp Thr Ser Leu Arg Tyr Ser Ile 3995 4000 4005 Asn Val Gly Gln Leu Asn Gly Pro Asn Cys Thr Arg Leu Leu Thr 4010 4015 4020 Asn Met Ala Gly Glu Pro Tyr Ala Ile Ala Val Asn Pro Lys Arg 4025 4030 4035 Gly Met Met Tyr Trp Thr Val Val Gly Asp His Ser His Ile Glu 4040 4045 4050 Glu Ala Ala Met Asp Gly Thr Leu Arg Arg Ile Leu Val Gln Lys 4055 4060 4065 Asn Leu Gln Arg Pro Thr Gly Leu Ala Val Asp Tyr Phe Ser Glu 4070 4075 4080 Arg Ile Tyr Trp Ala Asp Phe Glu Leu Ser Ile Ile Gly Ser Val 4085 4090 4095 Leu Tyr Asp Gly Ser Asn Ser Val Val Ser Val Ser Ser Lys Gln 4100 4105 4110 Gly Leu Leu His Pro His Arg Ile Asp Ile Phe Glu Asp Tyr Ile 4115 4120 4125 Tyr Gly Ala Gly Pro Lys Asn Gly Val Phe Arg Val Gln Lys Phe 4130 4135 4140 Gly His Gly Ser Val Glu Tyr Leu Ala Leu Asn Ile Asp Lys Thr 4145 4150 4155 Lys Gly Val Leu Ile Ser His Arg Tyr Lys Gln Leu Asp Leu Pro 4160 4165 4170 Asn Pro Cys Leu Asp Leu Ala Cys Glu Phe Leu Cys Leu Leu Asn 4175 4180 4185 Pro Ser Gly Ala Thr Cys Val Cys Pro Glu Gly Lys Tyr Leu Ile 4190 4195 4200 Asn Gly Thr Cys Asn Asp Asp Ser Leu Leu Asp Asp Ser Cys Lys 4205 4210 4215 Leu Thr Cys Glu Asn Gly Gly Arg Cys Ile Leu Asn Glu Lys Gly 4220 4225 4230 Asp Leu Arg Cys His Cys Trp Pro Ser Tyr Ser Gly Glu Arg Cys 4235 4240 4245 Glu Val Asn His Cys Ser Asn Tyr Cys Gln Asn Gly Gly Thr Cys 4250 4255 4260 Val Pro Ser Val Leu Gly Arg Pro Thr Cys Ser Cys Ala Leu Gly 4265 4270 4275 Phe Thr Gly Pro Asn Cys Gly Lys Thr Val Cys Glu Asp Phe Cys 4280 4285 4290 Gln Asn Gly Gly Thr Cys Ile Val Thr Ala Gly Asn Gln Pro Tyr 4295 4300 4305 Cys His Cys Gln Pro Glu Tyr Thr Gly Asp Arg Cys Gln Tyr Tyr 4310 4315 4320 Val Cys His His Tyr Cys Val Asn Ser Glu Ser Cys Thr Ile Gly 4325 4330 4335 Asp Asp Gly Ser Xaa Glu Cys Val Cys Pro Thr Arg Tyr Glu Gly 4340 4345 4350 Pro Lys Cys Glu Val Asp Lys Cys Val Arg Cys His Gly Gly His 4355 4360 4365 Cys Ile Ile Asn Lys Asp Ser Glu Asp Ile Phe Cys Asn Cys Thr 4370 4375 4380 Asn Gly Lys Ile Ala Ser Ser Cys Gln Leu Cys Asp Gly Tyr Cys 4385 4390 4395 Tyr Asn Gly Gly Thr Cys Gln Leu Asp Pro Glu Thr Asn Val Pro 4400 4405 4410 Val Cys Leu Cys Ser Thr Asn Trp Ser Gly Thr Gln Cys Glu Arg 4415 4420 4425 Pro Ala Pro Lys Ser Ser Lys Ser Asp His Ile Ser Thr Arg Ser 4430 4435 4440 Ile Ala Ile Ile Val Pro Leu Val Leu Leu Val Thr Leu Ile Thr 4445 4450 4455 Thr Leu Val Ile Gly Leu Val Leu Cys Lys Arg Lys Arg Arg Thr 4460 4465 4470 Lys Thr Ile Arg Arg Gln Pro Ile Ile Asn Gly Gly Ile Asn Val 4475 4480 4485 Glu Ile Gly Asn Pro Ser Tyr Asn Met Tyr Glu Val Asp His Asp 4490 4495 4500 His Asn Asp Gly Gly Leu Leu Asp Pro Gly Phe Met Ile Asp Pro 4505 4510 4515 Thr Lys Ala Arg Tyr Ile Gly Gly Gly Pro Ser Ala Phe Lys Leu 4520 4525 4530 Pro His Thr Ala Pro Pro Ile Tyr Leu Asn Ser Asp Leu Lys Gly 4535 4540 4545 Pro Leu Thr Ala Gly Pro Thr Asn Tyr Ser Asn Pro Val Tyr Ala 4550 4555 4560 Lys Leu Tyr Met Asp Gly Gln Asn Cys Arg Asn Ser Leu Gly Ser 4565 4570 4575 Val Asp Glu Arg Lys Glu Leu Leu Pro Lys Lys Ile Glu Ile Gly 4580 4585 4590 Ile Arg Glu Thr Val Ala 4595 5 963 PRT Homo sapiens 5 Met Gly Leu Pro Glu Pro Gly Pro Leu Arg Leu Leu Ala Leu Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Leu Leu Leu Arg Leu Gln His Leu Ala Ala Ala 20 25 30 Ala Ala Asp Pro Leu Leu Gly Gly Gln Gly Pro Ala Lys Glu Cys Glu 35 40 45 Lys Asp Gln Phe Gln Cys Arg Asn Glu Arg Cys Ile Pro Ser Val Trp 50 55 60 Arg Cys Asp Glu Asp Asp Asp Cys Leu Asp His Ser Asp Glu Asp Asp 65 70 75 80 Cys Pro Lys Lys Thr Cys Ala Asp Ser Asp Phe Thr Cys Asp Asn Gly 85 90 95 His Cys Ile His Glu Arg Trp Lys Cys Asp Gly Glu Glu Glu Cys Pro 100 105 110 Asp Gly Ser Asp Glu Ser Glu Ala Thr Cys Thr Lys Gln Val Cys Pro 115 120 125 Ala Glu Lys Leu Ser Cys Gly Pro Thr Ser His Lys Cys Val Pro Ala 130 135 140 Ser Trp Arg Cys Asp Gly Glu Lys Asp Cys Glu Gly Gly Ala Asp Glu 145 150 155 160 Ala Gly Cys Ala Thr Leu Cys Ala Pro His Glu Phe Gln Cys Gly Asn 165 170 175 Arg Ser Cys Leu Ala Ala Val Phe Val Cys Asp Gly Asp Asp Asp Cys 180 185 190 Gly Asp Gly Ser Asp Glu Arg Gly Cys Ala Asp Pro Ala Cys Gly Pro 195 200 205 Arg Glu Phe Arg Cys Gly Gly Asp Gly Gly Gly Ala Cys Ile Pro Glu 210 215 220 Arg Trp Val Cys Asp Arg Gln Phe Asp Cys Glu Asp Arg Ser Asp Glu 225 230 235 240 Ala Ala Glu Leu Cys Gly Arg Pro Gly Pro Gly Ala Thr Ser Ala Pro 245 250 255 Ala Ala Cys Ala Thr Val Ser Gln Phe Ala Cys Arg Ser Gly Glu Cys 260 265 270 Val His Leu Gly Trp Arg Cys Asp Gly Asp Arg Asp Cys Lys Asp Lys 275 280 285 Ser Asp Glu Ala Asp Cys Pro Leu Gly Thr Cys Arg Gly Asp Glu Phe 290 295 300 Gln Cys Gly Asp Gly Thr Cys Val Leu Ala Ile Lys His Cys Asn Gln 305 310 315 320 Glu Gln Asp Cys Pro Asp Gly Ser Asp Glu Ala Gly Cys Leu Gln Gly 325 330 335 Leu Asn Glu Cys Leu His Asn Asn Gly Gly Cys Ser His Ile Cys Thr 340 345 350 Asp Leu Lys Ile Gly Phe Glu Cys Thr Cys Pro Ala Gly Phe Gln Leu 355 360 365 Leu Asp Gln Lys Thr Cys Gly Asp Ile Asp Glu Cys Lys Asp Pro Asp 370 375 380 Ala Cys Ser Gln Ile Cys Val Asn Tyr Lys Gly Tyr Phe Lys Cys Glu 385 390 395 400 Cys Tyr Pro Gly Tyr Glu Met Asp Leu Leu Thr Lys Asn Cys Lys Ala 405 410 415 Ala Gly Gly Lys Ser Pro Ser Leu Ile Phe Thr Asn Arg Tyr Glu Val 420 425 430 Arg Arg Ile Asp Leu Val Lys Arg Asn Tyr Ser Arg Leu Ile Pro Met 435 440 445 Leu Lys Asn Val Val Ala Leu Asp Val Glu Val Ala Thr Asn Arg Ile 450 455 460 Tyr Trp Cys Asp Leu Ser Tyr Arg Lys Ile Tyr Ser Ala Tyr Met Asp 465 470 475 480 Lys Ala Ser Asp Pro Lys Glu Gln Glu Val Leu Ile Asp Glu Gln Leu 485 490 495 His Ser Pro Glu Gly Leu Ala Val Asp Trp Val His Lys His Ile Tyr 500 505 510 Trp Thr Asp Ser Gly Asn Lys Thr Ile Ser Val Ala Thr Val Asp Gly 515 520 525 Gly Arg Arg Arg Thr Leu Phe Ser Arg Asn Leu Ser Glu Pro Arg Ala 530 535 540 Ile Ala Val Asp Pro Leu Arg Gly Phe Met Tyr Trp Ser Asp Trp Gly 545 550 555 560 Asp Gln Ala Lys Ile Glu Lys Ser Gly Leu Asn Gly Val Asp Arg Gln 565 570 575 Thr Leu Val Ser Asp Asn Ile Glu Trp Pro Asn Gly Ile Thr Leu Asp 580 585 590 Leu Leu Ser Gln Arg Leu Tyr Trp Val Asp Ser Lys Leu His Gln Leu 595 600 605 Ser Ser Ile Asp Phe Ser Gly Gly Asn Arg Lys Thr Leu Ile Ser Ser 610 615 620 Thr Asp Phe Leu Ser His Pro Phe Gly Ile Ala Val Phe Glu Asp Lys 625 630 635 640 Val Phe Trp Thr Asp Leu Glu Asn Glu Ala Ile Phe Ser Ala Asn Arg 645 650 655 Leu Asn Gly Leu Glu Ile Ser Ile Leu Ala Glu Asn Leu Asn Asn Pro 660 665 670 His Asp Ile Val Ile Phe His Glu Leu Lys Gln Pro Arg Ala Pro Asp 675 680 685 Ala Cys Glu Leu Ser Val Gln Pro Asn Gly Gly Cys Glu Tyr Leu Cys 690 695 700 Leu Pro Ala Pro Gln Ile Ser Ser His Ser Pro Lys Tyr Thr Cys Ala 705 710 715 720 Cys Pro Asp Thr Met Trp Leu Gly Pro Asp Met Lys Arg Cys Tyr Arg 725 730 735 Ala Pro Gln Ser Thr Ser Thr Thr Thr Leu Ala Ser Thr Met Thr Arg 740 745 750 Thr Val Pro Ala Thr Thr Arg Ala Pro Gly Thr Thr Val His Arg Ser 755 760 765 Thr Tyr Gln Asn His Ser Thr Glu Thr Pro Ser Leu Thr Ala Ala Val 770 775 780 Pro Ser Ser Val Ser Val Pro Arg Ala Pro Ser Ile Ser Pro Ser Thr 785 790 795 800 Leu Ser Pro Ala Thr Ser Asn His Ser Gln His Tyr Ala Asn Glu Asp 805 810 815 Ser Lys Met Gly Ser Thr Val Thr Ala Ala Val Ile Gly Ile Ile Val 820 825 830 Pro Ile Val Val Ile Ala Leu Leu Cys Met Ser Gly Tyr Leu Ile Trp 835 840 845 Arg Asn Trp Lys Arg Lys Asn Thr Lys Ser Met Asn Phe Asp Asn Pro 850 855 860 Val Tyr Arg Lys Thr Thr Glu Glu Glu Asp Glu Asp Glu Leu His Ile 865 870 875 880 Gly Arg Thr Ala Gln Ile Gly His Val Tyr Pro Ala Ala Ile Ser Ser 885 890 895 Phe Asp Arg Pro Leu Trp Ala Glu Pro Cys Leu Gly Glu Thr Arg Glu 900 905 910 Pro Glu Asp Pro Ala Pro Ala Leu Lys Glu Leu Phe Val Leu Pro Gly 915 920 925 Glu Pro Arg Ser Gln Leu His Gln Leu Pro Lys Asn Pro Leu Ser Glu 930 935 940 Leu Pro Val Val Lys Ser Lys Arg Val Ala Leu Ser Leu Glu Asp Asp 945 950 955 960 Gly Leu Pro 6 4544 PRT Homo sapiens 6 Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu 1 5 10 15 Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe 20 25 30 Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp 35 40 45 Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys 50 55 60 Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu 65 70 75 80 Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln 85 90 95 Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln 100 105 110 Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu 115 120 125 Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp 130 135 140 Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys 145 150 155 160 Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val 165 170 175 Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn 180 185 190 Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn 195 200 205 Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro 210 215 220 Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu 225 230 235 240 Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu 245 250 255 Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr 260 265 270 Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp 275 280 285 Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile 290 295 300 Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu 305 310 315 320 Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys 325 330 335 Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp 340 345 350 Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe 355 360 365 Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala 370 375 380 Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly 385 390 395 400 Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu 405 410 415 Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn 420 425 430 Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr 435 440 445 Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile 450 455 460 Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn 465 470 475 480 Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala 485 490 495 Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu 500 505 510 Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu 515 520 525 Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly 530 535 540 Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn 545 550 555 560 Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala 565 570 575 Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu 580 585 590 Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala 595 600 605 Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys 610 615 620 Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys 625 630 635 640 Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp 645 650 655 Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys 660 665 670 Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His 675 680 685 Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu 690 695 700 Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr 705 710 715 720 Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val 725 730 735 Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly 740 745 750 Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu 755 760 765 Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser 770 775 780 Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln 785 790 795 800 Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser 805 810 815 Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp 820 825 830 Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr 835 840 845 Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser 850 855 860 Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu 865 870 875 880 Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro 885 890 895 Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp 900 905 910 Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn 915 920 925 Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala 930 935 940 Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp 945 950 955 960 Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys 965 970 975 Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile 980 985 990 Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu 995 1000 1005 Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn 1010 1015 1020 Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn 1025 1030 1035 Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn 1040 1045 1050 Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln 1055 1060 1065 Cys Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp 1070 1075 1080 Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu 1085 1090 1095 Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys 1100 1105 1110 Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp 1115 1120 1125 Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu 1130 1135 1140 Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val 1145 1150 1155 Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly 1160 1165 1170 Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn 1175 1180 1185 Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro Gly Glu Gly 1190 1195 1200 Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro Asp Asn 1205 1210 1215 His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys Cys 1220 1225 1230 Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys 1235 1240 1245 Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser 1250 1255 1260 Leu Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu 1265 1270 1275 Ile Arg Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val 1280 1285 1290 Pro Gly Leu Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln 1295 1300 1305 Ser Ala Leu Tyr Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg 1310 1315 1320 Gly Lys Leu Leu Asp Asn Gly Ala Leu Thr Ser Phe Glu Val Val 1325 1330 1335 Ile Gln Tyr Gly Leu Ala Thr Pro Glu Gly Leu Ala Val Asp Trp 1340 1345 1350 Ile Ala Gly Asn Ile Tyr Trp Val Glu Ser Asn Leu Asp Gln Ile 1355 1360 1365 Glu Val Ala Lys Leu Asp Gly Thr Leu Arg Thr Thr Leu Leu Ala 1370 1375 1380 Gly Asp Ile Glu His Pro Arg Ala Ile Ala Leu Asp Pro Arg Asp 1385 1390 1395 Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala Ser Leu Pro Arg Ile 1400 1405 1410 Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg 1415 1420 1425 Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr 1430 1435 1440 Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile 1445 1450 1455 Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg 1460 1465 1470 Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly 1475 1480 1485 Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys 1490 1495 1500 Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr 1505 1510 1515 Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln 1520 1525 1530 Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro 1535 1540 1545 Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys 1550 1555 1560 Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys 1565 1570 1575 Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile 1580 1585 1590 Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser 1595 1600 1605 Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp 1610 1615 1620 Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala 1625 1630 1635 Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly Val Glu Thr Val Val 1640 1645 1650 Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala Val Asp Trp Val 1655 1660 1665 Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn Lys Lys Gln 1670 1675 1680 Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala Val Val 1685 1690 1695 Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu Arg 1700 1705 1710 Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn 1715 1720 1725 Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly 1730 1735 1740 Pro Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp 1745 1750 1755 Ile Ser Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly 1760 1765 1770 Ser Gly Leu Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys 1775 1780 1785 Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp 1790 1795 1800 Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser 1805 1810 1815 Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met 1820 1825 1830 Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn 1835 1840 1845 Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro 1850 1855 1860 Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser 1865 1870 1875 Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu 1880 1885 1890 Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro 1895 1900 1905 Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu 1910 1915 1920 Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp 1925 1930 1935 Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln 1940 1945 1950 Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu 1955 1960 1965 Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp 1970 1975 1980 Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe 1985 1990 1995 Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile 2000 2005 2010 Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly 2015 2020 2025 Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg 2030 2035 2040 Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser 2045 2050 2055 Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr 2060 2065 2070 Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu 2075 2080 2085 Val Val Leu Ser Ser Asn Asn Met Asp Met Phe Ser Val Ser Val 2090 2095 2100 Phe Glu Asp Phe Ile Tyr Trp Ser Asp Arg Thr His Ala Asn Gly 2105 2110 2115 Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala Thr Asp Ser Val Pro 2120 2125 2130 Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp Ile Lys Val Phe 2135 2140 2145 Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala Val Ala Asn 2150 2155 2160 Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly Gln Arg 2165 2170 2175 Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala Ser 2180 2185 2190 Cys Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile 2195 2200 2205 Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro 2210 2215 2220 Val Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala 2225 2230 2235 Leu Ala Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn 2240 2245 2250 Arg Ile Phe Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile 2255 2260 2265 Asn Asp Asp Gly Ser Arg Arg Ile Thr Ile Val Glu Asn Val Gly 2270 2275 2280 Ser Val Glu Gly Leu Ala Tyr His Arg Gly Trp Asp Thr Leu Tyr 2285 2290 2295 Trp Thr Ser Tyr Thr Thr Ser Thr Ile Thr Arg His Thr Val Asp 2300 2305 2310 Gln Thr Arg Pro Gly Ala Phe Glu Arg Glu Thr Val Ile Thr Met 2315 2320 2325 Ser Gly Asp Asp His Pro Arg Ala Phe Val Leu Asp Glu Cys Gln 2330 2335 2340 Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser Ile 2345 2350 2355 Met Arg Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu 2360 2365 2370 Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile Asp His Arg Ala 2375 2380 2385 Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys Ile Glu Arg 2390 2395 2400 Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys Ser Glu 2405 2410 2415 Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile Phe 2420 2425 2430 Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His 2435 2440 2445 Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln 2450 2455 2460 Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu 2465 2470 2475 Leu Ser Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys 2480 2485 2490 Leu Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly 2495 2500 2505 Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val Asn Ser Ser 2510 2515 2520 Cys Arg Ala Gln Asp Glu Phe Glu Cys Ala Asn Gly Glu Cys Ile 2525 2530 2535 Asn Phe Ser Leu Thr Cys Asp Gly Val Pro His Cys Lys Asp Lys 2540 2545 2550 Ser Asp Glu Lys Pro Ser Tyr Cys Asn Ser Arg Arg Cys Lys Lys 2555 2560 2565 Thr Phe Arg Gln Cys Ser Asn Gly Arg Cys Val Ser Asn Met Leu 2570 2575 2580 Trp Cys Asn Gly Ala Asp Asp Cys Gly Asp Gly Ser Asp Glu Ile 2585 2590 2595 Pro Cys Asn Lys Thr Ala Cys Gly Val Gly Glu Phe Arg Cys Arg 2600 2605 2610 Asp Gly Thr Cys Ile Gly Asn Ser Ser Arg Cys Asn Gln Phe Val 2615 2620 2625 Asp Cys Glu Asp Ala Ser Asp Glu Met Asn Cys Ser Ala Thr Asp 2630 2635 2640 Cys Ser Ser Tyr Phe Arg Leu Gly Val Lys Gly Val Leu Phe Gln 2645 2650 2655 Pro Cys Glu Arg Thr Ser Leu Cys Tyr Ala Pro Ser Trp Val Cys 2660 2665 2670 Asp Gly Ala Asn Asp Cys Gly Asp Tyr Ser Asp Glu Arg Asp Cys 2675 2680 2685 Pro Gly Val Lys Arg Pro Arg Cys Pro Leu Asn Tyr Phe Ala Cys 2690 2695 2700 Pro Ser Gly Arg Cys Ile Pro Met Ser Trp Thr Cys Asp Lys Glu 2705 2710 2715 Asp Asp Cys Glu His Gly Glu Asp Glu Thr His Cys Asn Lys Phe 2720 2725 2730 Cys Ser Glu Ala Gln Phe Glu Cys Gln Asn His Arg Cys Ile Ser 2735 2740 2745 Lys Gln Trp Leu Cys Asp Gly Ser Asp Asp Cys Gly Asp Gly Ser 2750 2755 2760 Asp Glu Ala Ala His Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser 2765 2770 2775 Phe Ser Cys Pro Gly Thr His Val Cys Val Pro Glu Arg Trp Leu 2780 2785 2790 Cys Asp Gly Asp Lys Asp Cys Ala Asp Gly Ala Asp Glu Ser Ile 2795 2800 2805 Ala Ala Gly Cys Leu Tyr Asn Ser Thr Cys Asp Asp Arg Glu Phe 2810 2815 2820 Met Cys Gln Asn Arg Gln Cys Ile Pro Lys His Phe Val Cys Asp 2825 2830 2835 His Asp Arg Asp Cys Ala Asp Gly Ser Asp Glu Ser Pro Glu Cys 2840 2845 2850 Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg Cys Ala Asn Gly 2855 2860 2865 Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly Glu Asn Asp 2870 2875 2880 Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His Cys Thr 2885 2890 2895 Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys Ser 2900 2905 2910 Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp 2915 2920 2925 Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu 2930 2935 2940 Cys Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp 2945 2950 2955 Leu Lys Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu 2960 2965 2970 Lys Asp Asp Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr 2975 2980 2985 Thr Phe Pro Cys Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr 2990 2995 3000 Lys Cys Leu Cys Val Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro 3005 3010 3015 His Ser Cys Lys Ala Val Thr Asp Glu Glu Pro Phe Leu Ile Phe 3020 3025 3030 Ala Asn Arg Tyr Tyr Leu Arg Lys Leu Asn Leu Asp Gly Ser Asn 3035 3040 3045 Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Ala Val Ala Leu Asp 3050 3055 3060 Phe Asp Tyr Arg Glu Gln Met Ile Tyr Trp Thr Asp Val Thr Thr 3065 3070 3075 Gln Gly Ser Met Ile Arg Arg Met His Leu Asn Gly Ser Asn Val 3080 3085 3090 Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro Asp Gly Leu Ala 3095 3100 3105 Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp Lys Gly Arg 3110 3115 3120 Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg Thr Val 3125 3130 3135 Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val Asp 3140 3145 3150 Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser 3155 3160 3165 Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile 3170 3175 3180 Val Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr 3185 3190 3195 Val Thr Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile 3200 3205 3210 Glu Phe Ala Ser Leu Asp Gly Ser Asn Arg His Val Val Leu Ser 3215 3220 3225 Gln Asp Ile Pro His Ile Phe Ala Leu Thr Leu Phe Glu Asp Tyr 3230 3235 3240 Val Tyr Trp Thr Asp Trp Glu Thr Lys Ser Ile Asn Arg Ala His 3245 3250 3255 Lys Thr Thr Gly Thr Asn Lys Thr Leu Leu Ile Ser Thr Leu His 3260 3265 3270 Arg Pro Met Asp Leu His Val Phe His Ala Leu Arg Gln Pro Asp 3275 3280 3285 Val Pro Asn His Pro Cys Lys Val Asn Asn Gly Gly Cys Ser Asn 3290 3295 3300 Leu Cys Leu Leu Ser Pro Gly Gly Gly His Lys Cys Ala Cys Pro 3305 3310 3315 Thr Asn Phe Tyr Leu Gly Ser Asp Gly Arg Thr Cys Val Ser Asn 3320 3325 3330 Cys Thr Ala Ser Gln Phe Val Cys Lys Asn Asp Lys Cys Ile Pro 3335 3340 3345 Phe Trp Trp Lys Cys Asp Thr Glu Asp Asp Cys Gly Asp His Ser 3350 3355 3360 Asp Glu Pro Pro Asp Cys Pro Glu Phe Lys Cys Arg Pro Gly Gln 3365 3370 3375 Phe Gln Cys Ser Thr Gly Ile Cys Thr Asn Pro Ala Phe Ile Cys 3380 3385 3390 Asp Gly Asp Asn Asp Cys Gln Asp Asn Ser Asp Glu Ala Asn Cys 3395 3400 3405 Asp Ile His Val Cys Leu Pro Ser Gln Phe Lys Cys Thr Asn Thr 3410 3415 3420 Asn Arg Cys Ile Pro Gly Ile Phe Arg Cys Asn Gly Gln Asp Asn 3425 3430 3435 Cys Gly Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys 3440 3445 3450 Ala Pro Asn Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro 3455 3460 3465 Arg Val Trp Val Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser 3470 3475 3480 Asp Glu Pro Ala Asn Cys Thr Gln Met Thr Cys Gly Val Asp Glu 3485 3490 3495 Phe Arg Cys Lys Asp Ser Gly Arg Cys Ile Pro Ala Arg Trp Lys 3500 3505 3510 Cys Asp Gly Glu Asp Asp Cys Gly Asp Gly Ser Asp Glu Pro Lys 3515 3520 3525 Glu Glu Cys Asp Glu Arg Thr Cys Glu Pro Tyr Gln Phe Arg Cys 3530 3535 3540 Lys Asn Asn Arg Cys Val Pro Gly Arg Trp Gln Cys Asp Tyr Asp 3545 3550 3555 Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Ser Cys Thr Pro Arg 3560 3565 3570 Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn Gly Arg Cys Ile 3575 3580 3585 Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys Ala Asp Gly 3590 3595 3600 Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp Gln Phe 3605 3610 3615 Gln Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys Asp 3620 3625 3630 Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly 3635 3640 3645 Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn 3650 3655 3660 Thr Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp 3665 3670 3675 Cys Gly Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe 3680 3685 3690 Val Cys Pro Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val 3695 3700 3705 Cys Leu Trp Ile Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly 3710 3715 3720 Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr 3725 3730 3735 Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg 3740 3745 3750 Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly 3755 3760 3765 Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr 3770 3775 3780 Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys 3785 3790 3795 Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe 3800 3805 3810 His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys 3815 3820 3825 Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly 3830 3835 3840 Gly His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr His Asn 3845 3850 3855 Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile Ala 3860 3865 3870 Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser 3875 3880 3885 Ala Tyr Glu Gln Ala Phe Gln Gly Asp Glu Ser Val Arg Ile Asp 3890 3895 3900 Ala Met Asp Val His Val Lys Ala Gly Arg Val Tyr Trp Thr Asn 3905 3910 3915 Trp His Thr Gly Thr Ile Ser Tyr Arg Ser Leu Pro Pro Ala Ala 3920 3925 3930 Pro Pro Thr Thr Ser Asn Arg His Arg Arg Gln Ile Asp Arg Gly 3935 3940 3945 Val Thr His Leu Asn Ile Ser Gly Leu Lys Met Pro Arg Gly Ile 3950 3955 3960 Ala Ile Asp Trp Val Ala Gly Asn Val Tyr Trp Thr Asp Ser Gly 3965 3970 3975 Arg Asp Val Ile Glu Val Ala Gln Met Lys Gly Glu Asn Arg Lys 3980 3985 3990 Thr Leu Ile Ser Gly Met Ile Asp Glu Pro His Ala Ile Val Val 3995 4000 4005 Asp Pro Leu Arg Gly Thr Met Tyr Trp Ser Asp Trp Gly Asn His 4010 4015 4020 Pro Lys Ile Glu Thr Ala Ala Met Asp Gly Thr Leu Arg Glu Thr 4025 4030 4035 Leu Val Gln Asp Asn Ile Gln Trp Pro Thr Gly Leu Ala Val Asp 4040 4045 4050 Tyr His Asn Glu Arg Leu Tyr Trp Ala Asp Ala Lys Leu Ser Val 4055 4060 4065 Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile Val Ala Ala 4070 4075 4080 Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp Val Phe 4085 4090 4095 Glu Asp Tyr Ile Tyr Gly Val Thr Tyr Ile Asn Asn Arg Val Phe 4100 4105 4110 Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly 4115 4120 4125 Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys 4130 4135 4140 Gln Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp 4145 4150 4155 Leu Cys Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn 4160 4165 4170 Gly Lys Arg Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro 4175 4180 4185 Thr Pro Pro Pro Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln 4190 4195 4200 Cys Phe Asn Gly Gly Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro 4205 4210 4215 Lys Cys Arg Cys Gln Pro Arg Tyr Thr Gly Asp Lys Cys Glu Leu 4220 4225 4230 Asp Gln Cys Trp Glu His Cys Arg Asn Gly Gly Thr Cys Ala Ala 4235 4240 4245 Ser Pro Ser Gly Met Pro Thr Cys Arg Cys Pro Thr Gly Phe Thr 4250 4255 4260 Gly Pro Lys Cys Thr Gln Gln Val Cys Ala Gly Tyr Cys Ala Asn 4265 4270 4275 Asn Ser Thr Cys Thr Val Asn Gln Gly Asn Gln Pro Gln Cys Arg 4280 4285 4290 Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln Tyr Arg Gln Cys 4295 4300 4305 Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met Ala Ala Asp 4310 4315 4320 Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly Ser Arg 4325 4330 4335 Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys Val 4340 4345 4350 Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly 4355 4360 4365 Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn 4370 4375 4380 Gly Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln 4385 4390 4395 Cys Pro Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe 4400 4405 4410 Ser Gln Gln Gln Pro Gly His Ile Ala Ser Ile Leu Ile Pro Leu 4415 4420 4425 Leu Leu Leu Leu Leu Leu Val Leu Val Ala Gly Val Val Phe Trp 4430 4435 4440 Tyr Lys Arg Arg Val Gln Gly Ala Lys Gly Phe Gln His Gln Arg 4445 4450 4455 Met Thr Asn Gly Ala Met Asn Val Glu Ile Gly Asn Pro Thr Tyr 4460 4465 4470 Lys Met Tyr Glu Gly Gly Glu Pro Asp Asp Val Gly Gly Leu Leu 4475 4480 4485 Asp Ala Asp Phe Ala Leu Asp Pro Asp Lys Pro Thr Asn Phe Thr 4490 4495 4500 Asn Pro Val Tyr Ala Thr Leu Tyr Met Gly Gly His Gly Ser Arg 4505 4510 4515 His Ser Leu Ala Ser Thr Asp Glu Lys Arg Glu Leu Leu Gly Arg 4520 4525 4530 Gly Pro Glu Asp Glu Ile Gly Asp Pro Leu Ala 4535 4540 7 873 PRT Homo sapiens 7 Met Gly Thr Ser Ala Leu Trp Ala Leu Trp Leu Leu Leu Ala Leu Cys 1 5 10 15 Trp Ala Pro Arg Glu Ser Gly Ala Thr Gly Thr Gly Arg Lys Ala Lys 20 25 30 Cys Glu Pro Ser Gln Phe Gln Cys Thr Asn Gly Arg Cys Ile Thr Leu 35 40 45 Leu Trp Lys Cys Asp Gly Asp Glu Asp Cys Val Asp Gly Ser Asp Glu 50 55 60 Lys Asn Cys Val Lys Lys Thr Cys Ala Glu Ser Asp Phe Val Cys Asn 65 70 75 80 Asn Gly Gln Cys Val Pro Ser Arg Trp Lys Cys Asp Gly Asp Pro Asp 85 90 95 Cys Glu Asp Gly Ser Asp Glu Ser Pro Glu Gln Cys His Met Arg Thr 100 105 110 Cys Arg Ile His Glu Ile Ser Cys Gly Ala His Ser Thr Gln Cys Ile 115 120 125 Pro Val Ser Trp Arg Cys Asp Gly Glu Asn Asp Cys Asp Ser Gly Glu 130 135 140 Asp Glu Glu Asn Cys Gly Asn Ile Thr Cys Ser Pro Asp Glu Phe Thr 145 150 155 160 Cys Ser Ser Gly Arg Cys Ile Ser Arg Asn Phe Val Cys Asn Gly Gln 165 170 175 Asp Asp Cys Ser Asp Gly Ser Asp Glu Leu Asp Cys Ala Pro Pro Thr 180 185 190 Cys Gly Ala His Glu Phe Gln Cys Ser Thr Ser Ser Cys Ile Pro Ile 195 200 205 Ser Trp Val Cys Asp Asp Asp Ala Asp Cys Ser Asp Gln Ser Asp Glu 210 215 220 Ser Leu Glu Gln Cys Gly Arg Gln Pro Val Ile His Thr Lys Cys Pro 225 230 235 240 Ala Ser Glu Ile Gln Cys Gly Ser Gly Glu Cys Ile His Lys Lys Trp 245 250 255 Arg Cys Asp Gly Asp Pro Asp Cys Lys Asp Gly Ser Asp Glu Val Asn 260 265 270 Cys Pro Ser Arg Thr Cys Arg Pro Asp Gln Phe Glu Cys Glu Asp Gly 275 280 285 Ser Cys Ile His Gly Ser Arg Gln Cys Asn Gly Ile Arg Asp Cys Val 290 295 300 Asp Gly Ser Asp Glu Val Asn Cys Lys Asn Val Asn Gln Cys Leu Gly 305 310 315 320 Pro Gly Lys Phe Lys Cys Arg Ser Gly Glu Cys Ile Asp Ile Ser Lys 325 330 335 Val Cys Asn Gln Glu Gln Asp Cys Arg Asp Trp Ser Asp Glu Pro Leu 340 345 350 Lys Glu Cys His Ile Asn Glu Cys Leu Val Asn Asn Gly Gly Cys Ser 355 360 365 His Ile Cys Lys Asp Leu Val Ile Gly Tyr Glu Cys Asp Cys Ala Ala 370 375 380 Gly Phe Glu Leu Ile Asp Arg Lys Thr Cys Gly Asp Ile Asp Glu Cys 385 390 395 400 Gln Asn Pro Gly Ile Cys Ser Gln Ile Cys Ile Asn Leu Lys Gly Gly 405 410 415 Tyr Lys Cys Glu Cys Ser Arg Gly Tyr Gln Met Asp Leu Ala Thr Gly 420 425 430 Val Cys Lys Ala Val Gly Lys Glu Pro Ser Leu Ile Phe Thr Asn Arg 435 440 445 Arg Asp Ile Arg Lys Ile Gly Leu Glu Arg Lys Glu Tyr Ile Gln Leu 450 455 460 Val Glu Gln Leu Arg Asn Thr Val Ala Leu Asp Ala Asp Ile Ala Ala 465 470 475 480 Gln Lys Leu Phe Trp Ala Asp Leu Ser Gln Lys Ala Ile Phe Ser Ala 485 490 495 Ser Ile Asp Asp Lys Val Gly Arg His Val Lys Met Ile Asp Asn Val 500 505 510 Tyr Asn Pro Ala Ala Ile Ala Val Asp Trp Val Tyr Lys Thr Ile Tyr 515 520 525 Trp Thr Asp Ala Ala Ser Lys Thr Ile Ser Val Ala Thr Leu Asp Gly 530 535 540 Thr Lys Arg Lys Phe Leu Phe Asn Ser Asp Leu Arg Glu Pro Ala Ser 545 550 555 560 Ile Ala Val Asp Pro Leu Ser Gly Phe Val Tyr Trp Ser Asp Trp Gly 565 570 575 Glu Pro Ala Lys Ile Glu Lys Ala Gly Met Asn Gly Phe Asp Arg Arg 580 585 590 Pro Leu Val Thr Ala Asp Ile Gln Trp Pro Asn Gly Ile Thr Leu Asp 595 600 605 Leu Ile Lys Ser Arg Leu Tyr Trp Leu Asp Ser Lys Leu His Met Leu 610 615 620 Ser Ser Val Asp Leu Asn Gly Gln Asp Arg Arg Ile Val Leu Lys Ser 625 630 635 640 Leu Glu Phe Leu Ala His Pro Leu Ala Leu Thr Ile Phe Glu Asp Arg 645 650 655 Val Tyr Trp Ile Asp Gly Glu Asn Glu Ala Val Tyr Gly Ala Asn Lys 660 665 670 Phe Thr Gly Ser Glu Leu Ala Thr Leu Val Asn Asn Leu Asn Asp Ala 675 680 685 Gln Asp Ile Ile Val Tyr His Glu Leu Val Gln Pro Ser Gly Lys Asn 690 695 700 Trp Cys Glu Glu Asp Met Glu Asn Gly Gly Cys Glu Tyr Leu Cys Leu 705 710 715 720 Pro Ala Pro Gln Ile Asn Asp His Ser Pro Lys Tyr Thr Cys Ser Cys 725 730 735 Pro Ser Gly Tyr Asn Val Glu Glu Asn Gly Arg Asp Cys Gln Ser Thr 740 745 750 Ala Thr Thr Val Thr Tyr Ser Glu Thr Lys Asp Thr Asn Thr Thr Glu 755 760 765 Ile Ser Ala Thr Ser Gly Leu Val Pro Gly Gly Ile Asn Val Thr Thr 770 775 780 Ala Val Ser Glu Val Ser Val Pro Pro Lys Gly Thr Ser Ala Ala Trp 785 790 795 800 Ala Ile Leu Pro Leu Leu Leu Leu Val Met Ala Ala Val Gly Gly Tyr 805 810 815 Leu Met Trp Arg Asn Trp Gln His Lys Asn Met Lys Ser Met Asn Phe 820 825 830 Asp Asn Pro Val Tyr Leu Lys Thr Thr Glu Glu Asp Leu Ser Ile Asp 835 840 845 Ile Gly Arg His Ser Ala Ser Val Gly His Thr Tyr Pro Ala Ile Ser 850 855 860 Val Val Ser Thr Asp Asp Asp Leu Ala 865 870 8 2887 PRT Homo sapiens 8 Met Met Lys Gln Pro Gln Gly Glu Gln Ile Gln Ile Asn Phe Thr His 1 5 10 15 Val Glu Leu Gln Cys Gln Ser Asp Ser Ser Gln Asn Tyr Ile Glu Val 20 25 30 Arg Asp Gly Glu Thr Leu Leu Gly Lys Val Cys Gly Asn Gly Thr Ile 35 40 45 Ser His Ile Lys Ser Ile Thr Asn Ser Val Trp Ile Arg Phe Lys Ile 50 55 60 Asp Ala Ser Val Glu Lys Ala Ser Phe Arg Ala Val Tyr Gln Val Ala 65 70 75 80 Cys Gly Asp Glu Leu Thr Gly Glu Gly Val Ile Arg Ser Pro Phe Phe 85 90 95 Pro Asn Val Tyr Pro Gly Glu Arg Thr Cys Arg Trp Thr Ile His Gln 100 105 110 Pro Gln Ser Gln Val Ile Leu Leu Asn Phe Thr Val Phe Glu Ile Gly 115 120 125 Ser Ser Ala His Cys Glu Thr Asp Tyr Val Glu Ile Gly Ser Ser Ser 130 135 140 Ile Leu Gly Ser Pro Glu Asn Lys Lys Tyr Cys Gly Thr Asp Ile Pro 145 150 155 160 Ser Phe Ile Thr Ser Val Tyr Asn Phe Leu Tyr Val Thr Phe Val Lys 165 170 175 Ser Ser Ser Thr Glu Asn His Gly Phe Met Ala Lys Phe Ser Ala Glu 180 185 190 Asp Leu Ala Cys Gly Glu Ile Leu Thr Glu Ser Thr Gly Thr Ile Gln 195 200 205 Ser Pro Gly His Pro Asn Val Tyr Pro His Gly Ile Asn Cys Thr Trp 210 215 220 His Ile Leu Val Gln Pro Asn His Leu Ile His Leu Met Phe Glu Thr 225 230 235 240 Phe His Leu Glu Phe His Tyr Asn Cys Thr Asn Asp Tyr Leu Glu Val 245 250 255 Tyr Asp Thr Asp Ser Glu Thr Ser Leu Gly Arg Tyr Cys Gly Lys Ser 260 265 270 Ile Pro Pro Ser Leu Thr Ser Ser Gly Asn Ser Leu Met Leu Val Phe 275 280 285 Val Thr Asp Ser Asp Leu Ala Tyr Glu Gly Phe Leu Ile Asn Tyr Glu 290 295 300 Ala Ile Ser Ala Ala Thr Ala Cys Leu Gln Asp Tyr Thr Asp Asp Leu 305 310 315 320 Gly Thr Phe Thr Ser Pro Asn Phe Pro Asn Asn Tyr Pro Asn Asn Trp 325 330 335 Glu Cys Ile Tyr Arg Ile Thr Val Arg Thr Gly Gln Leu Ile Ala Val 340 345 350 His Phe Thr Asn Phe Ser Leu Glu Glu Ala Ile Gly Asn Tyr Tyr Thr 355 360 365 Asp Phe Leu Glu Ile Arg Asp Gly Gly Tyr Glu Lys Ser Pro Leu Leu 370 375 380 Gly Ile Phe Tyr Gly Ser Asn Leu Pro Pro Thr Ile Ile Ser His Ser 385 390 395 400 Asn Lys Leu Trp Leu Lys Phe Lys Ser Asp Gln Ile Asp Thr Arg Ser 405 410 415 Gly Phe Ser Ala Tyr Trp Asp Gly Ser Ser Thr Gly Cys Gly Gly Asn 420 425 430 Leu Thr Thr Ser Ser Gly Thr Phe Ile Ser Pro Asn Tyr Pro Met Pro 435 440 445 Tyr Tyr His Ser Ser Glu Cys Tyr Trp Trp Leu Lys Ser Ser His Gly 450 455 460 Ser Ala Phe Glu Leu Glu Phe Lys Asp Phe His Leu Glu His His Pro 465 470 475 480 Asn Cys Thr Leu Asp Tyr Leu Ala Val Tyr Asp Gly Pro Ser Ser Asn 485 490 495 Ser His Leu Leu Thr Gln Leu Cys Gly Asp Glu Lys Pro Pro Leu Ile 500 505 510 Arg Ser Ser Gly Asp Ser Met Phe Ile Lys Leu Arg Thr Asp Glu Gly 515 520 525 Gln Gln Gly Arg Gly Phe Lys Ala Glu Tyr Arg Gln Thr Cys Glu Asn 530 535 540 Val Val Ile Val Asn Gln Thr Tyr Gly Ile Leu Glu Ser Ile Gly Tyr 545 550 555 560 Pro Asn Pro Tyr Ser Glu Asn Gln His Cys Asn Trp Thr Ile Arg Ala 565 570 575 Thr Thr Gly Asn Thr Val Asn Tyr Thr Phe Leu Ala Phe Asp Leu Glu 580 585 590 His His Ile Asn Cys Ser Thr Asp Tyr Leu Glu Leu Tyr Asp Gly Pro 595 600 605 Arg Gln Met Gly Arg Tyr Cys Gly Val Asp Leu Pro Pro Pro Gly Ser 610 615 620 Thr Thr Ser Ser Lys Leu Gln Val Leu Leu Leu Thr Asp Gly Val Gly 625 630 635 640 Arg Arg Glu Lys Gly Phe Gln Met Gln Trp Phe Val Tyr Gly Cys Gly 645 650 655 Gly Glu Leu Ser Gly Ala Thr Gly Ser Phe Ser Ser Pro Gly Phe Pro 660 665 670 Asn Arg Tyr Pro Pro Asn Lys Glu Cys Ile Trp Tyr Ile Arg Thr Asp 675 680 685 Pro Gly Ser Ser Ile Gln Leu Thr Ile His Asp Phe Asp Val Glu Tyr 690 695 700 His Ser Arg Cys Asn Phe Asp Val Leu Glu Ile Tyr Gly Gly Pro Asp 705 710 715 720 Phe His Ser Pro Arg Ile Ala Gln Leu Cys Thr Gln Arg Ser Pro Glu 725 730 735 Asn Pro Met Gln Val Ser Ser Thr Gly Asn Glu Leu Ala Ile Arg Phe 740 745 750 Lys Thr Asp Leu Ser Ile Asn Gly Arg Gly Phe Asn Ala Ser Trp Gln 755 760 765 Ala Val Thr Gly Gly Cys Gly Gly Ile Phe Gln Ala Pro Ser Gly Glu 770 775 780 Ile His Ser Pro Asn Tyr Pro Ser Pro Tyr Arg Ser Asn Thr Asp Cys 785 790 795 800 Ser Trp Val Ile Arg Val Asp Arg Asn His Arg Val Leu Leu Asn Phe 805 810 815 Thr Asp Phe Asp Leu Glu Ser Gln Asp Ser Cys Ile Met Ala Tyr Asp 820 825 830 Gly Leu Ser Ser Thr Met Ser Arg Leu Ala Arg Thr Cys Gly Arg Glu 835 840 845 Gln Leu Ala Asn Pro Ile Val Ser Ser Gly Asn Ser Leu Phe Leu Arg 850 855 860 Phe Gln Ser Gly Pro Ser Arg Gln Asn Arg Gly Phe Arg Ala Gln Phe 865 870 875 880 Arg Gln Ala Cys Gly Gly His Ile Leu Thr Ser Ser Phe Asp Thr Val 885 890 895 Ser Ser Pro Arg Phe Pro Ala Asn Tyr Pro Asn Asn Gln Asn Cys Ser 900 905 910 Trp Ile Ile Gln Ala Gln Pro Pro Leu Asn His Ile Thr Leu Ser Phe 915 920 925 Thr His Phe Glu Leu Glu Arg Ser Thr Thr Cys Ala Arg Asp Phe Val 930 935 940 Glu Ile Leu Asp Gly Gly His Glu Asp Ala Pro Leu Arg Gly Arg Tyr 945 950 955 960 Cys Gly Thr Asp Met Pro His Pro Ile Thr Ser Phe Ser Ser Ala Leu 965 970 975 Thr Leu Arg Phe Val Ser Asp Ser Ser Ile Ser Ala Gly Gly Phe His 980 985 990 Thr Thr Val Thr Ala Ser Val Ser Ala Cys Gly Gly Thr Phe Tyr Met 995 1000 1005 Ala Glu Gly Ile Phe Asn Ser Pro Gly Tyr Pro Asp Ile Tyr Pro 1010 1015 1020 Pro Asn Val Glu Cys Val Trp Asn Ile Val Ser Ser Pro Gly Asn 1025 1030 1035 Trp Leu Gln Leu Ser Phe Ile Ser Phe Gln Leu Glu Asp Ser Gln 1040 1045 1050 Asp Cys Ser Arg Asp Phe Val Glu Ile Arg Glu Gly Asn Ala Thr 1055 1060 1065 Gly His Leu Val Gly Arg Tyr Cys Gly Asn Ser Phe Pro Leu Asn 1070 1075 1080 Tyr Ser Ser Ile Val Gly His Thr Leu Trp Val Arg Phe Ile Ser 1085 1090 1095 Asp Gly Ser Gly Ser Gly Thr Gly Phe Gln Ala Thr Phe Met Lys 1100 1105 1110 Ile Phe Gly Asn Asp Asn Ile Val Gly Thr His Gly Lys Val Ala 1115 1120 1125 Ser Pro Phe Trp Pro Glu Asn Tyr Pro His Asn Ser Asn Tyr Gln 1130 1135 1140 Trp Thr Val Asn Val Asn Ala Ser His Val Val His Gly Arg Ile 1145 1150 1155 Leu Glu Met Asp Ile Glu Glu Ile Gln Asn Cys Tyr Tyr Asp Lys 1160 1165 1170 Leu Arg Ile Tyr Asp Gly Pro Ser Ile His Ala Arg Leu Ile Gly 1175 1180 1185 Ala Tyr Cys Gly Thr Gln Thr Glu Ser Phe Ser Ser Thr Gly Asn 1190 1195 1200 Ser Leu Thr Phe His Phe Tyr Ser Asp Ser Ser Ile Ser Gly Lys 1205 1210 1215 Gly Phe Leu Leu Glu Trp Phe Ala Val Asp Ala Pro Asp Gly Val 1220 1225 1230 Leu Pro Thr Ile Ala Pro Gly Ala Cys Gly Gly Phe Leu Arg Thr 1235 1240 1245 Gly Asp Ala Pro Val Phe Leu Phe Ser Pro Gly Trp Pro Asp Ser 1250 1255 1260 Tyr Ser Asn Arg Val Asp Cys Thr Trp Leu Ile Gln Ala Pro Asp 1265 1270 1275 Ser Thr Val Glu Leu Asn Ile Leu Ser Leu Asp Ile Glu Ser His 1280 1285 1290 Arg Thr Cys Ala Tyr Asp Ser Leu Val Ile Arg Asp Gly Asp Asn 1295 1300 1305 Asn Leu Ala Gln Gln Leu Ala Val Leu Cys Gly Arg Glu Ile Pro 1310 1315 1320 Gly Pro Ile Arg Ser Thr Gly Glu Tyr Met Phe Ile Arg Phe Thr 1325 1330 1335 Ser Asp Ser Ser Val Thr Arg Ala Gly Phe Asn Ala Ser Phe His 1340 1345 1350 Lys Ser Cys Gly Gly Tyr Leu His Ala Asp Arg Gly Ile Ile Thr 1355 1360 1365 Ser Pro Lys Tyr Pro Glu Thr Tyr Pro Ser Asn Leu Asn Cys Ser 1370 1375 1380 Trp His Val Leu Val Gln Ser Gly Leu Thr Ile Ala Val His Phe 1385 1390 1395 Glu Gln Pro Phe Gln Ile Pro Asn Gly Asp Ser Ser Cys Asn Gln 1400 1405 1410 Gly Asp Tyr Leu Val Leu Arg Asn Gly Pro Asp Ile Tyr Ser Pro 1415 1420 1425 Pro Leu Gly Pro Pro Gly Gly Asn Gly His Phe Cys Gly Ser His 1430 1435 1440 Ala Ser Ser Thr Leu Phe Thr Ser Asp Asn Gln Met Phe Val Gln 1445 1450 1455 Phe Ile Ser Asp His Ser Asn Glu Gly Gln Gly Phe Lys Ile Lys 1460 1465 1470 Tyr Glu Ala Lys Ser Leu Ala Cys Gly Gly Asn Val Tyr Ile His 1475 1480 1485 Asp Ala Asp Ser Ala Gly Tyr Val Thr Ser Pro Asn His Pro His 1490 1495 1500 Asn Tyr Pro Pro His Ala Asp Cys Ile Trp Ile Leu Ala Ala Pro 1505 1510 1515 Pro Glu Thr Arg Ile Gln Leu Gln Phe Glu Asp Arg Phe Asp Ile 1520 1525 1530 Glu Val Thr Pro Asn Cys Thr Ser Asn Tyr Leu Glu Leu Arg Asp 1535 1540 1545 Gly Val Asp Ser Asp Ala Pro Ile Leu Ser Lys Phe Cys Gly Thr 1550 1555 1560 Ser Leu Pro Ser Ser Gln Trp Ser Ser Gly Glu Val Met Tyr Leu 1565 1570 1575 Arg Phe Arg Ser Asp Asn Ser Pro Thr His Val Gly Phe Lys Ala 1580 1585 1590 Lys Tyr Ser Ile Ala Gln Cys Gly Gly Arg Val Pro Gly Gln Ser 1595 1600 1605 Gly Val Val Glu Ser Ile Gly His Pro Thr Leu Pro Tyr Arg Asp 1610 1615 1620 Asn Leu Phe Cys Glu Trp His Leu Gln Gly Leu Ser Gly His Tyr 1625 1630 1635 Leu Thr Ile Ser Phe Glu Asp Phe Asn Leu Gln Asn Ser Ser Gly 1640 1645 1650 Cys Glu Lys Asp Phe Val Glu Ile Trp Asp Asn His Thr Ser Gly 1655 1660 1665 Asn Ile Leu Gly Arg Tyr Cys Gly Asn Thr Ile Pro Asp Ser Ile 1670 1675 1680 Asp Thr Ser Ser Asn Thr Ala Val Val Arg Phe Val Thr Asp Gly 1685 1690 1695 Ser Val Thr Ala Ser Gly Phe Arg Leu Arg Phe Glu Ser Ser Met 1700 1705 1710 Glu Glu Cys Gly Gly Asp Leu Gln Gly Ser Ile Gly Thr Phe Thr 1715 1720 1725 Ser Pro Asn Tyr Pro Asn Pro Asn Pro His Gly Arg Ile Cys Glu 1730 1735 1740 Trp Arg Ile Thr Ala Pro Glu Gly Arg Arg Ile Thr Leu Met Phe 1745 1750 1755 Asn Asn Leu Arg Leu Ala Thr His Pro Ser Cys Asn Asn Glu His 1760 1765 1770 Val Ile Val Phe Asn Gly Ile Arg Ser Asn Ser Pro Gln Leu Glu 1775 1780 1785 Lys Leu Cys Ser Ser Val Asn Val Ser Asn Glu Ile Lys Ser Ser 1790 1795 1800 Gly Asn Thr Met Lys Val Ile Phe Phe Thr Asp Gly Ser Arg Pro 1805 1810 1815 Tyr Gly Gly Phe Thr Ala Ser Tyr Thr Ser Ser Glu Asp Ala Val 1820 1825 1830 Cys Gly Gly Ser Leu Pro Asn Thr Pro Glu Gly Asn Phe Thr Ser 1835 1840 1845 Pro Gly Tyr Asp Gly Val Arg Asn Tyr Ser Arg Asn Leu Asn Cys 1850 1855 1860 Glu Trp Thr Leu Ser Asn Pro Asn Gln Gly Asn Ser Ser Ile Ser 1865 1870 1875 Ile His Phe Glu Asp Phe Tyr Leu Glu Ser His Gln Asp Cys Gln 1880 1885 1890 Phe Asp Val Leu Glu Phe Arg Val Gly Asp Ala Asp Gly Pro Leu 1895 1900 1905 Met Trp Arg Leu Cys Gly Pro Ser Lys Pro Thr Leu Pro Leu Val 1910 1915 1920 Ile Pro Tyr Ser Gln Val Trp Ile His Phe Val Thr Asn Glu Arg 1925 1930 1935 Val Glu His Ile Gly Phe His Ala Lys Tyr Ser Phe Thr Asp Cys 1940 1945 1950 Gly Gly Ile Gln Ile Gly Asp Ser Gly Val Ile Thr Ser Pro Asn 1955 1960 1965 Tyr Pro Asn Ala Tyr Asp Ser Leu Thr His Cys Ser Ser Leu Leu 1970 1975 1980 Glu Ala Pro Gln Gly His Thr Ile Thr Leu Thr Phe Ser Asp Phe 1985 1990 1995 Asp Ile Glu Pro His Thr Thr Cys Ala Trp Asp Ser Val Thr Val 2000 2005 2010 Arg Asn Gly Gly Ser Pro Glu Ser Pro Ile Ile Gly Gln Tyr Cys 2015 2020 2025 Gly Asn Ser Asn Pro Arg Thr Ile Gln Ser Gly Ser Asn Gln Leu 2030 2035 2040 Val Val Thr Phe Asn Ser Asp His Ser Leu Gln Gly Gly Gly Phe 2045 2050 2055 Tyr Ala Thr Trp Asn Thr Gln Thr Leu Gly Cys Gly Gly Ile Phe 2060 2065 2070 His Ser Asp Asn Gly Thr Ile Arg Ser Pro His Trp Pro Gln Asn 2075 2080 2085 Phe Pro Glu Asn Ser Arg Cys Ser Trp Thr Ala Ile Thr His Lys 2090 2095 2100 Ser Lys His Leu Glu Ile Ser Phe Asp Asn Asn Phe Leu Ile Pro 2105 2110 2115 Ser Gly Asp Gly Gln Cys Gln Asn Ser Phe Val Lys Val Trp Ala 2120 2125 2130 Gly Thr Glu Glu Val Asp Lys Ala Leu Leu Ala Thr Gly Cys Gly 2135 2140 2145 Asn Val Ala Pro Gly Pro Val Ile Thr Pro Ser Asn Thr Phe Thr 2150 2155 2160 Ala Val Phe Gln Ser Gln Glu Ala Pro Ala Gln Gly Phe Ser Ala 2165 2170 2175 Ser Phe Val Ser Arg Cys Gly Ser Asn Phe Thr Gly Pro Ser Gly 2180 2185 2190 Tyr Ile Ile Ser Pro Asn Tyr Pro Lys Gln Tyr Asp Asn Asn Met 2195 2200 2205 Asn Cys Thr Tyr Val Ile Glu Ala Asn Pro Leu Ser Val Val Leu 2210 2215 2220 Leu Thr Phe Val Ser Phe His Leu Glu Ala Arg Ser Ala Val Thr 2225 2230 2235 Gly Ser Cys Val Asn Asp Gly Val His Ile Ile Arg Gly Tyr Ser 2240 2245 2250 Val Met Ser Thr Pro Phe Ala Thr Val Cys Gly Asp Glu Met Pro 2255 2260 2265 Ala Pro Leu Thr Ile Ala Gly Pro Val Leu Leu Asn Phe Tyr Ser 2270 2275 2280 Asn Glu Gln Ile Thr Asp Phe Gly Phe Lys Phe Ser Tyr Arg Ile 2285 2290 2295 Ile Ser Cys Gly Gly Val Phe Asn Phe Ser Ser Gly Ile Ile Thr 2300 2305 2310 Ser Pro Ala Tyr Ser Tyr Ala Asp Tyr Pro Asn Asp Met His Cys 2315 2320 2325 Leu Tyr Thr Ile Thr Val Ser Asp Asp Lys Val Ile Glu Leu Lys 2330 2335 2340 Phe Ser Asp Phe Asp Val Val Pro Ser Thr Ser Cys Ser His Asp 2345 2350 2355 Tyr Leu Ala Ile Tyr Asp Gly Ala Asn Thr Ser Asp Pro Leu Leu 2360 2365 2370 Gly Lys Phe Cys Gly Ser Lys Arg Pro Pro Asn Val Lys Ser Ser 2375 2380 2385 Asn Asn Ser Met Leu Leu Val Phe Lys Thr Asp Ser Phe Gln Thr 2390 2395 2400 Ala Lys Gly Trp Lys Met Ser Phe Arg Gln Thr Leu Gly Pro Gln 2405 2410 2415 Gln Gly Cys Gly Gly Tyr Leu Thr Gly Ser Asn Asn Thr Phe Ala 2420 2425 2430 Ser Pro Asp Ser Asp Ser Asn Gly Met Tyr Asp Lys Asn Leu Asn 2435 2440 2445 Cys Val Trp Ile Ile Ile Ala Pro Val Asn Lys Val Ile His Leu 2450 2455 2460 Thr Phe Asn Thr Phe Ala Leu Glu Ala Ala Ser Thr Arg Gln Arg 2465 2470 2475 Cys Leu Tyr Asp Tyr Val Lys Leu Tyr Asp Gly Asp Ser Glu Asn 2480 2485 2490 Ala Asn Leu Ala Gly Thr Phe Cys Gly Ser Thr Val Pro Ala Pro 2495 2500 2505 Phe Ile Ser Ser Gly Asn Phe Leu Thr Val Gln Phe Ile Ser Asp 2510 2515 2520 Leu Thr Leu Glu Arg Glu Gly Phe Asn Ala Thr Tyr Thr Ile Met 2525 2530 2535 Asp Met Pro Cys Gly Gly Thr Tyr Asn Ala Thr Trp Thr Pro Gln 2540 2545 2550 Asn Ile Ser Ser Pro Asn Ser Ser Asp Pro Asp Val Pro Phe Ser 2555 2560 2565 Ile Cys Thr Trp Val Ile Asp Ser Pro Pro His Gln Gln Val Lys 2570 2575 2580 Ile Thr Val Trp Ala Leu Gln Leu Thr Ser Gln Asp Cys Thr Gln 2585 2590 2595 Asn Tyr Leu Gln Leu Gln Asp Ser Pro Gln Gly His Gly Asn Ser 2600 2605 2610 Arg Phe Gln Phe Cys Gly Arg Asn Ala Ser Ala Val Pro Val Phe 2615 2620 2625 Tyr Ser Ser Met Ser Thr Ala Met Val Ile Phe Lys Ser Gly Val 2630 2635 2640 Val Asn Arg Asn Ser Arg Met Ser Phe Thr Tyr Gln Ile Ala Asp 2645 2650 2655 Cys Asn Arg Asp Tyr His Lys Ala Phe Gly Asn Leu Arg Ser Pro 2660 2665 2670 Gly Trp Pro Asp Asn Tyr Asp Asn Asp Lys Asp Cys Thr Val Thr 2675 2680 2685 Leu Thr Ala Pro Gln Asn His Thr Ile Ser Leu Phe Phe His Ser 2690 2695 2700 Leu Gly Ile Glu Asn Ser Val Glu Cys Arg Asn Asp Phe Leu Glu 2705 2710 2715 Val Arg Asn Gly Ser Asn Ser Asn Ser Pro Leu Leu Gly Lys Tyr 2720 2725 2730 Cys Gly Thr Leu Leu Pro Asn Pro Val Phe Ser Gln Asn Asn Glu 2735 2740 2745 Leu Tyr Leu Arg Phe Lys Ser Asp Ser Val Thr Ser Asp Arg Gly 2750 2755 2760 Tyr Glu Ile Ile Trp Thr Ser Ser Pro Ser Gly Cys Gly Gly Thr 2765 2770 2775 Leu Tyr Gly Asp Arg Gly Ser Phe Thr Ser Pro Gly Tyr Pro Gly 2780 2785 2790 Thr Tyr Pro Asn Asn Thr Tyr Cys Glu Trp Val Leu Val Ala Pro 2795 2800 2805 Ala Gly Arg Leu Val Thr Ile Asn Phe Tyr Phe Ile Ser Ile Asp 2810 2815 2820 Asp Pro Gly Asp Cys Val Gln Asn Tyr Leu Thr Leu Tyr Asp Gly 2825 2830 2835 Pro Asn Ala Ser Ser Pro Ser Ser Gly Pro Tyr Cys Gly Gly Asp 2840 2845 2850 Thr Ser Ile Ala Pro Phe Val Ala Ser Ser Asn Gln Val Phe Ile 2855 2860 2865 Lys Phe His Ala Asp Tyr Ala Arg Arg Pro Ser Ala Phe Arg Leu 2870 2875 2880 Thr Trp Asp Ser 2885 

1. An in vitro method for screening for a compound which alters uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor, said method comprising a) providing an assay for measuring binding to or uptake by the steroid hormone binding protein receptor of steroid hormones bound to or complexed with a steroid hormone binding protein, b) adding the compound to be tested to the assay, and c) determining the amount of steroid hormones bound to or complexed with a steroid hormone binding protein which is bound to or taken up by the steroid hormone binding protein receptor, d) comparing the amount determined in step c) with an amount measured in the absence of the compound to be tested, e) wherein a difference in the two amounts identifies a compound which alters the binding or uptake of steroid hormones bound to or complexed with steroid hormone binding proteins.
 2. The method according to claim 1, wherein the steroid hormone is selected from the group consisting of androgens, estrogens, progestogens and corticoids.
 3. The method according to claim 1, wherein the steroid hormone is selected from the group consisting of androgens and estrogens.
 4. The method according to claim 1, wherein the steroid hormone is selected from the group consisting of testosterone, dihydrotestosterone, estrion and estradiol.
 5. The method according to claim 1, wherein the steroid hormone binding protein is selected from the group consisting of sex hormone binding globulin, corticosteroid-binding globulin, Clara cell secretory protein (CCSP), apolipoprotein D (apoD) and 24p3.
 6. The method according to claim 1, wherein the steroid hormone binding protein is the sex hormone binding globulin.
 7. The method according to claim 1, wherein the steroid hormone binding protein is a human steroid hormone binding protein.
 8. The method according to claim 1, wherein the steroid hormone binding protein receptor is selected from a group of receptors of low density lipoprotein (LDL) receptor gene family, said group comprising VLDL receptor, LRP-1B, MEGF-7, ApoE receptor-2, chicken VTG receptor, Drosophila Y1 protein, LDL receptor-related protein, gp 330/megalin and C. elegans gp330/megalin-related protein receptor.
 9. The method according to claim 1, wherein the steroid hormone binding protein receptor is selected from the group consisting of LRP, megalin, VLDL receptor, MGEF-7, LRP1B and ApoE receptor-2.
 10. The method according to claim 1, wherein the steroid hormone binding protein receptor is selected from the group consisting of ApoE receptor-2 and megalin.
 11. The method according to claim 1, wherein the steroid hormone binding protein receptor is megalin.
 12. The method according to claim 1, wherein the steroid hormone binding protein receptor is a human steroid hormone binding receptor.
 13. The method according to claim 1, wherein the cells presenting the steroid hormone binding protein receptors are selected from the group consisting of prostate cells, cells in epididymis, endometrial cells, ovarial cells, breast parenchymal cells, prostate carcinoma cells and breast carcinoma cells.
 14. The method according to claim 1, wherein the assay is a non-radioactive microtiter plate assay using purified steroid hormone binding protein receptors or fragments thereof immobilized on the plate surface.
 15. The method according to claim 1, wherein the assay comprises the steps of a) providing a non-radioactive microtiter plate having purified steroid hormone binding protein receptors and/or steroid hormone binding protein co-receptors or fragments thereof immobilised on the plate surface, b) incubating the plate with the compound to be tested, and c) incubating the plate with fluorescent labelled steroid binding proteins or fragments thereof and/or with fluorescent labelled steroid hormones, d) determining the amount of fluorescence of the plate.
 16. The method according to claim 1, wherein the assay comprises the steps of a) providing a cell which comprises a steroid hormone protein binding receptor, a steroid hormone nuclear receptor and a first nucleic acid sequence encoding a directly or indirectly detectable protein, said first nucleic acid sequence being operably linked to a second nucleic acid sequence, which can direct transcription depending on the presence of steroid hormone nuclear receptor complexed with steroid hormone. b) detecting said detectable protein. c) correlating the amount of detectable protein to the uptake of steroid hormone into said cell.
 17. The method according to claim 1, wherein the compound to be tested is selected from steroid hormone binding protein receptor domains or fragments thereof, natural steroid hormone binding protein receptor ligands, modified steroid hormone binding proteins or fragments thereof, steroid hormone binding protein receptor antagonists, such as receptor associated protein, or small organic molecules.
 18. The method according to claim 1, wherein the compound is selected from a library of naturally occurring and synthetic compounds which are randomly tested for alteration of the binding.
 19. The method according to claim 17, wherein the steroid hormone binding protein receptor domain is capable of binding a steroid hormone binding protein.
 20. The method according to claim 17, wherein the steroid hormone binding protein receptor domain is selected from steroid hormone binding protein receptor domains which comprise at least one complement type repeat.
 21. The method according to claim 17, wherein the steroid hormone binding protein receptor domain is selected from the group consisting of fragments of the MGEF-7 polypeptide sequence (SEQ ID NO: 2), fragments of the megalin polypeptide sequence (SEQ ID NO: 3), fragments of the LRP1B polypeptide sequence (SEQ ID NO: 4), fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5), fragments of the LRP polypeptide sequence (SEQ ID NO: 6) and fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7).
 22. The method according to claim 1, wherein the assay includes a cell expressing the steroid hormone binding protein receptor and the compound is a nucleic acid sequence which potentially alters the expression of the receptor.
 23. The method according to claim 1, wherein the compound competitively inhibits the binding or complexing of a steroid hormone to a steroid hormone binding protein.
 24. The method according to claim 1, wherein the compound competitively inhibits the binding of a steroid hormone binding protein to a steroid hormone binding protein receptor.
 25. The method according to claim 1, wherein the compound competitively inhibits the binding of a steroid hormone binding protein to a steroid hormone binding protein co-receptor.
 26. The method according to claim 1, wherein the compound increases the uptake of the steroid hormone.
 27. The method according to claim 26, wherein the compound alters dimerisation of steroid hormone binding proteins.
 28. A compound which alters the uptake of steroid hormone into cells presenting a steroid hormone binding protein receptor as identified by the method in claim
 1. 29. The compound of claim 28, selected from steroid hormone binding protein receptor domains or fragments thereof, natural steroid hormone binding protein receptor ligands, steroid hormone binding protein co-receptor domains and fragments thereof, modified steroid hormone binding proteins or fragments thereof, fragments of steroid hormone binding proteins, steroid hormone binding protein receptor antagonists, such as receptor associated protein (RAP), or small organic molecules.
 30. The compound according to claim 28, wherein the compound is selected from a library of naturally occurring and synthetic compounds which are randomly tested for alteration of the binding.
 31. The compound according to claim 29, wherein the steroid hormone binding protein receptor domain is capable of binding a steroid hormone binding protein.
 32. The compound according to claim 29, wherein the steroid hormone binding protein receptor domain is selected from steroid hormone binding protein receptor domains which comprise at least one complement type repeat.
 33. The compound according to claim 29, wherein the steroid hormone binding protein receptor domain is selected from the group consisting of fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7), fragments of the megalin polypeptide sequence (SEQ ID NO: 3) and fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5).
 34. The compound according to claim 29, wherein the steroid hormone binding protein co-receptor domain is selected from the group consisting of fragments of the cubilin polypeptide sequence (SEQ ID NO: 8).
 35. The compound according to claim 28, wherein the compound competitively inhibits the binding or complexing of a steroid hormone to a steroid hormone binding protein.
 36. The compound according to claim 28, wherein the compound competitively inhibits the binding of a steroid hormone binding protein to a steroid hormone binding protein receptor.
 37. The compound according to claim 29, wherein said fragment is capable of associating with a steroid hormone binding protein receptor and furthermore said fragment is not capable of associating with a steroid hormone.
 38. The compound according to claim 28, wherein said compound is a fragment of a steroid hormone binding protein capable of associating with a steroid hormone binding protein receptor, wherein said fragment is selected from the group consisting of: i. fragments consisting of amino acid 47 to 167 of human SHBG (SEQ ID NO: 1); and ii. fragments consisting of amino acid 128 to 137 of human SHBG (SEQ ID NO: 1); and iii. fragments consisting of amino acid 106 to 125 of human SHBG (SEQ ID NO:1); and iv. functional homologues of fragments of i) to iii), consisting of fragments at least 90% homologues to the fragments of i) to iii); and v. functional homologues of fragments of i) to iii), consisting of said fragments or fragments at least 90% homologues thereto with addition of in the range of 2 to 50 amino acids.
 39. The compound according to claim 39, wherein said functional homologues consists of fragments at least 90% homologues to the fragments of i), wherein amino acid residues 47, 106, 123, 125, 166 and 167 of SEQ ID No: 1 are selected from the group consisting of Arg and Lys.
 40. The compound according to claim 39, wherein said functional homologues consists of fragments at least 90% homologues to the fragments of iii), wherein amino acid residues 106, 123, 125 of SEQ ID No: 1 are selected from the group consisting of Arg and Lys.
 41. The compound according to claim 28 wherein said compound is selected from fragments of RAP that can associate with a steroid hormone binding protein receptor.
 42. The compound according to claim 28, wherein said compound is a nucleic acid sequence selected from the group consisting of a DNA sequence encoding for an antisense RNA of a steroid hormone binding protein receptor and an antisense RNA of a steroid hormone binding protein receptor.
 43. The compound according to claim 28, wherein the compound competitively inhibits the binding of a steroid hormone binding protein to a steroid hormone binding protein co-receptor.
 44. The compound according to claim 28, wherein the compound alters the uptake of the steroid hormone.
 45. The compound according to claim 28, wherein the compound alters dimerisation of steroid hormone binding proteins.
 46. A method for determining the effect of a compound on uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor, said method comprising the steps of a) administering said compound to a mammal naturally expressing the receptor, b) measuring expression of receptor mRNA or protein in tissues of the mammal or measuring receptor-mediated binding or transport of steroid hormones bound to or complexed with steroid hormone binding proteins or measuring uptake of steroid hormones or steroid hormone/steroid hormone binding protein complexes into cells of said mammal, c) comparing the measurement of step b) with a measurement measured in the absence of the compound to be tested, d) wherein the difference in the two measurements identifies the effect of said compound on the uptake of steroid hormones into cells presenting a steroid hormone binding protein receptor.
 47. The method of claim 47 wherein said compound is selected from steroid hormone binding protein receptor domains or fragments thereof, natural steroid hormone binding protein receptor ligands, steroid hormone binding protein co-receptor domains and fragments thereof, modified steroid hormone binding proteins or fragments thereof, fragments of steroid hormone binding proteins, steroid hormone binding protein receptor antagonists, such as receptor associated protein (RAP), or small organic molecules.
 48. The method according to claim 46, wherein step b) comprise an assay involving the use of immunoreactive species.
 49. The method according to claim 46, wherein step b) comprise an assay involving the use of one or more purified species selected from the group consisting of steroid hormones, steroid hormone binding proteins, steroid hormone binding protein receptors, steroid hormone binding protein co-receptors and fragments thereof and functional homologues thereof.
 50. The method according to claim 46, wherein said method further comprises administering said compound to a mammal lacking expression of said steroid hormone binding protein receptor.
 51. The method according to claim 50, wherein said mammal only lacks expression of said steroid hormone binding protein receptor in one or more selected tissues.
 52. A method of treating a clinical condition comprising administering to an individual in need thereof a sufficient amount of a compound comprising a steroid hormone binding protein receptor domain is selected from the group consisting of fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7), fragments of the megalin polypeptide sequence (SEQ ID NO: 3), fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5), and combinations thereof.
 53. A method of treating prostate cancer comprising administering to an individual having prostate cancer a sufficient amount of a compound selected from steroid hormone binding protein receptor domains or fragments thereof, natural steroid hormone binding protein receptor ligands, steroid hormone binding protein co-receptor domains and fragments thereof, modified steroid hormone binding proteins or fragments thereof, fragments of steroid hormone binding proteins, steroid hormone binding protein receptor antagonists, such as receptor associated protein (RAP), or small organic molecules.
 54. A method of treating breast cancer comprising administering to an individual having breast cancer a sufficient amount of a compound comprising a steroid hormone binding protein receptor domain is selected from the group consisting of fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7), fragments of the megalin polypeptide sequence (SEQ ID NO: 3), fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5), and combinations thereof.
 55. A method of preventing pregnancy comprising administering to an individual in need thereof a sufficient amount of a compound selected from steroid hormone binding protein receptor domains or fragments thereof, natural steroid hormone binding protein receptor ligands, steroid hormone binding protein co-receptor domains and fragments thereof, modified steroid hormone binding proteins or fragments thereof, fragments of steroid hormone binding proteins, steroid hormone binding protein receptor antagonists, such as receptor associated protein (RAP), or small organic molecules.
 56. The method according to claim 55, wherein said individual is a male.
 57. A pharmaceutical composition comprising a compound comprising a steroid hormone binding protein receptor domain is selected from the group consisting of fragments of the VLDL receptor polypeptide sequence (SEQ ID NO: 7), fragments of the megalin polypeptide sequence (SEQ ID NO: 3), fragments of the ApoE receptor 2 polypeptide sequence (SEQ ID NO: 5), and combinations thereof. 58-60 (Cancelled) 